TOWARDS UNDERSTANDING MODE-OF-ACTION OF TRADITIONAL MEDICINES BY USING IN SILICO TARGET PREDICTION by BINTI MOHAMAD ZOBIR, SITI ZURAIDAH
 TOWARDS UNDERSTANDING 
MODE-OF-ACTION OF 
TRADITIONAL MEDICINES BY 
USING IN SILICO TARGET 
PREDICTION 
 
Siti Zuraidah Binti Mohamad Zobir 
Hughes Hall 
 
April 2017 
 
This dissertation is submitted for the degree of Doctor of Philosophy of the 
University of Cambridge 
 
 
 
Supervisor: 
Dr Andreas Bender 
 i 
Name: SITI ZURAIDAH BINTI MOHAMAD ZOBIR 
Title: IN SILICO TARGET PREDICTION: TOWARDS UNDERSTANDING MODE-OF-ACTION 
OF TRADITIONAL MEDICINES 
Abstract 
Traditional medicines (TM) have been used for centuries to treat illnesses, but in many cases 
their modes-of-action (MOAs) remain unclear. Given the increasing data of chemical 
ingredients of traditional medicines and the availability of large-scale bioactivity data linking 
chemical structures to activities against protein targets, we are now in a position to propose 
computational hypotheses for the MOAs using in silico target prediction. The MOAs were 
established from supporting literature. The in silico target prediction, which is based on the 
“Molecular Similarity Principle”, was modelled via two models: a Naïve Bayes Classifier and 
a Random Forest Classifier. Chapter 2 discovered the relationship of 46 traditional Chinese 
medicine (TCM) therapeutic action subclasses by mapping them into a dendrogram using the 
predicted targets. Overall, the most frequent top three enriched targets/pathways were 
immune-related targets such as tyrosine-protein phosphatase non-receptor type 2 (PTPN2) 
and digestive system such as mineral absorption. Two major protein families, G-protein 
coupled receptor (GPCR), and protein kinase family contributed to the diversity of the 
bioactivity space, while digestive system was consistently annotated pathway motif. Chapter 3 
compared the chemical and bioactivity space of 97 anti-cancer plants’ compounds of TCM, 
Ayurveda and Malay traditional medicine. The comparison of the chemical space revealed 
that benzene, anthraquinone, flavone, sterol, pentacyclic triterpene and cyclohexene were the 
most frequent scaffolds in those TM. The annotation of the bioactivity space with target 
classes showed that kinase class was the most significant target class for all groups. From a 
phylogenetic tree of the anti-cancer plants, only eight pairs of plants were phylogenetically 
related at either genus, family or order level. Chapter 4 evaluated synergy score of pairwise 
compound combination of Shexiang Baoxin Pill (SBP), a TCM formulation for myocardial 
infarction. The score was measured from the topological properties, pathway dissimilarity and 
mean distance of all the predicted targets of a combination on a representative network of the 
disease. The method found four synergistic combinations, ginsenoside Rb3 and cholic acid, 
ginsenoside Rb2 and ginsenoside Rb3, ginsenoside Rb3 and 11-hydroxyprogesterone and 
ginsenoside Rb2 and ginsenoside Rd agreed with the experimental results. The modulation of 
androgen receptor, epidermal growth factor and caspases were proposed for the synergistic 
actions. Altogether, in silico target prediction was able to discover the bioactivity space of 
different TMs and elucidate the MOA of multiple formulations and two major health 
concerns: cancer and myocardial infarction. Hence, understanding the MOA of the traditional 
medicine could be beneficial in providing testable hypotheses to guide towards finding new 
molecular entities. 
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Chapter 1:  
Introduction 
 
 
1.1 A brief history of traditional medicine 
Humanity is dependent on natural products and has been so for millennia. These plants, 
animal parts and minerals are used both to treat many diseases (1, 2). Indeed, the knowledge 
of curative plants may be traced back at least 60,000 years where remains of medicinal plants 
such as opium poppies, ephedra, and cannabis were documented during archaeological 
excavations of Neanderthals burial sites at Shanidar in Iraq (3). The discovery of natural 
products with healing properties posed a massive challenge to early humans. Empirical 
discoveries of both healing and harmful properties of natural products resulted from trial and 
error, which can be fatal when experimenting poisonous natural products. Progressively, the 
knowledge of empirical discoveries was collected in the form of traditional medicine (4). The 
first written record of the use of natural products dates from 2600 BC of Mesopotamia, in 
which hundreds of clay tablets in cuneiform described, among others, the oils of Cedrus 
species (cedar) and Cupressus sempevirens (cypress), Glycyrrhiza glabra (licorice), 
Commiphora species (myrrh), and Papaver somniferum (poppy juice) were used for treating 
cold, cough, and inflammation (2, 4, 5). “Ebers Papyrus”, an ancient Egyptian pharmaceutical 
record (1500 BC), documented not only plants but also animal parts and minerals to constitute 
its 700 drugs (2, 4, 5). In other parts of the world, the ancient Greeks also documented the 
compilation of the uses of natural products for medicinal purposes (2, 4, 5). In Asia, 
traditional Chinese medicine (TCM) and Ayurveda (India) have been developed. These are 
two of the most extensively documented traditional medicines and so are considered in detail 
in this study (2, 4, 5). The practice of traditional medicine, over thousands of years, matured 
into systematic healthcare. Traditional medicine is defined by the World Health Organization 
(WHO) as sum total of the knowledge, skills, and practices based on the theories, beliefs, and 
experiences indigenous to different cultures, whether explicable or not, used in the 
maintenance of health as well as in the prevention, diagnosis, improvement or treatment of 
physical and mental illness (6)Ultimately, the goal of traditional medicine is to apply a 
holistic approach to maintain the overall balance of a human body. 
 
1.2 Natural products in drug discovery 
The identification of chemical compounds for observed therapeutic effects is still an on-
going process, despite the historical uses of natural products in traditional medicines for 
treating various diseases. The elucidation of chemical compounds for an observed therapeutic 
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effect was first reported in 1775 from the extract of Digatalis purpurea that was previously 
observed to treat arrhythmia (7). Subsequently, more compounds have been successfully 
discovered such as salicin, quinine and penicillin to name a few (5, 8). Some plant-derived 
drug have been developed with the same medicinal values of their sources (9). Table 1.1 lists 
some representatives of drugs based on their ethnomedicinal uses. The previous historical 
success could be partly responsible for the results of a recent report, which indicated that at 
least 40% of the 1,562 drugs that were approved between 1981 to 2014, were natural products 
or inspired by natural compounds (10). Scientifically, natural products have been exploited in 
drug discovery, as they inherently offer a large structural diversity, much of which has yet to 
be explored (1). In addition, natural products offer a biological readiness to bind to many 
molecular targets resulting from the interactions with multi-enzymes during their synthesis, 
thus mimicking endogenous metabolites (1, 5). Natural products also show better solubility 
as, on average, they retain relatively low log P values, which in order to do so natural 
products, generally, have higher molecular weights to contain more hydrogen bond acceptors 
(1, 11). Given these points, natural products, with or without known indications from 
traditional medicines could provide a valuable alternate therapeutic space to explore new 
molecular entities leading to more efficacious drugs. 
 
Table 1.1: A representative list of drugs that were developed based on the indications of their 
ethnomedicinal uses (9). 
Drug Action/Clinical use Plant source Traditional 
medicine 
Digitoxin Cardiotonic/arrhythmia Digatalis pupurea L. Europe 
Asiaticoside Wound healing/Tissue 
repair 
Centella asiatica Asia, Southeast 
Asia 
Khellin Asthma/Bronchodilator Amni visnaga Egypt 
Scopolamine Narcotic/Sedative Datura metel Arab 
Theophylline Diuretic/Diuretic Camellia sinensis Sri Lanka 
 
Although natural products have contributed a fair share in drug discovery (10), they are 
still undervalued for various reasons. The first is technical: natural products are difficult to be 
fully synthesised due to their complex structures. This difficulty cannot be easily avoided by 
isolating compounds as the method of isolation could create a supply issue for target 
validation as well as being expensive in both time and finance (1, 12). Second, the shift from 
cell-based assay to target-based assay has discounted natural products from drug discovery 
process due to the incompatibility issue of natural product extracts in high throughput 
screening (HTS). The extracts contain a mixture of compounds thus, interfering with the 
process of elucidating mode-of-action (MOA) (12-14). Third, the rise of combinatorial 
chemistry, which allows the synthesis of large numbers of structurally distinct molecules, is 
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viewed to increase the chances of finding a ‘hit’ alongside to repress known issues posed by 
natural products (1, 12, 13). The limitations described above might also contribute to less 
attraction of looking into traditional medicine. In this study, we aim to propose the MOA of 
traditional medicines by exploring and assessing the applicability of in silico approaches 
towards this goal. 
 
1.3 Approaches to elucidate mode-of-action 
Initially, phenotypic-based screening was a primary focus in drug discovery, where 
compounds were tested on organisms, tissues or cells showing a desired phenotype (15, 16). 
The prior knowledge of ‘target’ is not required in this method because a compound is simply 
considered a ‘hit’ if it elicits a desired phenotype and a ‘miss’ if not (15, 16). With the advent 
of HTS technology and the Human Genome Project, the strategy in drug discovery shifted to 
target-based screening (16, 17). One of the strengths of target-based screening is that the 
target is readily identified and validated, therefore, explaining the MOA. This approach can 
expedite the drug discovery process but does so with a significant drawback that is to interpret 
the therapeutic effect of a compound, it must be considered in a relevant disease model (16, 
17). Hence, phenotypic screening can be regarded to show higher potential to find a ‘hit’ but 
target identification is still required to understand the MOA. The target identification 
approaches can be described from the field of genetics, proteomics, and computational 
inference methods and reverse pharmacology (17-19). A brief description of each approach 
can be found in Table 1.2. In this study, we applied ligand-based in silico method to predict 
targets of traditional medicine compounds in order to rapidly improve mechanistic 
understanding of their ethnomedicinal uses.  
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Table 1.2: The four different approaches for target identification as described by Schenone et 
al. (17) , Chan et al. (18) and Vaidya A. (19) 
Field of Approach Description 
Genetics The approach identifies a target by deleting a gene to reduce the 
expression of protein that is hypothesised to be modulated for 
the desired phenotypic effect. An example of such approach is 
gene-knockout organism. However, the compound could also 
modulate a different target of the same pathway for the same 
desired phenotypic effect.   
Proteomics The approach identifies a target based on the physical 
interaction between a protein and a chemical compound. One of 
the classical approaches is the affinity chromatography where 
compounds of interest are immobilised on a column. The 
compounds are incubated with proteins extracts and non-
specific bound proteins are moved by extensive washing. The 
bound proteins are eluted with excess free drug or under highly 
denaturing conditions and characterised by SDS–PAGE and 
mass spectrometry. Although, the method could provide the 
relative binding specificity, it is difficult to be implemented in 
HTS. 
Computational inference 
methods 
The approach is able to identify targets based on two methods; 
ligand-based and structure-based using computational 
algorithms. To put simply, the ligand-based method 
incorporates chemical structures to predict targets while the 
structure-based method relies on the three-dimensional structure 
of a protein to predict binding affinity. Whilst the method is 
fast, experimental analysis is still required to validate the 
predicted targets. 
Reverse pharmacology The approach identifies the target through genomic, proteomic 
and metabolomics studies. The potential hits are screened through 
target-binding assays where the highly selected hit the molecular 
target is identified. The highly selected hit undergoes in vivo 
studies significantly show the desired physiological effect. 
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1.4 Ligand-based in silico target prediction 
1.4.1 The principle behind ligand-based in silico target prediction 
Rapid development in both combinatorial chemistry and HTS has allowed the explosion in 
number and size of compound libraries and bioactivity databases(20-22). These two types of 
databases provide an interface to study both biology and chemistry concurrently using 
informatics approaches, which has given rise to computational chemogenomic (23, 24). Some 
of the examples of the compound libraries and/or bioactivity data can be found in Table 1.3 
and Table 1.4. In addition to aforementioned databases, compound libraries of natural 
products have also kept arising (Table 1.5). 
 
Table 1.3: The databases that stores compounds and their structural information. 
Database Description Size of database  
(as of Jan 2017) 
Ref. 
ChemSpider The database is publicly accessible 
database that contains chemical 
structures and their physical and 
chemical properties, spectral data, 
synthetic methods, known reactions, 
safety information and systematic 
nomenclature. 
(http://www.chemspider.com) 
58 million structures (25) 
ZINC The database is a collection of chemical 
compounds.  
(http://zinc15.docking.org) 
The current version 15 
contains more than 120 
million compounds. 
(26) 
 
Table 1.4: The databases that contain compounds and their structural information together 
with their bioactivity information. 
Database Description Size of database  
(as of Jan 2017) 
Ref. 
Binding DB The database is publicly accessible that 
stores experimental protein-small 
molecule interaction data. The data is 
curated from scientific articles and US 
patents.  
(www.bindingdb.org) 
A total of 1,325,129 
bioactivity data (US 
patents, journals, other 
databases) of 6,914 
protein targets and 
589,218 small 
molecules.  
(27) 
ChEMBL A public drug discovery database 
consisting of small bioactivity 
molecules derived from scientific 
journals. 
(https://www.ebi.ac.uk/chembldb) 
The current version 22 
consists of 14,371,197 
bioactivity data (HTS) 
of 1,686,695 
compounds and 11,224 
targets. 
(28) 
PubChem The public database contains chemical 
compounds and their activities against 
different biological assays. 
(https://pubchem.ncbi.nlm.nih.gov/#) 
A total of 232,660585 
bioactivity data (HTS) 
of 10,341 protein 
targets and 94,475,253 
compounds. 
(29) 
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Table 1.5: Compound libraries of natural products that contain their structural information, 
physicochemical properties or bioactivity activities. 
Database Description Size of database  
(as of Jan 2017) 
Ref. 
Traditional 
Chinese 
Medicine 
Systems 
Pharmacology 
Database and 
Analysis 
Platform 
(TCMSP) 
The database is publicly accessible 
and contains chemical compounds 
that link to their herbs and their 
associated targets and diseases. 
Associated targets and diseases are 
retrieved from DrugBank (30) and 
TTD database  database(31) and 
PharmGKB 
(https://www.pharmgkb.org/). 
(http://ibts.hkbu.edu.hk/LSP/tcmsp.ph
p) 
29, 384 structures from 
499 Chinese 
herbs registered in the 
Chinese pharmacopoeia 
and they are associated to 
3,311 targets and 837 
diseases. 
(32) 
Naturally 
occurring Plant 
based Anti-
cancerous 
Compound-
Activity-Target 
Database 
(NPACT) 
The database is publicly accessible 
and each record provides information 
on their structure, properties 
(physical, elemental and topological), 
cancer type, cell lines, inhibitory 
values (IC50, ED50, EC50, GI50), 
molecular targets, commercial 
suppliers and drug likeness of 
compounds. 
(http://crdd.osdd.net/raghava/npact/in
dex.html) 
1,574 compounds curated 
from 762 references, 
which include 353 cell 
lines of 19 cancer types. 
(33) 
Super Natural 
II 
It is publicly available database of 
natural compounds with additional 
information such as MOA, pathways, 
and toxicity. 
(http://bioinf-
applied.charite.de/supernatural_new/i
ndex.php?site=home) 
Approximately 326,000 
unique compounds, 
collected from 16 
suppliers. 
(34) 
 
 
Ligand-based in silico target prediction (“in silico target prediction” will be used hereinafter) 
applies chemogenomics that aims to systematically study the relationship of compounds and 
biactivity space by annotating compounds to their targets and implementing algorithms to 
measure compound-target classification, which is used to predict targets of an orphan 
compound (24, 35-37) (Figure 1.1). Two basic assumptions are applied in chemogenomics 
(38): 
1. Structurally similar compounds modulate similar targets 
2. Similar targets share similar patterns (binding sites) 
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From these assumptions, chemogenomics is able to identify molecular recognition between all 
possible ligands and all proteins in a biological system (23, 39). There are two main elements 
to in silico target prediction: 
1. Generating chemical compound descriptors 
2. Developing a machine learning model to identify patterns in the compound descriptors 
The first element characterises a chemical compound using properties called descriptors (23). 
Descriptors can be described through their dimensionality from one dimensional (1D) through 
to three dimensional (3D) (36, 40, 41). 1D descriptors describe the physicochemical 
properties of a molecular structure such as molecular weight, polarity, and molar refractivity 
(36, 40, 41). The 1D descriptors are easy to interpret but using only one type of 1D descriptor 
to characterise set of compounds does not offer sufficient discriminating power (36, 40, 41). 
Therefore, it is usually used in combinations with other 1D descriptors (36, 40, 41). 2D 
descriptors encode molecular connectivity, which can be described as topological indices and 
fingerprints (36, 40, 41). The topological indices are integers calculated from the 2D-graph 
representation of a compound (36, 40, 41). Fingerprints are encoded as bit strings, which the 
descriptors predefine the presence (1) or absence (0) of fragments or substructures in a 
particular chemical structure (36, 40, 41). 3D descriptors describe the shape of the chemical 
compound such as pharmacophore-type representation (36, 40). The 3D descriptors may be 
able to provide information on the binding properties of the compounds (36, 40). However, 
calculating 3D descriptors could require large computational time for a large set of 
compounds (36, 40). The descriptors are used to identify similarities between molecules. The 
similarity measure between two compounds, using a pair of bitstring, is usually computed 
using Tanimoto coefficient (Tc) or Jaccard Index. The Tc can be explained from the equation 
below: 
𝑇𝑐 =
𝑐
𝑎 + 𝑏 − 𝑐
 
(Equation 1.1) 
a is number of features present in compound A, b is number of features present in compound 
B and c is number of features present both in compound A and B. The Tc value is between 0 
and 1 with value closer to 1 shows higher similarity between the two compounds. Altogether, 
the first part describes the ligand space. 
The second element is mapping the features of the first component to an output 
property. This is done by building a chemogenomic database or ligand-bioactivity space from 
selected bioactivity databases (42). The bioactivity data is divided into ‘training set’ and ‘test 
set’ (42). In general, the ‘training set’ contains experimental results of x compounds acting on 
y targets, which are then ‘trained’ using an appropriate algorithm (23). The algorithm, such as 
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Naïve Bayes classifier, Random Forest and Support Vector Machine, will represent the 
training set in a form of classification model, for the machine to learn, which eventually 
enables target prediction of novel a compound (23, 36). The details of the algorithms will be 
explained in Chapter 2 (Naïve Bayes classifier) and Chapter 3 and 4 (Random Forest) as two 
different versions of in silico target prediction were used. Targets are predicted based on the 
similarity of the compounds in the training set to modulate the same targets (23). The 
performance of the model is validated by correctly predicting the targets of a ‘test set’, which 
is also known as internal set validation or the targets of a different bioactivity database, which 
is also known as external set validation (42). Therefore, by manipulating a large bioactivity 
data, in silico target prediction is perceived as one of the possible methods to potentially 
predict targets of TM compounds to eventually suggest their MOAs. The applications of in 
silico target prediction have been reported in the literature using different chemical 
fingerprint, different training sets of data and different classification algorithms, which will be 
further discussed next. 
 
Figure 1.1: Workflow of in silico target prediction tool using chemogenomic approach. A set 
of bioactivity compounds is compiled to build the chemogenomic database. An appropriate 
algorithm is used to learn the classification of the chemogenomic database. Then, using a 
novel compound as enquiry, the target(s) of a novel compound is predicted by comparing the 
similarity of the novel compound to the compounds in the chemogenomic database to produce 
a list of putative targets. 
 
1.4.2 Applications of in silico target prediction 
One of the earliest studies published on target prediction is the Prediction of 
Bioactivity Spectra for Substances (PASS) method (43). The model was developed using 
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structure-activity relationships for over 300,000 biologically active organic compounds 
representing for more than 4,000 types of biological activity collected from databases and 
literature. The structures were characterised by a set of descriptors of multilevel 
neighbourhood atom (MNA) and the prediction was based on Bayes estimates. The model’s 
performance showed it achieved average accuracy above 95% in the leave-one-out cross 
validation approach.  
Nidhi et al. used a large chemogenomic dataset to develop the in silico target 
prediction (44). In this work, ligand-target pairs from the WOrld of Molecular BioAcTivity 
(WOMBAT) database were extracted and the compounds were encoded using Extended-
Connectivity Fingerprint (ECFP). A multiple-category Laplacian naïve-Bayes algorithm was 
trained on the model consisted of 964 target classes. The model was employed to predict the 
top three most likely targets for all compounds from a different database, the MDL Drug 
Database Report (MDDR). The results showed that, on average for ten MDDR activity 
classes with known targets, the top three targets were predicted correctly for 77% of the 
compounds. 
In the Similarity Ensemble Approach (SEA), the target prediction was developed by 
grouping and relating the protein targets based on chemical similarity among their ligands, 
which were quantitatively measured using an algorithm adapted from BLAST (45). The 
model contained over 65,000 ligands and 246 targets of MDDR. The study discovered that the 
chemical structure of methadone, loparamide and emitidine showed close structural similarity 
to ligands for the muscarinic M3, α2 adrenergic and neurokinin NK2 receptors as their off-
targets. The experimental validations indicated the binding affinities of the drugs to 
antagonise the targets were in micro molar ranges. 
In contrast to different types of bioactivity classes, Mestres et al. conducted a study 
that focused on one class of target protein, nuclear human receptor, (NHR) (46). The model 
consisted of 2,033 molecules and 25 nuclear receptors extracted from literature. The 
molecules were characterised using Shannon Entropy descriptors (SHED), which described 
the topology of molecules by mapping the distributions of atom-cantered feature pairs. A 
nuclear receptor network derived from a matrix of minimum Euclidean distance of SHED 
profiles. The profiling of the nuclear receptors was tested against four external focused 
libraries of proteases, kinases, ion channel and GPCR, and 2,944 NHR drugs. The results 
showed that between 4.4% and 9.7% of the focused libraries and 5.2% of the drugs having 
affinities to binding NHR. Thus, this method does not only identify putative targets but also 
potential off-targets. 
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In regard to traditional medicine, the application of in silico target prediction was 
reported for TCM and Ayurveda compounds. Mohd Fauzi et al. employed a predictive model 
that was generated from ChEMBL bioactivity database version 10.0, which consisted of 
155,208 molecules across 894 targets (47). A Naïve Bayes classifier was utilised to train the 
model and the compounds were characterised based on ECFP_4 (48) with a diameter of four 
bonds. The model was validated using five-fold cross validation and achieved a recall of 68%. 
TCM compounds of ‘tonifying and replenishing’ medicinal class were successfully connected 
to their relevant targets that were associated to hypoglycaemic effect and Ayurveda cancer 
compounds were predicted to modulate primary anti-cancer targets. Both predictions were 
validated by literature. Given the previous studies, in silico target prediction can be extended 
to predict targets of traditional medicine by linking to their ethnomedicinal uses (Figure 1.2). 
 
 
Figure 1.2: Visualization of the link between a compound, target, and an indication. The 
compound’s mode-of-action can be elucidated from the targets predicted using an in silico 
target prediction method, which can be rationalised by the reported usage of the medicinal 
plant for treating an illness. The three elements are strongly interconnected with each other.  
 
1.4.3 Other methods of in silico target prediction 
In silico target prediction based on machine learning methods are not the only available tool. 
Various methods are available for in silico target prediction such as protein/ligand panel 
docking, chemical similarity searching and the analysis of “bioactivity spectra” (49). Protein 
panel docking is one of the earliest tools that has been widely used in traditional medicine, 
where a compound is docked to a wide panel of potential proteins and the proteins are 
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subsequently ranked based on calculated binding affinity scores (50). Chen et al., used 
INVDOCK, a ligand binding inverse docking strategy, against nine TCM compounds, 
genistein, ginsenoside Rg1, quercetin, acronycine, baicalin, emodin, allicin, cathecin and 
camptothecin (50). The study discovered that over 50% of the predicted targets had relevant 
literature support to suggest the compounds’ MOAs.  In a different study, where the in silico 
target prediction was further validated experimentally, Zhang et al. identified putative targets 
of 19 compounds isolated from two medicinal plants in TCM, which were used for the 
treatment of diabetes and inflammation using a reverse docking approach, TarFisDock (51). 
The natural products showed moderate inhibitory activities against the most frequent target 
candidate, dipeptidyl peptidase IV (DPP-IV) with IC50 values ranging from 14.14μM to 
113.76μM in an in vitro enzyme assay (51). Although this protein panel docking method 
requires only the chemical structures of the putative active ingredients, it is limited to high 
quality protein structures and the accuracy of the docking programs used (52).  
Chemical similarity searching is based on the “Molecular Similarity Principle” (41, 
49). In this method, the query compound is compared to a database of compounds with 
known targets and the compounds are represented as chemical fingerprints which the 
similarity between the two compounds is measured (52).  In a study by Cleves et al., (53), out 
of 1000 drugs, 700 drugs modulate approximately 85 biological targets from three different 
analysis; drug and target similarities, ligand-based virtual screening and selectivity of ligand-
based models. When the results were compared, the “chemical similarity” principle 
performed well when drug pairs sharing a target had higher similarity. Although this method 
does not require a training set, it does not prioritise which target is important for the query 
compound and prior knowledge of target class information is ignored (52). 
A method based on bioactivity spectra uses information from the response to a 
compound across a series of biological readouts such as cell lines, targets or genes expression 
profiles, which creates biological activity spectra (49). As bioactivity spectra are related to the 
compound’s structure, it can also be viewed as molecular descriptors and used for target 
prediction (52). For example, Chen et al., developed bioactivity profile similarity search 
(BASS) using 4,296 compounds that were tested against the NCI-60 cell lines (54). The 
annotated targets for all the compounds were extracted from public databases. Potential 
targets of a query compound were calculated based on bioactivity profile similarity between 
the query compound and all reference compounds in the database. The model demonstrated 
44.8% successful predictions from 237 query compounds with known target annotations. 
Although, this method could select a set of compounds with relevant bioactivity data, it 
requires the initial collection of experimental data across many targets, which can be difficult 
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to obtain (52). Given these points, ligand-based in silico target prediction could at least 
overcome some of these limitations by having a larger bioactivity space and statistically 
prioritised predicted targets.  
 
1.5 Systems biology to elucidate mode-of-action 
While target identification continues to be important to elucidate compounds’ MOA, the 
targets by themselves do not represent the complete mechanism of the MOA. Biologically, a 
measure of a compound’s response comes from systems biology (cells, tissues, animals) 
suggesting the target is not acting alone but interacting with neighbouring proteins (55, 56). 
The chain of interactions forms a dynamic biological network to produce phenotypic response 
(55, 56). The chain of interactions, which can be defined as a pathway, is the collection of 
proteins acting in collaboration that is part of a particular function or process (57). Multiple 
pathways of shared targets and proteins can be embedded into a biological network to provide 
a more comprehensive view of how systems biology functions to better understand the 
compound’s MOA (55, 56). However, analysing pathway in isolation from the network has 
also been done, in some cases, as pathway annotations are able to describe the compound’s 
MOA (57). The motive to include systems biology in drug discovery derives from a growing 
understanding of the physiology of a disease (58). The manifestation of a disease involves 
multiple interactions between targets of various pathways in a biological network (58). 
Therefore, by capturing beyond target space, the strategy is seen to be able to elucidate the 
MOA of a compound from the pathogenesis of a disease. In comparison, this concept aligns 
closely to the holistic approach of traditional medicine that aims to restore a healthy state of a 
patient with localising symptoms rather than to treat the source of the illness. 
Efforts have been seen in in silico drug discovery to include systems biology. One of 
the continuous efforts is the emergence of public databases of molecular interactions. At 
target level, several databases of interacting proteins have been compiled. The protein-protein 
interactions (PPI) databases are regularly collected from literature curation and high-
throughput protein interaction assays and in some cases, the databases include predicted 
interactions as well (59, 60). These PPIs are also put into biological contexts by creating 
pathway databases, which can have different emphasis and coverage (57, 60). Table 1.6 and 
Table 1.7 list the statistics/properties of the publicly available PPI and pathway databases. 
Consequently, the information stored in both types of databases can be combined to 
understand how the organisation at the molecular level contributes to cellular and organism 
phenotypes. 
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Table 1.6: The statistics of protein interactions (Homo sapiens only) databases. 
Acronym Database full name Proteins 
(as of Jan 
2017) 
Interactions 
(as of Jan 
2017) 
Publications 
(as of Jan 
2017) 
Ref. 
IntAct IntAct Molecular 
Interaction Database 
46,895 208,595 7,182 (61) 
HPRD Human Protein 
Reference Database 
30,047 41,327 453,521 (62) 
BioGRID Biological General 
Repository for 
Interaction Datasets 
20,931 278,358 25,759 (63) 
MINT Molecular Interaction 
Database 
10,807 61,143 8,644 (64) 
 
Table 1.7: The properties of pathway databases. 
Acronym Database full name Coverage Interactions 
(as of Jan 
2017) 
Ref. 
KEGG 
Pathway 
Kyoto 
Encyclopaedia Gene 
and Genome 
Pathway 
Represents collections of 
manually drawn pathway map 
of metabolism, genetic 
information processing, 
cellular processes, organismal 
systems, human disease, and 
drug development. 
(http://www.genome.jp/kegg/
pathway.html) 
481,160 (65) 
Signalink2.0 Signalling pathway 
resource with multi-
layered regulatory 
networks 
Includes signalling pathway 
cross-talks, transcription 
factors, miRNAs and 
regulatory enzymes. 
(http://signalink.org/) 
275,359 
(only for 
Homo 
sapiens) 
(66) 
Reactome Reactome Pathway 
Database 
Includes core human 
pathways such as DNA 
replication, transcription, 
translation, cell cycle, 
metabolism, and signalling 
cascades. 
(http://www.reactome.org/) 
209,988 (67) 
 
A few examples are discussed here to illustrate the inclusion of pathways to understand 
compound’s MOA. For instance, a study by Liggi et al., demonstrated that enriched KEGG 
pathways such as “axon guidance” and “endocytosis” of predicted targets could be linked to 
the frequently observed phenotype, pigmentation, of Xenopus laevis that were previously 
treated with the NCI Diversity Set II compounds (68). The functions of the targets and 
pathways to pigmentation were validated by literature (68). Relating to traditional medicine, 
Liu et al., generated a compound-target network of nine compounds that were identified to be 
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abundance in Reduning Injection TCM formulation used in combatting inflammation (69). 
Inflammation-related pathways were first extracted from literature, which also identified a 
few of major drug targets. The compound was connected to the drug targets if they were 
predicted targets of the compounds. Related targets, such as mitogen–activated protein 
kinases (MAPK1 and MAPK14), were identified from the network topology. Experimental 
results showed that the TCM formulation modulated the MAPK pathway to exert its anti-
inflammatory effects. Therefore, by annotating pathways of the targets, the MOA of 
compounds could be understood better for the reported indications. 
Because systems biology is more than discrete PPIs and pathways, thus, creating a 
biological network using either of both components could provide a more comprehensive 
insight of the compound’s MOA. Depending on a research question and available data, a 
biological network is regularly modelled using two different approaches (70). 
1. Top-down or data-base approach 
2. Bottom-up or knowledge-base approach 
In a top-down approach, experimental data is extracted to infer a biological network. Various 
methods can be employed to build the network namely statistical (correlation and regression) 
and probabilistic methods (Bayesian, logic models, and ordinary differential equations), in 
which the gene expression data can be either static or time-course (70). As a result, the 
approach attempts to correlate the molecule’s behaviour and underlying interactions in the 
genome-wide studies (71). For instance, Liu et al., applied correlation statistical method by 
generating a network using weighted gene co-expression network analysis (WGCNA) from 
gene expression samples of breast cancer patients who received Tamoxifen treatment. The 
aim was to identify the biomarkers in order to understand the underlying mechanism for 
Tamoxifen resistance (72). The analysis used unsupervised clustering to identify functional 
modules and significant genes, which were validated using independent samples of breast 
cancer survivors treated with Tamoxifen (72). The results indicated five hub genes (CDK1, 
DLGAP5, MELK, NUSAP1, and RRM2) were strongly related to poor survival (72). 
Therefore, the top-down approach could facilitate the causal relationship between phenotype 
and a drug. 
Contrary to the top-down approach, the bottom-up approach starts with single 
components or the proteins of interest as the building blocks of the network in order to 
simulate the dynamic properties of the resulting system (70). The physical interactions 
between these proteins could be retrieved from PPI or pathway databases, which eventually 
the interactions are combined to build a biological network (70). The outcome of this method 
maps all possible connections between proteins in the network because the overlapping 
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information between the databases is usually small (59, 60). To illustrate this approach, Zhu 
et al., used differentially expressed genes measured between non-failing heart and ischemic 
dilated cardiomyopathy (ICM) patients, in addition to validated cardiac myocyte proteins to 
build a representative network of dilated cardiomyopathy (73). The PPI were retrieved from 
DIP, BIND, Prolinks, KEGG and HPRD (73). The network was divided into four layers; 
extracellular, plasma membrane, cytoplasm and nuclease, which Gene Ontology (GO) 
analysis showed the over-represented biological processes were in the cytoplasm and nuclease 
layer (73). Network analysis revealed that the Janus family tyrosine kinase-signal transducer 
and activator of transcription (Jak-STAT) signalling pathway might play an important role in 
the development of ICM (73). Subsequently, treating related drugs in in vitro experiments 
could validate the biological processes discovered. Together, the applications discussed of 
systems biology are observed to prospectively fill the gap between chemistry and biology, 
thus potentially helping the drug discovery process in the future. 
 
1.6 Limitations of in silico mode-of-action methods 
Despite the applications of in silico target prediction able to elucidate the MOA, there are 
several limitations. First, the “Molecular Similarity Principle” is not always true. There are 
cases where molecules that are similar in structure but exhibit very different activities, which 
is known as the “activity cliff” (74). For example, a change in one functional group might 
prevent a compound from binding to the same target. To confirm the predicted target is 
modulated by the compound, a molecular docking method is proposed in order to learn about 
the molecular interactions between the compound and predicted target. Second, the data in the 
training set contains inconsistent results. The inconsistent results may be due to different 
experimental design and interpretation, such as insufficient description of assays, making it 
difficult to compare two similar assays from different experiments (75). This can be 
minimised by selecting bioactivity data based on several confidence criteria. Third, the 
predictions are still limited to the target space in the training set. Hence the model usually 
covers a fraction of proteins in the human genome. However, as more bioactivity data 
becomes available, the size of target space can be further expanded. Fourth, the algorithm is 
unable to report whether a novel compound either activates or inhibits the predicted targets, as 
this can be experimentally influenced by ADMET (Absorption, Distribution, Metabolism, 
Excretion and Toxicity) properties (68). Therefore, only a general justification could be 
established between the predicted targets/pathways and the phenotypic response. Finally, 
relating to the PPI and pathway databases, despite the large size of most databases, their 
curation is error-prone and the protein interactions coverage is still incomplete as many parts 
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of the systems biology have yet to be studied (57). Hence, these limitations remain to 
potentially affect the analysis of in silico MOA’s results. 
 
1.7 Structure of this thesis 
Given that, traditional medicines are known for the observed efficacies, the applicability of in 
silico target prediction in elucidating the MOA of the compounds, of one or different types of 
traditional medicine, is explored. The work is presented in self-contained chapters. Chapter 2 
discusses the mechanistic relationship between 46 TCM therapeutic action subclasses that 
each subclass describes a distinct healing property. In the subsequent chapter, Chapter 3, the 
work compares both chemical space and bioactivity space of three different traditional 
medicines, namely TCM, Ayurveda, and Malay traditional medicine (Malay TM) for treating 
cancers. The final work, Chapter 4, evaluates synergy of two compound combinations from a 
TCM formulation, Shexiang Baoxin Pill (SBP), by mapping the compounds predicted targets 
onto a representative biological network. The formulation is widely known for treating 
coronary heart disease. Finally, Chapter 5 discusses the results and conclusions from previous 
chapters. 
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Chapter 2:  
Global Mapping of Traditional Chinese Medicine onto Bioactivity Space and Pathway 
Annotation Improves Mechanistic Understanding and Discovers Relationships Between 
Therapeutic Action (Sub-)Classes 
 
 
2.1 Introduction 
Traditional Chinese medicine (TCM) has been practiced for thousands of years for the 
prevention and treatment of diseases using a unique system of theory, diagnosis and treatment 
(76, 77). The philosophical background of TCM is based on Yin and Yang, as well as the Five 
Elements (agents) theories (Figure 2.1). The Yin and Yang are the harmony of two opposite 
energies and the Five Elements describe the five interdependent functional organs; heart, 
liver, spleen, lung and kidney with its own Yin and Yang (78, 79). When a human body 
suffers from a disease, the dynamic balance and the relationship of the five elements are 
disturbed. Hence, to rectify the disturbance, TCM applies a holistic approach with the key 
therapeutic principles being “Zheng” (meaning syndrome or pathological patterns seen in 
patients) and “Fufang” or “Fang Ji”, (meaning compound formulations consisting of materia 
medica) (80-86). Note that a TCM Fufang are primarily based on medicinal plants, but may 
also contain fungi (e.g. Ganoderma lucidum), mineral (realgar), and occasionally animal 
products (e.g. Calculus bovis). Chinese medicines can be organised into several classifications 
such as therapeutic actions, source of the medicine and internal organs (87). In this study, the 
classification of the Chinese medicines follows the therapeutic actions, of which some also 
possess sub-classifications based on clinical applications recorded by TCM monographs (88). 
A combination of two or more Chinese medicine categories make up a treatment formulation, 
which then contains a considerable number of chemical compounds (89).  
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Figure 2.1: The philosophy of TCM defines yin and yang as opposite energies that 
complement the natural world. Water, earth, metal, wood and fire are the five elements that 
organise all natural phenomena into five patterns. Each element has its own organs of yin and 
yang characteristics. Each element can either nourish or restrain one another to keep a 
dynamic balance among the elements. TCM compounds of materia medica are used to correct 
the imbalance of yin and yang in the human body. 
 
The mixture of compounds in the formula works through the therapeutic principle 
Jun-Chen-Zuo-Shi, by maximizing the therapeutic effects and minimizing the side effects (76, 
90, 91). Based on the healing/pharmacological properties and constituents of each medicine, 
the Jun (emperor) component is the principal compound in the mixture targeting the major 
symptom of the disease. There are only a few varieties of Jun medicines that are administered 
as a single formula, usually in large doses. The Chen (minister) components synergise with 
Jun to strengthen its therapeutic effects, and may also treat secondary symptoms. The Zuo 
(assistant) medicine reduces or eliminates possible adverse or toxic effects of the Jun and/or 
Chen components, while also enhancing their effects and sometimes treating secondary 
symptoms. Finally, the Shi (courier) components facilitate delivery of the principal 
components to the lesion sites, or facilitate the overall action of the other components (92, 93). 
Therefore, at the molecular level, a TCM formula, which is a multi-component and multi-
target agent, is assumed to modulate a series of protein targets in an integrative manner to 
harmonise the body system (94). In brief, TCM is a well-structured system from diagnosis to 
healing, whose theories and medicines are rationally connected and interdependent.  
TCM contains a plethora of compounds, which originate from the biodiversity of 
natural product medicines, which is a rich resource for discovering new TCM-based drugs. 
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However, to develop a novel TCM-based drug still remains challenging. One of the factors 
that contribute to making it a challenge is an undefined medicine concoction. The 
characterisation of the complex formulation by using methods to isolate the compounds is an 
exhaustive task that is very time consuming (95, 96). Although many compounds have been 
isolated from Chinese herbs (97, 98), their MOAs, in many cases, are still not yet understood 
at the molecular level (96). Another challenging issue in TCM is measuring the efficacy, 
pharmacokinetic-pharmacodynamic profiles and dose-efficacy relationship of multiple 
compounds simultaneously, both in vitro and in vivo (95, 96, 99). However, as shown in this 
work, particularly related to MOAs, it is now possible to suggest the MOA of TCM 
compounds using in silico target prediction. For example, Zehler et al, applied inverse 
screening method for three indirubin (TCM active principle in against chronic myelogenous 
leukaemia) derivatives, 5-bromo-indirubin-3′oxime (5BIO), 6-bromo-indirubin-3′oxime 
(6BIO) and 7-bromo-indirubin- 3′oxime (7BIO) in order to identify their potential kinase 
targets (100). The predicted target phosphoinositide-dependent kinase 1 (PDK1) was 
functionally supported by an in vitro kinase assay, which showed inhibition activity of 6BIO 
at 1.5 μM (100). 
The motivation of the current study is prompted by the success to link TCM and 
Ayurveda compounds to the predicted targets that were relevant for the indications of various 
therapeutic action classes in TCM and cancer in Ayurveda (47). The aim of the study was to 
extend the analysis of the targets prediction compounds of TCM therapeutic action classes 
including their subclasses by first generating a hierarchical clustering. The first part of the 
study was to understand the MOAs of the subclasses from the predicted targets as well as 
from annotated KEGG pathways because a target alone is insufficient to provide a full 
biological profile towards the effect of the ligand on a biological system (65, 101). In the 
second part, bioactivity spaces of all therapeutic action (sub-)classes were compared in order 
to understand relationships between the clusters. Hence, the global mapping of TCM 
compounds explored in this work, based on the therapeutic action (sub-)classes, does not only 
provide the better insight of the MOAs of the TCM compounds but also describes for the first 
time the relationship between the therapeutic action (sub-)classes.  
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2.2 Materials and methods 
2.2.1 Dataset and dataset preparation 
TCM compounds were obtained from TCM Database@Taiwan (88) in structure-data (SD) 
format. A total of 13,091 compounds from 46 different therapeutic action (sub-)classes were 
imported into MOE (102). To prepare structures for further analysis, covalently bound Group 
I metals were disconnected into ionic representation, while keeping only the largest molecular 
fragments, neutralising the compound by removing salts and adjusting the hydrogens and 
partial charges using MMFF94 (modified) partial charges. The duplicates from each 
therapeutic action (sub-)class were removed, resulting in a total number of 10,749 distinct 
compounds. The list of classes with the final number of compounds for each (sub-)class is 
provided in Table 2.1. 
Table 2.1: The list of therapeutic action classes, subclasses and their number of respective 
Chinese medicine and compounds. A total 10,749 compounds from 46 therapeutic action 
subclasses were included in the analysis presented in this work.  
Chinese medicine 
Class 
Chinese medicine 
Subclass 
Chinese medicine (sub-
)class (Chinese Names) 
Abb. NoH NoC 
Exterior releasing 
Wind cold dispersing 
Sàn hán jiě biǎo yào 
 (散寒解表药) 
ER - wind 
cold 
21 538 
Wind heat dispersing 
Qīng rè jiě biǎo yào 
(清热解表药) 
ER -wind 
heat 
22 413 
Heat clearing 
medicinal 
Heat clearing and blood 
cooling 
Liáng xuè huó xuè yào 
(凉血活血药) 
HC - blood 
cool 
14 99 
Heat clearing and 
dampness drying 
Qīng rè lì shī yào 
(清热利湿药) 
HC - damp  11 264 
Deficiency 
Qīng xū rè yào  
(清虚热药) 
HC - def 10 186 
Heat clearing and 
detoxicating 
Qīng rè jiě dú yào 
(清热解毒药) 
HC - detox 54 1029 
Heat clearing and fire 
purging 
Qīng rè xiè huǒ yào 
(清热泻火药) 
HC - fire 
purge 
18 234 
Purgative medicinal 
Laxative medicinal 
Rùn xià yào  
(润下药) 
Purg - lax 3 27 
Offensive purgative 
Gōng xià yào  
(攻下药) 
Purg - off 6 54 
Drastic (purgative) 
water-expelling 
Jùn xià zhú shuǐ yào 
(峻下逐水药) 
Purg - water 
expel 
14 206 
Dampness resolving Water draining and anti-
icteric 
Lì shī tuì huáng yào 
(利湿退黄药) 
Damp - 
antiicteric 
6 189 
Water draining and 
strangury resolving 
Lì niào tōng lín yào 
(利尿通淋药) 
Damp - 
stran 
15 133 
Water draining and 
swelling dispersing 
Lì shuǐ xiāo zhǒng yào 
(利水消肿药) 
Damp - 
swell 
13 265 
Qi regulating 
 
Lǐ qì yào  
(理气药) 
Qi 36 699 
Digestant medicinal 
 
Xiāo shí yào  
(消食药) 
Digest 8 146 
Hemostatic medicinal 
Astringent hemostatic 
Shōu liǎn zhǐ xiě yào 
(收敛止血药) 
Hemo - 
astringent 
5 92 
Blood cooling Liáng xuè zhǐ xiě yào Hemo - 13 198 
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hemostatic (凉血止血药) blood cool 
Meridian warming 
hemostatic 
Wēn jīng zhǐ xuè yào 
(温经止血药) 
Hemo - 
meridian 
2 146 
Stasis-resolving 
hemostatic 
Huà yū zhǐ xiě yào 
(化瘀止血药) 
Hemo - 
stasis 
6 245 
Blood activating and 
stasis resolving 
Blood activating 
analgesic 
Huó xuè zhǐ tòng yào 
(活血止痛药) 
BASR - 
analgesic 
7 487 
Blood breaking mass 
eliminating 
Pò xiě xiāo zhēng yào 
(破血消癥药) 
BASR - 
break 
9 177 
Blood activating 
menstruation resolving 
Huó xuè tiáo jīng yào 
(活血调经药) 
BASR - 
menstrual 
15 457 
Blood activating trauma 
curing 
Huó xuè liáo shāng yào 
(活血疗伤药) 
BASR - 
trauma 
12 261 
Cough suppressing 
and panting-calming 
Clearing and Heat 
phlegm resolving 
Qīng huà rè tán yào 
(清化热痰药) 
CSPC - heat  30 237 
Cold phlegm resolving 
and warming 
Wēn huà hán tán yào 
(温化寒痰药) 
CSPC - cold 19 147 
Cough suppressing and 
panting calming 
Zhǐ ké píng chuǎn yào 
(止咳平喘药) 
CSPC - 
panting 
16 334 
Tranquilizing Heat nourishing 
tranquilizing 
Yǎng xīn ān shén yào 
(养心安神药) 
Tranquil - 
heat 
1 145 
Settling tranquilizing 
Zhòng zhèn ān shén yào 
(重镇安神药) 
Tranquil - 
settle 
6 1 
Orifice opening 
 
Kāi qiào yào  
(开窍药) 
Orifice 7 68 
Liver-pacifying and 
wind extinguishing 
Extinguish wind to 
resolve convulsion 
Xí fēng zhǐ jìng yào 
(息风止痉药) 
LPWE - 
convulsion 
8 85 
Liver yang calming 
Píng yì gān yáng yào 
(平抑肝阳药) 
LPWE - 
liver 
7 22 
Tonifying and 
replenishing Blood tonifying 
Bǔ xiě yào  
(补血药) 
TR - blood 7 388 
Qi tonifying 
Bǔ qì yào  
(补气药) 
TR - qi 15 474 
Yang tonifying 
Bǔ yáng yào  
(补阳药) 
TR - yang 23 559 
Yin tonifying 
Bǔ yīn yào  
(补阴药) 
TR - yin 17 259 
Astringent 
Anhidrotic 
Gù biǎo zhǐ hàn yào 
(固表止汗药) 
Ast - 
anhidro 
3 17 
Lung-intestine 
astringent 
Liǎn fèi sè cháng yào 
(敛肺涩肠药) 
Ast - lung 8 145 
Secure essence, reduce 
urination, and check 
vaginal discharge 
Gù jīng suō niào zhǐ dài yào  
(固精缩尿止带药) 
Ast - secure 6 125 
Wind-dampness 
dispelling 
Bone(sinew) 
strengthening 
Qū fēng shī qiáng jīn gǔ yào 
(祛风湿强筋骨药) 
WD - bone 5 44 
Heat clearing 
Qū fēng shī rè yào 
(祛风湿热药) 
WD - heat 8 175 
Cold dispersing 
Qū fēng hán shī yào 
(祛风寒湿药) 
WD - cold 13 309 
Interior warming 
 
Wēn lǐ yào  
(温里药) 
Warm 13 457 
Worm expelling 
medicinal  
Qū chóng yào  
(驱虫药) 
Worm 9 93 
Emetic medicinal 
 
Yǒng tǔ yào  
(涌吐药) 
Emetic 3 9 
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Parasite destroying, 
dampness eliminating 
and itchiness relieving 
 
Gōng dú shā chóng zhǐ yǎng 
yào (攻毒杀虫止痒药) 
Parasite 8 81 
Anti-malarial 
medicinal  
Kàng nüè yào  
(抗疟药) 
Malarial 4 30 
      Total compounds 10,749 
Abb. = Abbreviation 
NoH = Number of Chinese medicine 
NoC = Number of compounds 
2.2.2 Target prediction 
The processed molecular data was then subjected to a target prediction that was modelled 
using the Laplacian-modified Naive Bayes classifier, which detail of the target prediction 
algorithm can be found in (103). Briefly, this model contained 189,147 ligand-protein pairs 
extracted from ChEMBL v.14.0 (28) across 477 human targets which was used as the training 
set. The training set contained active compounds with reported activities (Ki/Kd/IC50/EC50) of 
at least 10 μM with a confidence score of 8 or 9 and at least 20 compounds were available to 
associate the chemical features with a target class. 
The molecular descriptors of the compounds were represented by Molprint2D circular 
fingerprints (104). In Molprint2D circular fingerprints (Figure 2.2), the atom environments of 
a molecule are directly calculated from molecular connectivity table, which can be described 
in two steps. First, a Sybyl atom type is assigned to each heavy atom of a molecule after 
removing the explicit hydrogen. Second, the individual atom fingerprint is calculated for 
every heavy atom by constructing a count vector that describes the neighbouring atoms from 
zero distance up to two bonds from the central atom. This second process creates features of 
atom environments, which are stored as a binary fingerprint of absence or presence of a 
feature. The second process is repeated for all assigned Sybyl atoms. 
 
 
Figure 2.2: The figure illustrates an example of how a Molprint2D fingerprint is generated 
for an aromatic carbon, <0>, of a molecule. After assigning Sybyl atom type for each heavy 
atom of a molecule, the atom environment of the heavy atom is generated by describing its 
neighbouring atoms up two bonds (layers).  
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The targets predicted for the new compound uses the Naïve Bayes classifier as a method for 
classification as follows (105). 
𝑃(𝜔𝛼|𝜘) =
𝑃(𝜘|𝜔𝛼)𝑃(𝜔𝛼)
𝑃(𝜘)
   
(Equation 2.1) 
Here, the probability of a new compound belonging to a target class, 𝜔𝛼, with a given vector 
molecular feature, 𝜘, is calculated. The prior target class probability, 𝑃(𝜔𝛼) is assumed to be 
equivalent to proportion of the molecules, 𝑁𝜔, modulate that class from the total number of 
molecules, 𝑁, in the training set. 
𝑃(𝐶 = 𝜔) =
𝑁𝜔𝛼
𝑁
 
(Equation 2.2) 
The denominator, 𝑃(𝜘) calculates the sum of the fraction of molecules from each class from 
𝛽 = 1 to 𝐿 in the training set multiplied by the probability of the vector of molecular feature 
given the target class.  
∑
𝑁𝜔𝛽
𝑁
𝑃(𝜘|𝜔𝛽 
𝐿
𝛽=1
) 
(Equation 2.3) 
The posterior probability, 𝑃(𝜘|𝜔𝛼) is the likelihood of the feature, 𝜘, given the class, 𝜔𝛼. 
The internal validation of the in silico target prediction was measured using 5-fold 
cross validation with a recall of correct targets that was larger than 80% in the top 1% of 
predictions. In the external validation, the algorithm showed a recall of 63.6% in the top 1% 
of predictions using dataset extracted from WOrld of Molecular BioAcTivity version 2011.1 
(WOMBAT) (106). Only target scores above a confidence score, which are defined 
individually for each target class, were taken as the output. The confidence scores for each 
class was calculated by the optimal balanced accuracy (precision and recall trade-off) on a per 
target class basis, and were used to retain protein targets likely to interact with the compounds 
in the dataset (107). 
 
2.2.3 Pathway annotation 
Each predicted target was annotated with its full set of pathways from the KEGG biological 
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pathways (release 58.1) (108). It was possible to annotate 405 out of 477 targets with KEGG 
biological pathways (68, 109). 
 
2.2.4 Enrichment calculations 
To normalise the classification results from target prediction/pathway annotation, enrichment 
calculations were performed by normalising frequencies of the target prediction/pathway 
annotation of each therapeutic action subclass of compound to a background of 10,000 
compounds that were selected randomly from PubChem (110) and ZINC (111), which 
consists of 194,849 compounds in total. Two methods were used to perform the enrichment 
calculation in this step, namely Estimation Score and Average Ratio. The calculation of the 
scores was performed as follows (68, 109). 
1. Estimation Score 
The Estimation Score is based on the frequency of the number of predicted targets/pathways 
in the random dataset, which is larger or equals the frequency of the number of predicted 
target/pathways in the test dataset. The absolute frequency, C, was divided by the total 
number of the random dataset, giving a value between 0 (enriched) and 1 (random). 
𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑖𝑜𝑛 𝑆𝑐𝑜𝑟𝑒 =
𝐶
1000
 
(Equation 2.4) 
2. Average Ratio 
The Average Ratio is calculated by the ratio of the frequency (F) of the predicted 
target/annotated pathway in each random dataset with the frequency (F) of predicted targets 
in the test dataset. 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑎𝑡𝑖𝑜 =  
𝐹(𝑟𝑎𝑛𝑑𝑜𝑚 𝑠𝑒𝑡1)
𝐹(𝑡𝑒𝑠𝑡 𝑠𝑒𝑡)
+
𝐹(𝑟𝑎𝑛𝑑𝑜𝑚 𝑠𝑒𝑡2)
𝐹(𝑡𝑒𝑠𝑡 𝑠𝑒𝑡)
+ ⋯ +
𝐹(𝑟𝑎𝑛𝑑𝑜𝑚 𝑠𝑒𝑡10000)
𝐹(𝑡𝑒𝑠𝑡 𝑠𝑒𝑡)
10000
 
(Equation 2.5) 
In this study, enriched targets/pathways were considered if they showed an Estimation 
Score ≤ 0.01, and descending Average Ratio was used to further discriminate important 
targets in agreement with previous work by Liggi et al. (68, 109). The relative cut-off of both 
Target Frequency (TF)/Pathway Frequency (PF) that was ≥ 5% of the highest predicted 
target/pathway frequency was used after ranking the targets using the Estimation Score and 
Average Ratio methods to determine which targets were considered to be enriched in a 
particular therapeutic action (sub-)classes. 
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2.2.5 Hierarchical clustering based on the bioactivity space of the therapeutic action 
(sub-)classes 
The frequencies of compounds across 477 targets for each therapeutic action (sub-)class were 
subjected to agglomerative hierarchical clustering (112, 113). The clustering method involved 
two steps as follows:  
1) Selecting measures of dissimilarity or similarity 
The dissimilarity distance between two therapeutic action (sub-)classes was calculated 
using the “dist” function of the ‘Euclidean’ method in R (114) after scaling the 
frequencies.  
2) Clustering 
Clustering was performed using the “hclust” function in R (114) based on the previously 
calculated Euclidean distance and Ward’s clustering method (115). In this method two 
clusters were merged if the sum of squared Euclidean distance was minimal.  
A cut-off dissimilarity distance of approximately 20 was applied in order to obtain a 
manageable number of clusters, defining 14 groups of therapeutic action (sub-) classes, 
namely cluster I to XIV.  
 
2.2.6 Targets and pathways analysis  
The top three enriched targets/pathways were inspected with regard to their ability to explain 
the MOA of the compounds classified in the therapeutic action (sub-)classes. To improve the 
mechanistic understanding of the MOA, the top three enriched targets/pathways were linked 
to the indications of the (sub-)classes with supporting evidence from literature and supporting 
in vitro or in vivo studies of the Chinese medicines’ extracts or isolated compounds. However, 
supporting in vitro and in vivo studies were excluded in the pathway analysis because, in 
many (sub-)classes, no information was found. The 14 clusters were grouped based on the 
number of (sub-)classes in a cluster, which ranged from ten (sub-)classes to only one (sub-) 
class that derived from different classes. Three clusters were analysed in detail in the next 
section. Cluster VII was the only cluster that composed of (sub-)classes with the same TCM 
vital substance of its meridian system, blood. Cluster X was picked as a representative of a 
cluster of different classes while cluster XII was selected as a representative of a cluster with 
only one type of (sub-)class. The top three enriched targets/pathways per selected (sub-) 
classes were summarised in Table 2.2 and Table 2.5 and the top three enriched 
targets/pathways of all (sub-)classes can be found in Table A2.1 and Table A2.2 
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(Appendices). 
To compare the bioactivity spaces among the clusters, all enriched targets in a cluster 
were classified according to their protein family as derived from UniProt (116). The enriched 
pathways for all clusters were also classified according to KEGG ortholog groups, which are 
derived by comparing sequence similarity of individual genes and defining the functional 
group from the list of genes in the respective group (65). The KEGG ortholog group will be 
described as a pathway motif from here onwards. All the enriched targets were annotated 
from 59 protein families and the enriched pathways were annotated from 33 pathway motifs. 
A major protein family/pathway motif for a cluster was defined if the number of enriched 
targets/pathways was at least 5% of the total number of enriched target/pathway in the 
respective cluster and presence for at least eight clusters. Only five major protein families and 
eight major pathway motifs were identified. The frequencies of enriched targets/pathways per 
cluster were normalised before constructing two different heatmaps using heatmap.2 function 
of the gplots package in R (114), in order to visualise whether the major protein 
families/pathway motifs were equally important across clusters. 
2.3 Results and Discussions 
2.3.1 Overview of the results 
The in silico target prediction of 10,749 TCM compounds yielded 409 unique targets, of 
which 183 were enriched targets. In the pathway annotation, the total number of unique 
pathways was 171, of which 99 were enriched pathways. The results discussed from here 
onwards cover 45 of the 46 therapeutic action (sub-)classes only. One therapeutic action 
subclass is not included because no target was retained from the “Tranquilizing - Settling” 
(Tranquil-settle) subclass, which contained only one compound. This subclass was therefore 
omitted from hierarchical clustering and all subsequent analysis. In Figure 2.3, a dendrogram 
shows the hierarchical clustering of 45 TCM therapeutic action (sub-)classes based on their 
bioactivity fingerprints. The cluster tree generates a diverse spread of the 45 therapeutic 
action (sub-)classes, which is defined into 14 clusters. In many instances, branches of the 
dendrogram paired up from different type of classes or subclasses. Based on the molecular 
similarity principle (41), this observation indicates that many similar compounds are present 
in both (sub-)classes despite having different therapeutic actions. The link of the top three 
enriched targets of the therapeutic action (sub-)classes are discussed in the next sections as 
well as their top three enriched pathways.  
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Figure 2.3: Hierarchical cluster analysis of TCM classes and subclasses is based on the similarity of the bioactivity fingerprint of each class. The 
‘Tranquil-settle’ subclass was not included here (and in the further analysis) since it only contained a single compound for which no reliable targets 
could be predicted. The (sub-)classes were defined into 14 clusters, which cluster VII, X, and XII were selected for further analysis based on the top 
three enriched targets/pathways.  
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2.3.2 Target analysis 
2.3.2.1 Clusters with four therapeutic action (sub-)classes (Cluster X) 
Only Cluster X represents this group. The subclasses in cluster X are “Wind-dampness 
dispelling, bone (sinew) strengthening” (WD – bone), “Tonifying and replenishing, qi 
tonifying” (TR – qi), “Cough suppressing and panting-calming, clearing and heat phlegm 
resolving” (CSPC – heat) and “Tranquilizing, heat nourishing tranquilizing” (Tranquil – 
heart). The top three enriched targets from cluster X are mainly implicated in 
immunomodulation, namely steryl-sulfatase (STS) (117), tyrosine-protein phosphatase non-
receptor type 2 (PTPN2) (118), and peptidyl-prolyl cis-trans isomerase FKBP1A (FKB1A) 
(119), glucose homeostasis such as sodium glucose transporter 1 (SGLT1) and 2 (SGLT2) 
(120), cancer which is, DNA topoisomerase 1 (TOPO1) (121), reproductive system such as 
testosterone 17-beta-dehydrogenase 3 (17-beta-HSD 3) (122) and central nervous system 
(CNS) such as glutamate carboxypeptidase 2 (CGPII) (123).  
Dissecting the in silico target prediction per subclass, starting from the “Wind-
dampness dispelling, bone strengthening” (WD – bone), the top three enriched targets are 
TOPO1 (Estimation Score (ES)=0, Average Ratio (AR)=0.0144), SGLT1 (ES=0, 
AR=0.0342), and STS (ES=0, AR=0.0370). From the in silico target prediction, 
acankoreoside A-C derived from Acanthopanax gracilistylus were suggested to modulate 
TOPO1 and SGLT1 in the subclass, while compounds from Homalomena occulta such as 
asterpenoid, bullatantriol, and homalomenol were suggested to modulate STS, as well as 
compounds such as quercetin of Taxillus chinensis. The target prediction of compounds from 
Acanthopanax gracilistylus is supported by an in vitro study that the herb’s extract inhibits 
cell proliferation in several types of cancer cells (124). It is also reported that the extract of 
Taxillus chinensis exhibits significant anti-inflammatory activity in vitro (125). The herbs 
from this class are used to relieve pain, relax muscle and tendons, open channels and 
collaterals, and strengthen tendons and bones (87, 126). The actions of the herbs are related to 
the disturbance of muscular function in diabetes (127) and cancer cachexia which affects 
protein and lipid metabolism in skeletal muscle (128). 
 The top three enriched targets for “Tonifying and replenishing, qi tonifying” (TR – qi) 
subclass are PTPN2 (ES=0, AR=0.0174), SGLT2 (ES=0, AR=0.0282) and SGLT1 (ES=0, 
AR=0.0321). Many compounds from Glycyrrhiza glabra, Glycyrrhiza uralensis, Dolichos 
lablab, Panax ginseng, and Astragalus membranaceus were predicted to modulate PTPN2 
and SGLT1. In particular to PTPN2 (129), a compound, glycyrrhizin from Glycyrrhiza glabra 
and Glycyrrhiza uralensis is supported by an in-vivo study that suggests the compound 
ameliorates all established chronic histopathologic changes of lung tissue in the mouse model 
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of asthma (130). TCM describes the medicines from this subclass act on the spleen and lung, 
which the deficiency of lung qi is characterised by shortness of breath such in asthma (87).  
 A sub-cluster consists of two therapeutic action subclasses is seen to have highly a 
similar bioactivity space. The first subclass is “Cough suppressing and panting-calming, 
clearing and heat phlegm resolving” (CSPC – heat) with the top three enriched targets being 
PTPN2 (ES=0, AR=0.0112), TOPO1 (ES=0, AR=0.0236), and 17-beta-HSD 3 (ES=0, 
AR=0.0341). Compounds from Platycodon grandiflorum such as platycoside A-M were 
suggested to be modulated by all the top three enriched targets and compounds from Bambusa 
tuldoides, Peucedanum decursivum, and Trichosanthes kirilowii were mostly predicted to 
modulate 17-beta-HSD 3. Although Platycodon grandiflorum (131) and Trichosanthes 
kirilowii (132) are reported to exhibit anti-cancer properties, the reports do not support the 
link between the top three enriched targets and the indication of therapeutic action subclass to 
rationalise the MOA of the compounds.  
The second subclass, “Tranquilizing, heart nourishing tranquilizing” (Tranquil – 
heart), lists FKB1A (ES=0, AR=0.0077), PTPN2 (ES=0, AR=0.0167) and CGPII (ES=0, 
AR=0.0209) as its top three enriched targets. Compounds of three different herbs were 
predicted to modulate FKB1A and PTPN2 and only compounds of Ganoderma lucidum, such 
as ganoderic acid and lucidenic acid derivatives were predicted to modulate CGPII. The 
prediction of CGPII from triterpenoids of Ganoderma lucidum such as ganoderic acids are 
supported by Zhang et al., which triterpernoids exhibit nerve growth factor or brain-derived 
neurotrophic factor activities in vitro, which has the therapeutic potential in 
neurodegenerative diseases (133). The therapeutic actions of the herbs from the subclass are 
described to have effects on central nervous system (87). In conclusion, the MOAs of the 
compounds for three subclasses in cluster X can be suggested from their top three enriched 
targets.  
 
2.3.2.2 Clusters with three therapeutic action (sub-)classes (Cluster VII) 
Cluster VII is one of the clusters that consists of three therapeutic action subclasses, with two 
subclasses, “Hemostatic, stasis resolving” (Hemo-stasis) and “Tonifying and replenishing, 
blood” (TR-blood) that shows a highly similar bioactivity space. The third subclass is  “Heat-
clearing, blood cooling” (HC-blood cool). Overall, the top three enriched targets in the cluster 
can be classified into immunomodulation which are PTPN2 (118), protein kinase C beta type 
(PKC-β) (134), protein kinase C eta type (PKC-η) (135) and protein kinase C gamma type 
(PKC-γ) (136),cancer, namely TOPO1 (121), and glucose homeostasis such as SGLT2 (120). 
The top three enriched targets in “Hemostatic, stasis resolving” (Hemo-stasis) and  
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“Tonifying and replenishing, blood” (TR-blood) are PTPN2 (ES=0, AR=0.0089), PKC-η 
(ES=0, AR=0.0182), PKC-γ (ES=0, AR=0.0209) and PTPN2 (ES=0, AR=0.0140), PKC-β 
(ES=0, AR=0.0230) and PKC-ε (ES=0, AR=0.0240), which all of them is implicated in 
immunomodulation. In the “Hemostatic, stasis resolving” (Hemo-stasis) subclass, compounds 
such as ginsenosides and notoginsennosides of Panax notoginseng were predicted to 
modulate all top three enriched targets. The target prediction also showed that anthraquinone 
compounds from Rubia cordifolia such as purpurin, ruberythric acid and soranjidiol modulate 
PKC-β and PKC-ε. In support of the target prediction of anthraquinone compounds of the 
second herb, a study reported the herb’s ethanol extract shows wound healing activities in 
mice, which from histological evaluations indicate a marked infiltration of the inflammatory 
cells, increasing blood vessel formation and enhancing cells proliferation (137). This finding 
agrees with the description of the subclass of which is to stop bleeding with a stabbing pain at 
a fixed location (87). 
In the “Tonifying and replenishing, blood” (TR-blood) subclass, compounds from 
Paeonia lactiflora such as albiflorin, gallotannin, and casuarictin were predicted to modulate 
PKC-β and PKC-η. PTPN2 and PKC-η were both frequently predicted to be modulated by 
compounds from Panax notoginseng such as notoginsenoside and ginsenoside. It is found the 
ginsenoside Rg1 of Panax notoginseng ameliorates liver damage and suppresses 
proinflammatory cytokines secretion in concanvalin A-induced hepatitis in mice (138). This 
subclasses is described to have pharmacological effects on the liver, heart, and spleen and 
prevent failures of the organs (87). The top three enriched targets for “Heat-clearing, blood 
cooling” (HC-blood cool) subclass are PKC-β  (ES=0, AR=0.0100), TOPO1 (ES=0, 
AR=0.0123) and SGLT2 (ES=0, AR=0.0137). In this subclass, compounds from Paeonia 
lactiflora such as albiflorin, isopaenoflorin, and benzoylpaenoflorin were predicted to 
modulate both PKC-β  and TOPO1, while SGLT2 was predicted to be modulated by 
compounds from Rehmannia glutinosa such as rehmanionoside A and B. We found that the 
target prediction of SGLT2 is supported by a study on stachyose extract from Rehmania 
glutinosa, which shows a significant hypoglycaemic effect in diabetic mice (139). TCM views 
the action of the subclass is to promote the generation of body fluids from excessive heat (87, 
126) which the consumption of body fluid is one of the symptom in diabetes (140) and cancer 
patients (141). Altogether, in many instances, the MOAs of the compounds can be explained 
from the enriched targets and can also be linked to the indications of the (sub-)classes. 
 
2.3.2.3 Cluster with one therapeutic action (sub-)class (Cluster XII)  
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One out of five clusters, which has only one therapeutic action class is cluster XII, “Parasite 
destroying, dampness eliminating and itchiness relieving” (Parasite). The top three enriched 
targets are dihydrofolate reductase (DHFR), which plays a role in bacterial infection and 
cancer (142) (ES=0, AR= 0.0532), DNA-dependent protein kinase catalytic subunit (DNA-
PKcs), which is implicated in cancer (143) (ES=0, AR=0.0644) and tumour necrosis factor 
(TNF), which is found to exert activities in cancer, inflammation, and bacterial infection (144, 
145) (ES=0, AR=0.0687). From the target prediction compounds from Allium sativum were 
predicted to modulate DHFR, such as allicin, allilthiamine, and allyl disulphide. This 
prediction agrees with a study by Adetumbi et al., from which the extract of Allium sativum is 
found to inhibit the synthesis of proteins, nucleic acids, and lipids in Candida albicans where 
the major component of the herb was allicin (146). The finding relates to the phenotypes of 
the subclass, which is to kill and expel parasites and subsequently relieve pain (87, 126). In 
brief, the MOAs of the class can be linked to the enriched targets and the indications of the 
subclass. Table 2.2 summarises the top three enriched targets of the therapeutic action (sub-
)classes. 
The above analysis can be summarised into two different views namely biological space and 
chemical space. From the biological space’s view, many of the top three enriched targets, 
regardless of therapeutic action (sub-)classes in any of the clusters, are implicated in 
immunomodulation such as PTPN2, PKCs, FKBP1A and STS, which PTPN2 and PKCs of 
which were frequently predicted. Both PKC family and PTPN2 are implicated in 
immunomodulation. The frequency of immune-related targets can be related when TCM 
influences the immune system regulation by either promoting or suppressing the immune 
factors (147). The PKC isoenzymes act as important mediators in immune cellular signalling 
in T- and B-lymphocytes in acquired immune system (148). PTPN2 also plays a major role in 
the transmission of immune cell signalling events (118). From the chemical space’s view, 
triterpenoid is the most frequent phytochemical (Table 2.3), which was predicted to modulate 
some of the top three enriched target, such as TOPO1, PTPN2, and PKCs. The compounds 
are found in different herbs such as Acanthopanax gracilistylus, Glycyrrhiza glabra, 
Platycodon grandiflorum, Ganoderma lucidum and Panax notoginseng. To validate the result 
from the chemogenomic principle that similar targets share similar compounds, a compound, 
CHEMBL 486881, from ChEMBL database (28) is most similar to acankoreoside A, with 
Tanimoto coefficient (TC) value of 0.56 (Table 2.4). Anti-proliferative activity against 
human HEK293 cells after 72 hrs by MTT conversion assay inhibition assay with reported 
IC50 = 0.23uM. Hence, the chemogenomics principle appears to stand (at least for 
acankoreoside A) because both compounds are implicated in cancer and structurally similar.  
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Table 2.2: The top three enriched targets in clusters VII, X, and XII. It can be seen that, in many cases, top three enriched targets are implicated in 
immunomodulation. The Estimation Score = 0, for all top three enriched targets. 
  
TCM Therapeutic Action 
Class 
TCM Therapeutic 
Action Subclass 
Top three enriched targets  
Target function reported 
by literatures 
Average 
Score 
Cluster X 
Wind-dampness dispelling 
Bone(sinew) 
strengthening 
DNA topoisomerase 1 cancer 0.0144 
Sodium/glucose cotransporter 1 glucose homeostasis 0.0342 
Steryl-sulfatase immunomodulation 0.0370 
Tonifying and replenishing Qi tonifying 
Tyrosine-protein phosphatase 
non-receptor type 2 immunomodulation 0.0174 
Sodium/glucose cotransporter 2 glucose homeostasis 0.0282 
Sodium/glucose cotransporter 1 glucose homeostasis 0.0321 
Cough suppressing and 
panting-calming 
Clearing and Heat phlegm 
resolving 
Tyrosine-protein phosphatase 
non-receptor type 2 immunomodulation 0.0112 
DNA topoisomerase 1 cancer 0.0236 
Testosterone 17-beta-
dehydrogenase 3 reproduction system 0.0341 
Tranquilizing 
Heat nourishing 
tranquilizing 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A immunomodulation 0.0077 
Tyrosine-protein phosphatase 
non-receptor type 2 immunomodulation 0.0167 
Glutamate carboxypeptidase 2 CNS 0.0209 
Cluster 
VII 
Heat clearing medicinal 
Heat clearing and blood 
cooling 
Protein kinase C beta type immunomodulation 0.0100 
DNA topoisomerase 1 cancer 0.0123 
Sodium/glucose cotransporter 2 glucose homeostasis 0.0137 
Hemostatic medicinal 
Stasis-resolving 
hemostatic 
Tyrosine-protein phosphatase 
non-receptor type 2 
immunomodulation 0.0089 
Protein kinase C eta type immunomodulation 0.0182 
Protein kinase C gamma type immunomodulation 0.0209 
Tonifying and replenishing Blood tonifying 
Tyrosine-protein phosphatase 
non-receptor type 2 
immunomodulation 0.0140 
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Protein kinase C beta type immunomodulation 0.0230 
Protein kinase C eta type immunomodulation 0.0240 
Cluster 
XII 
Parasite destroying, 
dampness eliminating and 
itchiness relieving 
  
Dihydrofolate reductase cancer, bacterial infection 0.0532 
DNA-dependent protein kinase 
catalytic subunit 
cancer 0.0644 
Tumour necrosis factor cancer, bacterial infection 0.0687 
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Table 2.3: Compounds from Clusters VII, X, and XII, which were found to modulate the top three enriched targets of the therapeutic action classes 
from the respective clusters. The phytochemical, triterpenoids were frequently found in different herbs. The predicted targets were supported by 
published literature based on at least one of the herbs, suggesting that the other herbs that also contain the same compound could contribute to related 
therapeutic effects.  
Cluster X 
Therapeutic action (sub-
)class 
Herb Compound Predicted targets 
(based on the top 
three enriched 
targets) 
Literature Support 
“Wind-dampness 
dispelling, bone 
strengthening”  
(WD – bone) 
Acanthopanax 
gracilistylus 
Acankoreoside A 
 
 
TOPO1 
SGLT1 
The herb’s extract inhibited cell 
proliferation several types of 
cancer cells (124). 
Tonifying and 
replenishing, qi tonifying”  
(TR – qi) 
Glycyrrhiza 
glabra 
Glycyrrhiza 
uralensis 
Glycyrrhizin 
 
PTPN2 
 
An in vivo study that suggested 
the compound ameliorates all 
established chronic 
histopathologic changes of lung in 
the mouse model of asthma (130). 
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Cough suppressing and 
panting-calming, clearing 
and heat phlegm resolving 
(CSPC – heat) 
Platycodon 
grandiflorum 
Platycoside A 
 
PTPN2 
TOPO1 
17-beta-HSD 3 
No supporting literature. 
Tranquilizing, heart 
nourishing tranquilizing 
(Tranquil – heart) 
Ganoderma 
lucidum 
Ganoderic acid C1 
 
CGPII Triterpernoids of the herb 
exhibited nerve growth factor or 
brain-derived neurotrophic factor 
activities in vitro, which has the 
therapeutic potential in 
neurodegenerative diseases (133). 
Cluster VII 
Therapeutic action (sub-
)class 
Herb 
 
Compound Predicted targets 
(based on the top 
three enriched 
targets) 
Literature Support 
Hemostatic, stasis 
resolving 
(Hemo-stasis) 
Rubia cordifolia Purpurin 
 
 
 
 
 
 
PKC-β 
PKC-ε 
The ethanol extract showed 
wound healing activities in mice, 
which from histological 
evaluations indicated a marked 
infiltration of the inflammatory 
cells, increased blood vessel 
formation and enhanced 
proliferation of cells (137). 
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Tonifying and 
replenishing, blood 
(TR-blood) 
Panax 
notoginseng 
Ginsenoside Rg1 
 
PTPN2 
PKC-η 
The compound ameliorated liver 
damage and suppressed 
proinflammatory cytokines 
secretion in concanvalin A-
induced hepatitis in mice (138). 
“Heat-clearing, blood 
cooling” 
(HC-blood cool) 
Rehmania 
glutinosa 
Rehmannioside A 
 
SGLT2 The stachyose extract from the 
herb showed a significant 
hypoglycaemic effect in diabetic 
mice (139). 
Cluster XII 
Therapeutic action (sub-
)class 
Herb Compound Predicted targets 
(based on the top 
three enriched 
targets) 
Literature Support 
Parasite destroying, 
dampness eliminating and 
itchiness relieving 
(Parasite) 
Allium sativum Allicin 
 
DHFR The extract of Allium sativum was 
found to inhibit the synthesis of 
proteins, nucleic acids, and lipids 
in Candida albicans where the 
major component of the herb was 
allicin (146). 
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Table 2.4: Compound from ChEMBL database that is most similar to acankoreoside A (Table 2.3) and Its Activity Profile 
Reference compound Closest Similarity Reported Activity 
Profile 
Acankoreoside A 
 
 
CHEMBL 486881  
 
Anti-proliferative activity 
against human HEK293 
cells after 72 hrs by MTT 
conversion assay 
inhibition assay with 
reported IC50 = 0.23uM 
 
Tanimoto coefficient = 
0.56 
 39 
2.3.3 Pathway analysis 
2.3.3.1 Clusters with four therapeutic action (sub-)classes (Cluster X) 
The top three enriched pathways in cluster X are mainly implicated in digestive system 
(carbohydrate digestion and absorption, bile secretion and mineral absorption). In this cluster, 
only one pathway, from the top three enriched pathways, is not classified in the digestive 
system, which is terpenoid backbone biosynthesis.   
 In the “Wind-dampness dispelling, bone strengthening” (WD – bone) subclass, the top 
three enriched pathways are mineral absorption (ES=0, AR=0.0342), carbohydrate digestion 
and absorption (ES=0, AR=0.1427) and bile secretion (ES=0, AR=0.2050). To link the 
mineral absorption pathway to the indication of the subclass, it has been reported that 
minerals such as calcium is an important mineral for bone remodelling to strengthen the bone 
(149). In the second pathway, carbohydrate digestion and absorption, is associated to the 
indication of the subclass, when a study shows that a lower rate of mesenchymal stem cells 
differentiated into osteoblasts when mice were fed with low carbohydrate - high fat (LC-HF) 
diets, which explains the observation of reduced bone formation (150). However, no study 
can be found to link bile secretion to the indication of the subclass. 
 “Tonifying and replenishing, qi tonifying” (TR – qi) subclass has mineral absorption 
(ES=0, AR=0.0321), carbohydrate digestion and absorption (ES=0, AR=0.1251) and bile 
secretion (ES=0, AR=0.2678) in the top three enriched pathways. Minerals play vital roles in 
maintaining the cell functions to optimise health and prevent diseases. The first enriched 
pathway, mineral absorption, the process of recycling iron in erythrocytes is seen in splenic 
macrophages in the red pulp (151) and agrees with the indication of the subclass which is qi 
tonifying related to the maintenance of blood flow within the vessels that is implicated 
directly from spleen’s activity (126) In the second pathway, no study can be found to link 
carbohydrate digestion and absorption to the indication of the subclass. Relating to the third 
enriched pathway, bile secretion, it has been reported that the major components of bile acid, 
chemodeoxycholic acid and glycochenodeoxycholic acid can induce cyclooxygenase-2 
expression and cell proliferation in esophageal squamous cells, suggesting that bile acids may 
contribute to the inflammation and mucosal thickening (152). Another paper demonstrates 
that bile acids may induce airway fibrosis through the production of TGF- β1 and fibroblast 
proliferation (153). These findings can be associated with the indication of the subclass, 
which is related to lung deficiency (87). 
 The top enriched pathways of “Cough suppressing and panting-calming, clearing and 
heat phlegm resolving” (CSPC – heat) subclass are minerals absorption (ES=0, AR=0.0380), 
carbohydrate digestion and absorption (ES=0, AR=0.1572) and bile secretion (ES=0, 
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AR=0.1958). Relating to the first enriched pathway, mineral absorption, the abnormal 
distribution of trace elements such as zinc, selenium and copper have been reported to 
aggravate oxidative damage and inflammation in the airways and subsequently decreased the 
lung’s function in asthmatic patient (154), in which an asthmatic condition is described as 
retention of heat phlegm in the lung (155). In the second enriched pathway, carbohydrate 
digestion and absorption, the ingestion of carbohydrate is reported to attenuate the migration 
of T lymphocytes to the bronchial epithelial cell line when it is infected with the common 
respiratory pathogen human rhinovirus during strenuous exercise (156). This effect agrees 
with the indication of the subclass which is to dissolve phlegm upon infection in the lung (87, 
126). However, no strong evidence can be found to link bile secretion to the indication of the 
subclass. 
 The “Tranquilizing, heart nourishing tranquilizing” (Tranquil – heart) subclass lists 
mineral absorption (ES=0, AR=0.0387), carbohydrate digestion and absorption (ES=0, 
AR=0.1163) and terpenoid backbone biosynthesis (ES=0, AR=0.2166). In the first enriched 
pathway, mineral absorption, it is reported that selenium plays an important role in the brain 
where its deficiency is implicated in senility and Alzheimer’s disease (157). In the third 
enriched pathway, terpenoid backbone biosynthesis includes mevalonate and non-mevalonate 
pathway. The mevalonate pathway is a pathway implicated in cholesterol biosynthesis in the 
brain and deficiencies in cholesterol metabolism can lead to diseases of the central central 
nervous system (CNS) diseases (158). Both findings agree with the indication of the subclass, 
which is the pharmacological effects are on the central nervous system (87). Although no 
strong evidence to support, the second enriched pathway, carbohydrate digestion and 
absorption, the two enriched pathways can be linked to the indication of the subclass. In short, 
in many instances, the top three enriched pathways can be associated to the indications of the 
(sub-)classes to explain their MOAs. 
 
2.3.3.2 Cluster with three therapeutic action (sub-)classes (Cluster VII) 
The top three enriched pathways in the cluster can be classified into digestive system 
(carbohydrate digestion and absorption, bile secretion and mineral absorption), cellular 
communication (tight junction) and membrane transport (ABC transporters). The top three 
enriched targets in “Hemostatic, stasis resolving” (Hemo-stasis) subclass are mineral 
absorption (ES=0, AR=0.0267), carbohydrate digestion and absorption (ES=0, AR=0.0987) 
and bile secretion (ES=0, AR=0.1872) and “Tonifying and replenishing, blood” (TR-blood) 
subclass lists mineral absorption (ES=0, AR=0.0329), carbohydrate digestion and absorption 
(ES=0, AR=0.1055) and tight junction (ES=0, AR=0.2053). In “Hemostatic, stasis resolving” 
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(Hemo-stasis) subclass, the mineral absorption pathway can be related to zinc deficiency, 
which has been reported to delay wound healing (159). In the bile secretion pathway, bile 
acids are implicated in platelet inhibition by solubilising the platelets, which patients with 
obstructive jaundice were exposed to abnormal hemostasis due to high level of bile acids 
(160). Both enriched pathways are related to the indication of the subclass, which is to 
achieve hemostasis (87) and no study can be found to associate carbohydrate digestion and 
absorption pathway to the indication of the subclass. In “Tonifying and replenishing, blood” 
(TR-blood), the first enriched pathway, mineral absorption, can be linked to the indication of 
the subclass which is to strengthen the heart that controls blood vessel (87), when selenium is 
reported to be protective against cardiovascular disease by contributing to the production of 
vasodilatory prostacyclin by the endothelium (157). No study can be found to support the link 
between the second pathway, carbohydrate digestion and absorption to the indication of the 
subclass. The third enriched pathway, tight junction, the presence of tight junctions in the bile 
epitheliums act as barriers from toxic diffusion from bile into hepatic interstitial tissue, which 
could impair the organ’s function(161). TCM enriched can be associated with the indication 
of the subclass, which is to strengthen the function of liver (87).  
 The top three enriched targets for “Heat-clearing, blood cooling” (HC-blood cool) 
subclass are mineral absorption (ES=0, AR=0.0276), carbohydrate digestion and absorption 
(ES=0, AR=0.0753) and ABC transporter (ES=0, AR=0.0769). The mineral absorption 
pathway can be linked to the subclass when a decreased in intracellular magnesium 
concentration is implicated in type 2 diabetes (162) and the disease, according to TCM, is 
described as the deficiency of body liquid due to heat syndrome (163). Similar to previous 
subclass, no study can be found to link the second enriched pathway, the carbohydrate 
digestion and absorption, to the indication of the subclass. In the third pathway, ABC 
transporter, it is reported that the high expression of ABCG5 and ABG8 in 
hypercholesteromic condition of the heart is involved in cardiovascular protection by 
lowering plasma cholesterol level (164). The pathway can be linked to the indication of the 
subclass when the herbs are described to act on liver and heart (87). All in all, in many cases, 
the top three enriched pathways can be linked to the indications of the subclasses to explain 
their MOAs. 
 
2.3.3.3 Cluster with one therapeutic action (sub-)classes (Cluster XII)  
In the “Parasite destroying, dampness eliminating and itchiness relieving” (Parasite) class, the 
top three enriched pathways are steroid biosynthesis (ES=0, AR=0.2530), 
glycerophospholipid metabolism (ES=0, AR=0.2941) and collecting duct acid secretion 
 42 
(ES=0, AR=0.3420). Both of the first two pathways, steroid biosynthesis and 
glycerophospholipid metabolism are part of lipid metabolism, and many reports have 
suggested their link to immune response. For instance,  steroid biosynthesis is down-regulated 
by interferon type I upon viral infection (165) and the chlamydia exploits the nutrient-rich 
host cell cytosol by trafficking the glycerophospholipid from the host cell for survival (166). 
In relation to the collecting duct acid secretion pathway, bacterial infection in the kidney is 
reported to affect the collecting duct acid secretion because the presence of 
lipopolysaccharide (LPS) of the bacteria inhibits the HCO3
− absorption (167). These pathways 
agree with the functions of the subclass, which is to kill and expel parasites (87, 126). 
Altogether, the top enriched pathways can be linked to the indication of the class to explain 
the MOAs. Table 2.5 summarises the top three enriched pathways of the therapeutic action 
(sub-)classes. 
The above analysis can be summarised into three observations as follows. First, a type 
therapeutic action (sub-)class is implicated in different enriched pathways and each pathway 
is involved in a different disease. Second, more than one therapeutic action (sub-)classes are 
implicated in a pathway that is involved in multiple diseases. Third, more than one therapeutic 
action (sub-)classes are implicated in different pathways but involved in only one type of a 
disease. The first observation is indicated, in many cases, by the (sub-)classes in any of the 
three clusters such as bile secretion and mineral absorption in “Tonifying and replenishing” 
(TR-qi). The top three enriched pathways in a therapeutic action (sub-)class are implicated in 
different pathways and diseases. The modulation of one pathway to a disease could provide a 
better insight on the (sub-)class MOA in the biological system. In the second observation, the 
mineral absorption in cluster VII and cluster X and carbohydrate digestion and absorption in 
cluster VII are implicated in various types of diseases. The redundancy of a pathway in the 
pathogenesis of various diseases implies that a pathway could serve multiple purposes; for 
instance, the mitogen-activated protein kinase (MAPK) signalling pathway was implicated in 
inflammation, cancer, cardiovascular dysfunction and Alzheimer’s disease (168). The third 
observation shows that different pathways from different therapeutic action subclasses in a 
cluster, are implicated in a type of physiological function, such as the ABC transporter and 
mineral absorption from “Heat-clearing, blood cooling” (HC-blood cool) and “Tonifying and 
replenishing, blood” (TR-blood) respectively is implicated in physiological function of the 
heart. The different pathways for a particular physiological function explain that a pathway 
does not function alone in the manifestation of a disease but through the interactions of 
multiple pathways (169), which account for the different clinical symptoms. To put it briefly, 
the pathways annotation is not only beneficial to suggest the MOAs of the (sub-)classes based 
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on their indications, but also show that one pathway could have manifold functions and 
multiple pathways contribute to the pathogenesis of a disease. From the TCM perspective, it 
is suggested that the involvement of multiple pathways in the pathogenesis of a disease 
explains the complex TCM formulation, which consist of a set of herbs from various 
therapeutic action (sub-)classes. 
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Table 2.5: The top three enriched pathways in clusters VII, X, XII. It can be seen that, in many cases, similar pathways appear in the top three enriched 
targets regardless of clusters and subclasses. The Estimation Score = 0, for all top three enriched pathways.  
 
  
TCM Therapeutic Action Class TCM Therapeutic Action Subclass Top three enriched pathways  
Average 
Score 
Cluster X 
Wind-dampness dispelling Bone (sinew) strengthening 
hsa04978  Mineral absorption 0.0342 
hsa04973  Carbohydrate digestion and absorption 0.1427 
hsa04976  Bile secretion 0.2050 
Tonifying and replenishing Qi tonifying 
hsa04978  Mineral absorption 0.0321 
hsa04973  Carbohydrate digestion and absorption 0.1251 
hsa04976  Bile secretion 0.2678 
Cough suppressing and panting-
calming 
Clearing and Heat phlegm resolving 
hsa04978  Mineral absorption 0.0380 
hsa04973  Carbohydrate digestion and absorption 0.1572 
hsa04976  Bile secretion 0.1958 
Tranquilizing Heat nourishing tranquilizing 
hsa04978  Mineral absorption 0.0387 
hsa04973  Carbohydrate digestion and absorption 0.1163 
hsa00900  Terpenoid backbone biosynthesis 0.2166 
Cluster VII 
Heat clearing medicinal Heat clearing and blood cooling 
hsa04978  Mineral absorption 0.0276 
hsa04973  Carbohydrate digestion and absorption 0.0753 
hsa02010  ABC transporters 0.0769 
Hemostatic medicinal Stasis-resolving hemostatic 
hsa04978  Mineral absorption 0.0267 
hsa04973  Carbohydrate digestion and absorption 0.0987 
hsa04976  Bile secretion 0.1872 
Tonifying and replenishing Blood tonifying 
hsa04978  Mineral absorption 0.0329 
hsa04973  Carbohydrate digestion and absorption 0.1055 
hsa04530  Tight junction 0.2053 
Cluster XII 
Parasite destroying, dampness 
eliminating and itchiness 
relieving 
  
hsa00100  Steroid biosynthesis 0.253 
hsa00564  Glycerophospholipid metabolism 0.294 
hsa04966  Collecting duct acid secretion 0.342 
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2.3.4 Comparison of bioactivity spaces of clusters  
In this part of study, the aim was to investigate the differences of bioactivity spaces among all 
clusters by classifying all the enriched targets in the cluster to their respective protein 
families. The 181 enriched targets were classified into 59 protein families. Out of 59 protein 
families, five protein families were frequently annotated in all clusters, which are GPCR, 
protein kinase, NHR, carbonic anhydrase and cytochrome P450. The heatmap in Figure 2.4 
compares the five major protein families that were annotated based on the enriched targets in 
each cluster. The more saturated colour represents the more significant the protein family 
across all clusters. The numbers of protein families in the clusters were normalised because 
the distribution of enriched targets were not consistent due to numbers of therapeutic action 
(sub-)classes per cluster were different.  
What can be seen from the graph is that GPCRs and protein kinases are the most 
highly clustered protein families in almost all clusters. The results were expected as both of 
the families are the two most largest protein families that are involved in many physiological 
processes (170, 171), thus, explaining why these two protein families were observed to be 
significant in many of the clusters. In addition, the diversity of the compounds in the (sub-) 
classes also contributed to the prediction of enriched targets from these protein families. At 
least four protein families were significant across all clusters, except for cluster VII and X in 
cytochrome P450. The number of enriched targets in the cluster was amongst the lowest 
across all clusters, cytochrome P450 were less classified. NHRs were found to be annotated in 
all clusters and the frequent predictions of the nuclear hormone receptor family can be 
explained by the presence of naturally occurring steroids in natural compounds (172). For the 
remaining two major protein families, the cytochrome P450 family was also expected to be 
modulated by most of the subclasses because this protein family plays an important role in the 
degradation of structurally rather diverse exogenous compounds (173). The carbonic 
anhydrase family, which is an ubiquitous enzyme, involved in the inter-conversion between 
carbon dioxide and the bicarbonate ion that is important for many physiological processes 
(174). All in all, five major protein families were observed to occur frequently in most of the 
clusters and were heavily implicated in the biological processes such as cell regulation, 
sensory system and steroid metabolism. This analysis has allowed the discovery of the 
bioactivity space connection between subclasses in TCM based on the sets of enriched targets 
from our in silico target prediction. The TCM compounds of a significant cluster for a 
particular protein family can be further explored in finding new molecular entities for a 
disease related to the protein family. 
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Figure 2.4: The heatmap compares the five major protein families that were annotated based 
on the enriched targets in each cluster, which were normalized. The more saturated colour 
across clusters represents the more significant the protein family. GPCR and protein kinase 
are observed to be significant protein families in almost all clusters. It appears that all the 
protein families are heavily implicated in the biological processes such as cell regulation, 
sensory system and steroid metabolism. The TCM compounds of significant cluster for a 
particular protein family can be suggested to be further explored for finding new molecular 
entities. 
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2.3.5 Comparison of pathway annotation of clusters  
In this part of the study, we aimed to investigate the differences in pathway motifs among all 
clusters by classifying the enriched pathways according to KEGG ortholog. The 99 enriched 
pathways were classified to 33 pathway motifs, which were almost half the number of total 
pathway motifs available in KEGG. The major pathway motifs from the classification were 
infectious diseases, digestive system, immune system, signal transduction, lipid metabolism, 
cancer and cellular community. The heatmap in Figure 2.5 compares the seven major 
pathway motifs that were annotated based on the enriched pathways in each cluster. The more 
saturated colour across clusters represents the more significant the pathway motif. The 
numbers of pathway motifs in the clusters were normalised due to the differences in numbers 
of the pathways that were enriched among all (sub-)classes 
Figure 2.5, it is seen that that the digestive system is consistently classified in all 
clusters, which in many cases, the plots’ colour are more saturated compare to other pathway 
motifs. The digestive system includes the digestion and absorption of macro- and 
micronutrients and shows that the majority of the enriched pathways are bile secretion, 
pancreatic secretion and gastric acid secretion. The bile secretion controls the cholesterol 
homeostasis by routing the elimination of cholesterol, in addition to harmful exogenous 
lipophilic substance (175). In addition to the digestive system, infectious diseases, signal 
transduction, and lipid metabolism are significant pathway motifs in many of the clusters. The 
significance of infectious diseases can be deduced from frequently predicted 
immunomodulatory targets as the pathogenic factors are described to attack weakened 
immune system (176). The signal transduction pathway motif can be deduced from the 
classification of one of the major protein families, GPCR which translates the extracellular 
signals for the downstream effectors that produce a physiological response in a target cell 
(177). Many Chinese medicines have been reported to have lipid regulating effects by 
influencing the intestinal lipid absorption and lipid metabolism, to name a few (178). Also, 
one of the highly observed enriched pathways in the lipid metabolism pathway motif was 
steroid hormone biosynthesis, in which the cytochrome P450 protein family is involved in 
(179). It also appears that a few of the pathway motifs are insignificant for some clusters such 
as the immune system for cluster II and the excretory system in cluster XIV, which resulted 
from a low number of compounds influencing the target prediction and pathway annotation. 
The list of compounds that were annotated for the Chinese medicines in the subclasses might 
be incomplete in order to influence the classification of the immune system as well as the 
remaining missing pathway motifs. In addition, only enriched pathways were used in the 
classification. In a similar manner, for the major protein families, the compounds from 
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significant clusters for the major pathway motifs can be further explored for types of diseases 
that are well known to be implicated such as the digestive system, which is well known to be 
in involved in liver disease. 
Altogether, this analysis has allowed the discovery of major pathway motifs in all 
clusters. Despite having the different therapeutic action (sub-)classes in a cluster, in many 
cases, all the clusters can be classified of having the seven major pathway motifs. The 
classification of the major pathway motifs was associated with the major protein families 
analysed in the previous section. 
 
 
Figure 2.5: The heatmap compares the seven major pathway motifs that were annotated based 
on the number of enriched pathways in each cluster, which were normalized. The more 
saturated colour across clusters represents the more significant pathway motifs. The 
significant cluster for a particular pathway can be further explored for a disease with the 
known pathway motif such as digestive system in liver disease. 
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2.4 Conclusion 
The global mapping of relationships between TCM therapeutic action classes and subclasses, 
based on their predicted targets and annotated pathways, provides a novel approach to 
understand the MOAs of TCM formulations. The dendrogram, which was generated based on 
the in silico target prediction of TCM therapeutic action (sub-)classes compounds, has 
enabled the visualisation of their bioactivity space. In the first part of the study, it was to 
rationalise the link between the top three enriched targets/pathways to the description of the 
respective therapeutic action (sub-)classes with supporting literature. Overall, the most 
frequent top three enriched targets were immune-related targets such as tyrosine-protein PTPN2 
and PKC-family, while the most frequent enriched pathway was related to the digestive system 
such as mineral absorption and bile secretion. In TCM, symptoms are usually regarded as the 
invasion of pathogenic factors, thus sensitizing the immune system to response, and this 
might provide a mechanistic link between TCM and Western thinking. In the second part of 
the study, the annotation of the protein family in all clusters showed that the GPCR and protein 
kinase family were the two major protein families that contributed to the diversity of the 
bioactivity space. The highly annotated pathway motif indicated that the digestive system was 
consistently annotated, which agreed with the important treatment principle of TCM, “the 
foundation of acquired constitution” that includes spleen and stomach. With the global overview 
of the bioactivity space of the therapeutic action (sub-)classes, the similarity could be 
observed and the differences between them, which are not apparent from the name given to 
the (sub-)class itself. Hence, this analysis helps to reduce the gap between TCM and Western 
medicine. 
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Chapter 3:  
Exploring the Chemical Space and Bioactivity Space of Traditional Medicine from China, 
India and Malaysia for Treating Cancers 
 
 
3.1 Introduction 
Traditional medicines (TMs) from different geographical locations are often based on 
different ingredients and formulations; however, the diseases to be treated are in many cases 
related. In many TM practices, plants are usually the major resource but some animal parts 
and minerals are also frequently used. Each TM can use different types of plants (which is an 
aspect we will investigate further in the current work) to treat the same diseases such as 
infectious diseases (180), memory and cognitive function (181) and cancer (182). These 
different plants do not only have structurally different compounds but also similar 
compounds. These compounds, most of which exhibit pharmacological properties, are known 
as secondary metabolites. The distribution of similar compounds in different plants can be 
explained by two notions. First, the plants are closely related in the phylogenetic tree, thus, 
contributing to the distribution of similar compounds (183). The relationship between 
phylogeny and shared phytochemistry has been reported before (184, 185); it is described as 
the characteristics of the plants’ taxa despite being found in different regions. Second, the 
commonality, paradoxically, can also be explained by convergent evolution, where the 
production of secondary metabolites evolves independently in different plant phylogenetic 
lineages, in response to similar environmental challenges (186, 187). The occurrence of 
similar compounds from plants of unrelated taxa was found in a few studies (97, 188), which 
indicates the importance of a few types of secondary metabolites in plants defence 
mechanisms being exploited for medicinal purposes. Thus, it can be seen that structurally 
similar compounds can be found in either the same or unrelated niches of the phylogenetic 
tree of plants used to treat the same diseases. 
The variability of plants used in treating the same disease can also be attributed to 
different compounds modulating different related targets or different genetic background to 
respond to TM treatment. Knowledge of the therapeutic target may help uncover the MOA of 
TM compounds and how the genes contribute to the development of the disease. Hence, the 
common and differential MOAs of different TMs could be understood better by comparing 
their chemical and bioactivity spaces. Thus far, investigations to compare the bioactivity 
spaces of different TMs are still limited (180, 182), where both studies included different TMs 
only from within the same region. Unlike the bioactivity space, extensive studies have 
investigated the variability of the chemical space between TMs but in comparison to 
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combinatorial libraries (189, 190). Hence, previous comparison studies were either restricted 
to only chemical or target space, whereas we aim to compare them concurrently. 
To understand the relations between the likely MOAs of TMs, we used in silico target 
prediction. While previous studies have investigated links between TCM and Ayurveda and 
their putative targets on a large scale (47), in this work we explored the links between three 
TMs and their putative targets in cancer, which is one of the diseases treated by many TMs 
and where sufficient data for analysis is available. 
 Cancer was probably first defined by the physician Hippocrates (460–370 B.C) from 
a Greek word, karkinos, to describe carcinoma tumours (191). However, communities from 
different parts of the world had established their own philosophy of treatments to fight against 
cancer using TM long before the disease was defined. The three types of TM, namely 
Traditional Chinese Medicine (TCM), Ayurveda, and Malay TM, hold distinct views about 
cancer (Figure 3.1). According to TCM, cancer occurs when there is an imbalance between 
endogenous physical conditions, which is associated with the dysfunction of viscera and 
bowels, particularly the spleen and kidney deficiencies of the body and also the interference 
of exogenous pathogenic factors (141, 192). Cancer can be briefly concluded as the stagnation 
of toxin and heat, the obstruction of phlegm/dampness, Qi stagnation and blood stasis, and the 
imbalance of yin and yang in the viscera and bowels (192). On the other hand, Ayurveda 
believes that cancer is due to the disruption of aura that allows negative astral forces to enter 
the body (193). Cancer is described as inflammatory or non-inflammatory swelling which can 
either be a minor (Granthi) or major (Arbuda) neoplasm (194, 195). The swelling starts off 
when one or two of the three bodily systems, which are the nervous system (Vata or air), the 
venous system (Pitta or fire), and the arterial system (Kapha or water), which maintain the 
normal function of the body, are out of control in benign cancer and all of them become 
dysfunctional in malignant cancers due to clashes between Vata and Kapha forces resulting in 
morbidity (193, 194). In Malay TM, the physical characteristics of a person consist of four 
elements, which are fire (Suprawi), earth (Suddawi), wind (Dammawi) and water (Balpawi), 
by which a disease can be identified by recognizing the nature of the elements; damp, cold, 
hot and dry (196). Limited knowledge has been documented on how the Malay TM views 
cancer, but the symptom of cancer is described as a swelling that is due to the imbalance in 
the wind, which affects how the blood flows (197). Therefore, altogether, the above TMs 
agree that cancer is viewed as an obstruction in the normal body function, within the 
particular reference frame of each TM, which is described in modern medicine as the 
uncontrolled division of abnormal cells, that also will eventually disrupt the body function 
(191). 
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Figure 3.1: The comparison of the cancer definitions from TCM, Ayurveda, and Malay TM. 
In principle, each TM defines a healthy body through different elements. One of the elements 
is viewed to be disrupted when cancer develops. In TCM, the imbalance of yin and yang from 
spleen and kidney deficiencies are described as symptoms of cancer. Ayurveda believes that 
one of the three elements that holds a healthy body is disrupted in cancer. Similar in Malay 
TM, cancer happens when there is an imbalance of the wind element, which is a part of the 
four elements used to describe as state of a healthy body. 
 
This current study aims to undertake the analysis of predicted targets differently by 
comparatively exploring both chemical and target space of the three TMs, i.e. TCM, 
Ayurveda and Malay TM with respect to treating cancer. The chemical space of TM 
compounds was compared with anti-cancer drugs in addition to diversity analysis of different 
TMs by scaffold decomposition. TM compounds were predicted using an in silico target 
prediction algorithm and the bioactivity space between TMs was compared by analysing the 
relation between predicted targets and their annotated plants and the significant target class of 
a TM. A phylogenetic tree was also constructed to determine its influence in the comparison 
study. In the end, this study allowed us to better understand the relations between TMs in 
treating cancer by analysing their common and differential MOAs. 
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3.2 Materials and methods 
3.2.1 Compilation of traditional medicine datasets 
Three TM datasets were used for this study. The TCM (97) and Ayurveda (193, 194, 198) 
plants used for cancer treatments (cancer-related plants) were extracted from literature. All 
TCM compound structures were collected from the Traditional Chinese Medicine Systems 
Pharmacology Database Platform (TCMSP) database (32) by searching the plants’ scientific 
names. Out of 97 plants in (97), only 47 plants were found in the TCMSP. Due to limited 
Ayurveda databases available, the set of compounds of each Ayurveda plant was derived from 
the Dr. Duke's Phytochemical and Ethnobotanical Database (199) and the corresponding 
compound structures were downloaded from PubChem (110) using PubChem IDs as input in 
the PubChem Download Service. Where the structure was not available in PubChem (110), 
ChemSpider (25) or the Human Metabolome Data (HMDB) (200) were used as an alternative. 
The cancer-related plants and compound structures for Malay TM were derived from a 
commercial database, Natural Product Discovery System (NADI) (201). The cancer-related 
plants and their structures were compiled by using keywords “tumour” and “cancer” in the 
search engine of the database.  
In total, the numbers of cancer-related plants of TCM, Ayurveda, and Malay TM were 
47, 34, and 28 respectively. Due to identical plants being observed in the TMs, the set of 
compounds of those particular plants were revised so that the set of compounds of each plant 
was consistent. This was done by combining the set of compounds of the same plants 
followed by removing duplicate compounds. The final numbers of compounds were 2,292 
(TCM), 1,583 (Ayurveda) and 1,127 (Malay TM) (Table 3.1).  
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Table 3.1: The dataset of TCM, Ayurveda and Malay TM. It can be seen that the distribution 
of the compounds is variable. The order of the plants follows the order in the phylogenetic 
tree from right to left. 
 
Plant TCM Ayurveda 
Malay 
TM 
No of 
compounds 
Pteris multifida  16 
  
16 
Drynaria fortunei  50 
  
50 
Cedrus deodara  
 
6 
 
6 
Schisandra chinensis  66 
  
66 
Cinnamomum aromaticum  72 
  
72 
Magnolia officinalis  108 
  
108 
Annona squamosa  
 
41 
 
41 
Houttuynia cordata  27 
  
27 
Piper betle  
 
18 
 
18 
Piper nigrum  
  
35 35 
Aloe vera  
 
139 139 278 
Allium sativum  
 
163 163 326 
Imperata cylindrica  18 
  
18 
Cymbopogon citratus  
 
78 78 156 
Curcuma longa  89 89 89 267 
Kaempferia galanga  
  
2 2 
Alpinia officinarum  99 
  
99 
Zingiber montanum  
  
9 9 
Zingiber officinale  76 76 
 
152 
Aconitum kusnezoffii  9 
  
9 
Pulsatilla chinensis  27 
  
27 
Nigella sativa  
 
20 
 
20 
Paeonia suffruticosa  28 
  
28 
Portulaca oleracea  40 
  
40 
Persicaria orientalis  45 
  
45 
Polygonum aviculare  22 
  
22 
Polygonum cuspidatum  45 
  
45 
Vitis vinifera  
 
266 
 
266 
Terminalia arjuna  
 
42 
 
42 
Lawsonia inermis  
  
10 10 
Capparis spinosa  
 
39 
 
39 
Moringa oleifera  
 
35 35 70 
Raphanus sativus  
 
57 
 
57 
Isatis tinctoria  103 
  
103 
Anacardium occidentale  
 
19 
 
19 
Boswellia serrata  
 
22 
 
22 
Citrus aurantium  42 
  
42 
Zanthoxylum nitidum  41 
  
41 
Melia azedarach  
 
46 
 
46 
Azadirachta indica  
 
30 
 
30 
Eurycoma longifolia  
  
79 79 
Brucea javanica  9 
  
9 
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Samadera indica  
  
16 16 
Gynostemma pentaphyllum  47 
  
47 
Citrullus lanatus subsp. vulgaris  
  
15 15 
Momordica charantia  
  
47 47 
Trichosanthes kirilowii  50 
  
50 
Phyllanthus niruri  
 
6 6 12 
Ricinus communis  
 
50 
 
50 
Euphorbia hirta  
 
15 
 
15 
Garcinia atroviridis  
  
6 6 
Garcinia mangostana  
  
62 62 
Albizia lebbeck  
 
27 
 
27 
Senna tora  49 
 
49 98 
Senna alata  
  
4 4 
Astragalus complanatus  29 
  
29 
Spatholobus suberectus  48 
  
48 
Pisum sativum  
 
56 
 
56 
Abrus precatorius  
 
32 32 64 
Sophora tonkinensis  37 
  
37 
Sophora japonica  17 
  
17 
Cornus officinalis  140 
  
140 
Diospyros kaki  
  
28 28 
Centella asiatica  
 
38 38 76 
Angelica sinensis  90 
  
90 
Foeniculum vulgare  38 
  
38 
Elephantopus scaber  
 
24 24 48 
Carthamus tinctorius  121 
  
121 
Atractylodes lancea  23 
  
23 
Saussurea costus  
 
16 
 
16 
Gynura procumbens  
  
2 2 
Inula britannica  32 
  
32 
Eclipta prostrata  28 
  
28 
Centipeda minima  29 
  
29 
Artemisia argyi  106 
  
106 
Chrysanthemum x morifolium  50 
  
50 
Chrysanthemum indicum  19 
  
19 
Heliotropium indicum  
 
6 
 
6 
Cuscuta chinensis  19 
  
19 
Datura metel  
 
19 
 
19 
Physalis minima  
  
5 5 
Withania somnifera  
 
26 
 
26 
Calotropis gigantea  
 
16 
 
16 
Catharanthus roseus  
  
54 54 
Gardenia jasminoides  12 
  
12 
Rubia cordifolia  
 
12 
 
12 
Oldenlandia diffusa  22 
  
22 
Forsythia suspensa  86 
  
86 
Andrographis paniculata  
 
21 21 42 
Bacopa monnieri  
 
9 
 
9 
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Picrorhiza kurrooa  
 
11 
 
11 
Scutellaria baicalensis  43 
  
43 
Scutellaria barbata  69 
  
69 
Lycopus lucidus  11 
  
11 
Prunella vulgaris  45 
 
45 90 
Ocimum tenuiflorum  
 
13 
 
13 
Orthosiphon stamineus      34 34 
Total 2,292 1,583 1,127 5,002 
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3.2.2 A phylogenetic tree of anti-cancer plants 
The anti-cancer plants were converted into NCBI Taxonomy IDs and standardised scientific 
names by using the NCBI Taxonomy Database (202). The list of IDs was uploaded to the first 
web-based tool, Phylogenetic Tree Generator (phyloT) (203) to create an output file of 
phylogenetic tree in Newick format. The figure of the phylogenetic tree was generated by 
uploading the Newick file format to the second web-based tool, Interactive Tree Of Life 
(iTOL) v3.4 (204). A table of source(s) of the TM for each scientific name was created in a 
separate file to create a bar chart label at the end of each node of the phylogenetic tree.  
 
3.2.3 Structural similarities between TM compounds and anti-cancer drugs 
Both TM compounds and 151 anti–cancer drugs of DrugBank (30), in SMILES (simplified 
molecular-input line-entry system) format, were characterised as 2,048 bit of ECFP_4 circular 
Morgan-type fingerprints (Figure 3.2) using RDkit (205). The generation of ECFP_4 
fingerprints can be described in three steps (48). First, each heavy atom of a molecule is 
assigned with an identifier. Second, the features of each atom are described through two 
iterations that equal to four bonds diameter from the identifier. At iteration zero, the 
information only represents the initial atom identifier (atom 1). At iteration one, the 
information describes the immediate neighbours (atom 2) of atom 1. At iteration two, the 
information describes the immediate neighbours of atom1 and the immediate neighbours of 
atoms 2. The iteration step is repeated for all identifiers in a molecule. Third, duplicates of the 
same feature are removed by keeping only one representative of that particular feature. As a 
result, the fingerprint of a molecule contains sub-structural information from all parts of the 
molecule.  
 
Figure 3.2: The figure illustrates an example of how an ECFP4 fingerprint is generated for 
C1 of a molecule. Each iteration describes larger and larger circular neighbourhoods of C1 
atom. After two iterations, the description of C1 atom has grown further to include amide 
group, carboxylic group and as much of the aromatic ring. 
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After generating the ECFP_4 fingerprints, the pairwise similarity combinations were 
calculated using Tc. The conversion was done in a workflow built in KNIME v.2.10.4 (206). 
Only Tc values between TM compounds and anti-cancer drugs were extracted for analysis.  
 
3.2.4 Comparison of scaffold diversity 
The compound structures of the previously generated SMILES format were uploaded to 
DataWarrior v4.2.2 (207). The frameworks of the compounds were decomposed into Murcko 
scaffolds (208). Each type of scaffold was given a unique identifier for comparison purposes. 
To measure scaffold diversity, for each TM dataset, a ratio between the number of unique 
scaffolds and the total number of compounds was calculated. The ratios of the 
Order/Family/Genus to quantity unique scaffolds were measured to determine whether the 
scaffold diversity was influenced by the taxon. The distribution of scaffold diversity of each 
TM dataset was measured using cyclic systems retrieval (CSR) curves (209). This was done 
by plotting two types of fractions, fraction of scaffolds and fraction of database, from the 
most common scaffolds to the least common scaffold. The fraction of scaffolds was defined 
as the ratios of compounds to scaffold types, while the fraction of database was defined as the 
ratios of compound of the scaffold types to the total number of compounds. The diversity of a 
TM dataset was determined by the fraction of scaffolds accounting for 50% of the TM 
compounds, which is also known as F50 (209). 
 
3.2.5 Compounds pre-processing 
The compounds in SMILES format were uploaded to Standardizer (210) to standardise the 
compounds prior to in silico target prediction. Six pre-selected actions were specified in the 
configuration file; ‘Remove Fragment’, ‘Remove Explicit Hydrogens’, ‘Neutralize’, ‘Clean 
2D’, ‘Mesomerize’ and ‘Tautomerize’. The standardised TM compounds were saved in 
SMILES format.  
 
3.2.6 Target prediction 
The standardised compounds were run on an in silico target prediction algorithm that was 
modeled using the Random Forest (211). Briefly, the model contained a training set of active 
compounds extracted from ChEMBL v.21.0 (28) and inactive compounds extracted from the 
PubChem Compound and PubChem BioAssay databases (212). In total, the model contained 
5,888,615 ligand-target pairs of actives and inactive associate with 1,651 targets. The active 
training set were active compounds with reported activities (Ki/Kd/IC50/EC50) of lower than 10 
μM with a CONFIDENCE_SCORE of 5 or greater for ‘binding’ or ‘functional’ human 
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protein assays (28). The inactive training set were inactive compounds of assays submitted by 
researchers to PubChem Compound and PubChem BioAssay databases (28). The descriptor 
of a molecule was generated based on ECFP_4 circular Morgan-type fingerprints (48) with a 
2,048 bit length, hence stereochemistry of compounds was excluded. The algorithm calculates 
the probability of an orphan compound belonging to a target class by considering both 
chemical features of active and inactive compounds against target classes, giving a more 
holistic perspective of chemical features, which contribute towards or against bioactivity. 
To predict targets of TM compounds, the Random Forest (RF) classifier can be briefly 
described as follows. First, a Scikit-learn (Version 17) RF classifier of 100 trees, with the 
number of features and max depth set to ‘auto’ and the ‘class_weight’ set to ‘balanced’, was 
trained using the binary matrix of the active and inactive compound-target fingerprints on a 
per-target basis (213). Models generate a probability representing the number of trees in the 
forest that predict a target as active, represented as p(activity). Platt scaling (214), a 
calibration method in machine learning, is performed to convert the classification from the 
random forest into the probabilities of the prediction being correct, which is known as True 
Positive Rate (TPR). 
 
3.2.7 The TPR of predicted targets 
The TPR value was selected by assessing the distribution of fraction of targets predicted for 
each TPR interval of 0.1 between 0 and 1. A curve of the fraction of targets predicted TPR 
intervals was evaluated to define a TPR threshold of each TM (Figure 3.3). In general, the 
fraction of targets predicted decreases as the threshold value increases. A threshold value of 
0.7 was selected for all TM datasets because at least 60% of the targets in the model were 
predicted. The selected threshold value is a reasonable trade-off between false-negative 
predictions and number of predicted targets compares to larger threshold values. By using the 
selected TPR threshold, the target predictions algorithm was performed, which produced a 
binary matrix of predicted targets. 
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Figure 3.3: The curves of the fraction of targets predicted decreases when TPR values 
increases. A TPR threshold value of 0.7 was selected in this analysis because more than 60% 
of the targets were predicted. 
 
3.2.8 Annotating predicted targets as cancer-related targets  
The UniProt IDs of the predicted targets were mapped to their gene names in the Retrieve/ID 
mapping tab in UniProt (116). We found that three UniProt IDs, P47929, Q13748, and 
Q16637 were annotated with two gene names, while P62158 was annotated with three gene 
names. Only primary gene names defined by Uniprot (116) were used in the analysis. Two 
pairs of UniProt IDs, A2TJX0, Q13887 and P0DMS8, P33765 were synonyms. All the gene 
names were uploaded to Target Validation Platform (215) to annotate the gene names with 
cancer. By using the keyword ‘cancer’ in the search tab of the Target Validation Platform 
(215), a total of 28,019 genes associated with cancer was listed. The list was compared to the 
gene names of predicted targets.  
 
3.2.9 Heatmap with hierarchical clustering based on bioactivity space and target class  
Two heatmaps were generated in this study. The first heatmap compared the bioactivity space 
similarities of the TM plants, while the second heatmap compared the targets classes of TMs. 
Before constructing the heatmaps, the frequencies of compounds of per predicted target and 
the frequencies of predicted target per target class were normalised. The dissimilarity 
distances between the normalised frequencies of TM plants/target classes were calculated 
using ‘Euclidean’ method of the “dist” function. Clustering was performed using the Ward 
method of the “hclust” function, where two TM plants/target classes were merged if the sum 
of squared Euclidean distance was minimal. The heatmaps were generated using “heatmap” 
function. All the aforementioned functions were available in the stats package of R (114).  
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3.3 Results and Discussions 
3.3.1 Phylogenetic tree of anti-cancer plants  
In this study, a total of 97 anti-cancer plants were used to construct a phylogenetic tree 
(Figure 3.4) and each plant was annotated with its source of TM (TCM/Ayurveda/Malay 
TM). Altogether, nine identical plants were found in Ayurveda and Malay TM, two identical 
plants were observed between TCM and Malay TM, one identical plant was identified in 
TCM and Ayurveda and one plant was present in all three TMs. The distribution of the 
labelled TM plants is observed to be scattered along the phylogenetic tree and is not clustered 
according to the type of TM indicating that, in many cases, the plants from different TMs 
share common ancestors. In other words, TMs are, according to this analysis, intrinsically 
related to each other. Each terminal taxon is marked with filled circles that represent 
taxonomic ranks. For each plant, the rings around the filled circles represent superkingdom, 
kingdom, phylum, order, family and genus. These taxonomic ranks were consistently 
annotated. The remaining ranks that were annotated varied from class, subclass, subfamily, 
tribe, subtribe, subgenus, and subspecies. 
Figure 3.4 shows that all plants are rooted to phylum, Streptophyta. The TM plants 
were annotated with 27 orders, 48 families, and 90 genera, indicating that the most immediate 
evolutionary relationship of the plants is found at genus level. There are seven clades that 
share the same genus, Piper betle (Ayurveda) and Piper nigrum (Malay TM), Zingiber 
montanum (Malay TM) and Zingiber officinale (TCM and Ayurveda), Polygonum aviculare 
(TCM) and Polygonum cuspidatum (TCM), Garcinia atrovirdis (Malay TM) and Garcinia 
mangostana (Malay TM), Senna tora (TCM and Malay TM) and Senna alata (Malay TM), 
Sophora tonkinensis (TCM) and Sophora japonica (TCM), Chrysanthemum x morifolium 
(TCM) and Chrysanthemum indicum (TCM), and Scutellaria baicalensis (TCM) and 
Scutellaria barbata (TCM). For at least three pairs plants, the findings indicate that plants of 
different TMs with the same medicinal usage are evolutionary related. A similar observation 
was demonstrated by Saslis-Lagoudakis et. al (216). The study of the genus Pterocarpus that 
is geographically distributed in Neotropics, Tropical Africa and Indomalaya indicates the 
same ethnomedicinal uses of Pterocarpus plants, which have been largely used for gastro-
intestinal and skin illnesses. At a molecular level, the similar medicinal properties of plants of 
shared phylogeny was investigated by Lopez et. al (217). The screening of alkaloid extracts of 
26 wild plants belonging to the genus Narcissus L., for acetyl cholinesterase (AChE) 
inhibitory activity shows that the lowest IC50 values are expressed by those extracts 
containing galanthamine. 
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In general, the TM plants share different genera, which can be explained by 
convergent evolution (218). Independent evolution of the same trait is a result of unrelated 
plants in the phylogeny to adapt to similar environmental challenges. Hence, similar 
compounds of different TM plants might be responsible for the observed therapeutic effects. 
The screening of phytochemical constituents of different plants with overlapped medicinal 
uses could confirm the distribution of similar bioactive compounds. For example, the 
investigation of phytochemicals of ten medicinal plants of different families in the Mardan 
region of Pakistan shows that flavanoids are identified in six medicinal plants, which have 
been used traditionally for heart disease (219).  
Therefore, it was hypothesised that the common MOAs of TM plants for treating 
cancer would stem from similar compounds, and the phylogenetic distance between the plants 
could either be small or large. The phylogenetic tree of 97 TM plants was used to determine 
whether proximity in the phylogenetic tree resembled the similarity of chemical as well as 
cancer-related bioactivity space of the compounds of those plants. 
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Figure 3.4: The phylogenetic tree of 97 plants of three TCM, Ayurveda, and Malay TM. Each plant was labelled to its source(s). All plants were 
annotated (rings with filled circle) to the same superkingdom, kingdom and phylum (on the top right) with 27 orders, 47 families and 90 genera, 
implying diverse plants have been traditionally used for treating cancers. 
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3.3.2 Comparison of chemical space between TM compounds and anti-cancer drugs 
We next analysed the chemical space similarities between TM compounds and 151 anti-
cancer drugs from DrugBank (30). In this study, the Tc value of 0.3 was used to determine 
whether a TM compound is structurally similar to an anti-cancer drug, considering the 
previous report on the activity–relevant similarity of active compounds (220). Only 204 TM 
compounds (including identical compounds of different plants) were structurally similar to 28 
anti-cancer drugs. The list of 28 anti-cancer drugs and the similar TM compounds can be 
found in Table A3.1 (Appendices). 
The observation of Table A3.1 shows that the anti-cancer drugs can be classified into derived 
from natural products or resembling metabolites. Among the anti-cancer drugs in the first 
group are Abiraterone (DB05812), Cytarabine (DB00987), Ingenol Mebutate (DB05013), 
Vinblastine (DB00570), Vincristine (DB00541), Vindesine (DB00309) and Vinorelbine 
(DB00361) are derived from plants (Table 3.2), while the remaining anti-cancer drugs are 
derived from bacteria (221-224). Abiraterone (DB05812) is naturally derived from 
ketoconazole, an anti-fungal agent, which has caused serious side effects when the compound 
is given to prostate cancer patients (225, 226). Abiraterone has been used for castration 
resistant prostate cancer in men, in which the drug modulates CYP17, a catalysis enzyme for
the production of androgen, to inhibit the proliferation of prostate cancer cells (227). It was 
discovered that beta-sitosterol, which is structurally similar to Abiraterone (DB05812) (Tc = 
0.331), is widely distributed in 40 different plants (Table A3.1). Structurally, both beta-
sitosterol and Abiraterone contain steroid four-fused rings and differ in their side chains. 
Although beta-sitosterol is not developed into an anti-cancer drug, the compound has been 
studied extensively and showed to induce apoptosis in cancer cells in vitro (228). Cytarabine 
(DB000987) is inspired by a series of C-nucleoside-derived compounds isolated from the 
Caribbean sponge, Cryptotheca crypta, which is widely used for the treatment of leukaemia 
and lymphoma (229). Cytarabine shows structural similarities with guanosine (Tc=0.357) and 
adenosine (Tc=0.333) of Allium sativum (Ayurveda and Malay TM), adenosine (Tc=0.333) of 
Carthamus tinctorius (TCM), and uridine (Tc=0.420) of Isatis tinctorius (TCM). These TM 
compounds are also nucleosides. Ingenol Mebutate (DB05013), isolated from Euphorbia 
peplus, has been used for the treatment of skin cancer by inducing cellular necrosis (230). 
Table 3.2 shows that Ingenol-triacetate of Euphorbia hirta (Ayurveda) is structurally similar 
to Ingenol mebutate with a Tc value of 0.456. It has been reported that the methanol extract of 
Euphorbia hirta has been evaluated for cytotoxic activity with the most effective activity is 
the inhibition of HEp‐2 cell proliferation (231). All four drugs, Vinblastine (DB00570), 
Vincristine (DB00541), Vindesine (DB00309), and Vinorelbine (DB00361) are derived from 
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Catharanthus roseus (Malay TM) and two compounds of this plant (leurosidine and 
leurocristine) showed Tc values of 1.0 to Vinblastine and Vincristine. The MOA of 
Vinblastine has been reported by binding to tubulin and microtubules, which subsequently 
depolymerises the microtubules and destroys mitotic spindles to block mitosis of cancer cells 
(232). Among other TM compounds that are structurally similar to the four drugs is vindoline, 
which has been reported with cytotoxic activity against the human colorectal carcinoma cell 
line HCT 116 (233). In the second group, a few of the anti-cancer compounds resemble the 
naturally occurring compounds in the human body (guanosine, pehenylalanine, thymidne, 
uridine) such as Decitabine (DB01262), Clofarabine (DB00631) and Fluradabine (DB01073). 
These drugs act by interfering with cellular processes of naturally occurring nucleosides such 
as nucleic acid synthesis, cell signalling and enzyme metabolism (234). The summary of these 
seven anti-cancer drugs can be found in Table 3.2. Given that only seven anti-cancer drugs, 
which are derived from plants, are structurally similar to the TM compounds, the findings 
indicate the possibilities of finding more anti-cancer compounds from TM plants due to many 
unexplored compounds.  
 66 
Table 3.2: The structurally similar TM compounds and anti cancer drugs. The complete list of TM compounds that are similar (Tc ≥ 0.3) to the anti-
cancer drugs can be found in Table 1S in Supporting Information. Only the compounds with the highest Tc value are shown here. 
 
*PID : PubChem ID 
No Anti-cancer drugs DrugBank 
ID 
TM compounds Plants Source of TM Tc 
value 
1 Abiraterone  
(PID 132971) 
 
DB05812 Bassicaterol  
(PID 5281327) 
 
Houttuynia cordata 
Moringa oleifera 
 
TCM 
Ayurveda, 
Malay TM 
0.339 
2 Cytarabine  
(PID 6253) 
 
DB00987 Uridine  
(PID 6029) 
 
Isatis tinctoria TCM 0.420 
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3 Ingenol Mebutate 
(PID 6918670) 
 
DB05013 Ingenol-Triacetate 
(PID 65377) 
 
Euphorbia hirta Ayurveda 0.456 
4 Vinblastine  
(PID 13342) 
 
DB00570 Leurosidine (Vinrosidine)  
(PID 161115) 
 
Catharanthus roseus Malay TM 1.00 
 68 
5 Vincristine  
(PID 5978) 
 
 
 
 
 
DB00541 Leurocristine  
(PID 5978) 
 
 
 
 
Catharanthus roseus Malay TM 1.00 
6 Vindesine 
(PID 40839) 
 
 
 
 
DB00309 Leurosidine (Vinrosidine) 
(PID 161115) 
 
 
 
 
Catharanthus roseus Malay TM 0.733 
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7 Vinorelbine 
(PID 5311497) 
 
DB00361 3’,4’-Anhydrovinblastine 
(PID 443324) 
 
Catharanthus roseus Malay TM 0.756 
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3.3.3 Molecular scaffold analysis  
The decomposition of the compounds’ frameworks based on Murcko scaffolds (208) 
produced 776 unique scaffolds, which represented 76.63% of the compounds, while the 
remaining compounds were identified as macrocyclic and acyclic compounds (23.37%). From 
776 scaffolds, the highest common scaffold, 14.18%, was between Ayurveda and Malay TM, 
owing to the same plants found in both TMs. The three TMs shared 13.40% common 
scaffolds. The common scaffolds of TCM-Ayurveda and TCM-Malay TM was 3.87% and 
3.22% respectively. Nevertheless, each TM comprised a set of distinct scaffolds, which was 
29.12%, 18.30%, and 17.91% for TCM, Ayurveda, and Malay TM respectively. The higher 
percentages of distinct scaffolds than common scaffolds imply that the TMs were diverse 
from each other.  
To compare the diversity of the three TM datasets, various ratio metrics (N/M, 
Nsing/N, and Nsing/M) (190) were calculated in Table 3.3. In general, the higher the ratio, 
the more diverse the dataset is. From this analysis Malay TM is highly diverse followed by 
Ayurveda and TCM. In addition to ratio metrics, cyclic systems retrieval (CSR) curves, which 
have been used previously to assess the distribution of compound in cyclic systems, were 
generated (Figure 3.5) (190, 209). The curves also show that Malay TM is the most diverse 
dataset followed by Ayurveda and TCM, with the F50 values of TCM, Ayurveda, and Malay 
TM are 0.018, 0.028, and 0.052. Despite having the largest set of compounds, TCM has the 
least diverse scaffolds, where 50% of the TCM compounds were decomposed into six types 
of scaffolds. At one-half of the datasets, Ayurveda and Malay TM,compounds were 
decomposed into eleven and twenty types of scaffolds respectively. 
The low scaffold diversity of the TCM dataset is not influenced by the phylogeny 
where the ratio of scaffold to order and scaffold to genus are the highest compared to those of 
Ayurveda and Malay TM. Many similar compounds of TCM belong to unrelated plants. On 
the contrary, the high scaffold diversity of the Malay TM data set is influenced by the 
phylogeny where the ratio of scaffold to order, scaffold to family and scaffold to genus were 
the lowest. The results can be seen in the phylogenetic tree, where, in many cases, Malay TM 
plants are closely clustered. In brief, the findings demonstrate that TCM agrees with the 
convergent evolution process whereas the diverse scaffolds observed in Malay TM can be 
explained by divergent evolution (186). 
 71 
Table 3.3: Results of scaffolds diversity analysis. 
Database M N O F G N/M Nsing Nsing/N Nsing/M O/N F/N G/N 
TCM 2292 391 20 24 43 0.17 213 0.54 0.09 0.051 0.061 0.110 
Ayurveda 1583 392 19 28 36 0.25 236 0.60 0.15 0.048 0.071 0.092 
Malay TM 1127 383 16 19 26 0.34 252 0.66 0.22 0.042 0.050 0.068 
 
 
M=No of compound in database, N=No of unique scaffolds, O=No of Order taxon, F=No of Family taxon, G=No of Genus taxon,  
Nsing=No of singleton scaffolds 
 
 
Figure 3.5: The cyclic systems retrieval (CSR) curves indicate Malay TM has higher scaffold diversity than Ayurveda and TCM. At one-half of the 
dataset, the compounds of Malay TM were decomposed into 20 scaffold types compared to Ayurveda (eleven scaffold types) and TCM (seven scaffold 
types). 
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 To further analyse the prevalent scaffolds of TMs, we looked at the top ten most 
frequent scaffolds (Figure 3.6). Overall, six scaffolds were frequently present in all TMs, two 
scaffolds were frequently present in Ayurveda and Malay TM and one scaffold was 
frequently present in Ayurveda and TCM. No common scaffold was observed between TCM 
and Malay TM. Each TM showed three (TCM), two (Malay TM), one (Ayurveda) different 
scaffolds from each other. It was found that the benzene scaffold was the highest frequent 
scaffold identified across all TMs, which also has been commonly identified in other natural 
product databases (190). A few of these scaffolds are already explored scaffolds in drug 
discovery such as anthraquinone (235), coumarin (236), cyclohexene (237), flavone and 
isoflavone (238), sterol (239), pentacyclic tritepenes (240) and xanthone (241) with various or 
focused therapeutic activities. Regarding the cancer-related scaffolds anthraquinone, flavone, 
sterol and pentacyclic triterpenes are four frequent scaffolds in all TMs. 
Anthraquinone is a tricyclic planar ring system with various therapeutic properties (235). The 
reported MOA of anthraquinone derivatives is primarily by intercalating its aromatic structure 
with DNA between base pairs to possibly inhibit  DNA replication in cancer cells (235). The 
substitution patterns of the anthaquinone scaffold also contribute to the anti-cancer properties 
of the compounds (235). Flavone contains three-ring skeletons, and the MOAs of flavone 
derivatives are diverse. The functional groups of the scaffold makes it amenable to selective 
modulators for different targets (238). Phytosterol, which contains a tetracyclic lipid 
component, is implicated in cholesterol metabolism (239). One of the MOAs is by lowering 
blood cholesterol by incorporating less cholesterol in the lipid rafts of cancer cells, thus, 
promoting apoptosis through signal transduction (239). Pentacyclic triterpene is one of the 
widely spread secondary metabolites in plants with diverse biological properties. The MOAs 
of betulinic, ursolic, oleanolic and maslinic acids, a few of the representative compounds of 
the group, are implicated in cell apoptosis by activating either intrinsic (mitochondrial) or 
extrinsic (death receptor) apoptotic pathways (240). Xanthone, which is more frequently 
present in Malay TM, contains a three-membered heterocyclic ring. Similar to the 
anthraquinone, xanthone derivatives are also DNA-intercalating modulators (241). The 
stereochemistry of xanthonic derivatives is described to influence their MOAs (242). 
Coumarin, which is more frequently present in TCM, consists of a benzene ring joined with a 
pyrone ring. The MOAs of coumarin derivatives are diverse through the diverse substitution 
of the coumarin nucleus (236). Although cyclohexene is among the most frequently present 
scaffolds in all TMs, this scaffold is more known as an anti-influenza drug, Oseltamivir (243) 
than that anti-cancer scaffold. 
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To summarise, the most frequent scaffolds in the TMs, in many cases, are widely 
explored for their anti-cancer properties, where the MOAs can either stem from the core 
structure or functional group substitutions. The compounds are primarily reported to induce 
apoptosis of cancer cells. The remaining scaffolds in the top ten frequent scaffolds could be 
worth exploring for their anti-cancer activities, as they are found to abundance in anti-cancer 
plants. 
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0.98% 
Figure 3.6: The top ten most frequent scaffolds of TMs. Six scaffolds are frequent in all TMs, 
two scaffolds are frequent in Ayurveda and Malay TM and one scaffold is frequent in 
Ayurveda and TCM. No common scaffold is observed between TCM and Malay TM only. 
Each TM shows three (TCM), two (Malay TM), one (Ayurveda) different scaffolds that are 
more frequent in that TM than the remaining two TMs.   
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3.3.4 Comparison of bioactivity space of the plants  
We next performed the comparison of the bioactivity space. Out of 1,651 targets in the in 
silico target prediction model, 1,163 were predicted. All the predicted targets were annotated 
with cancers when compared to the list of associated cancer targets from a Target Validation 
Platform (215). The normalised frequency of predicted targets was used to generate a heatmap 
in Figure 3.7, which compares the bioactivity space of TM plants.  
Overall, the majority of TM plants show similarities of their bioactivity space but they 
are not phylogenetically related, except in a few cases. The similarities of the bioactivity 
space between TM plants with relation to their phylogeny can be observed in three clusters, I, 
II and III, which are labelled on the left dendrogram of the heatmap. The main difference of 
the three clusters is that the plants of Cluster I contain a higher number of compounds than 
plants in Cluster II and III, hence more similar predicted targets are observed between plants 
in Cluster I. Despite the parse distribution of compounds in TM plants, the heatmap shows 
that the similar bioactivity space between eight pairs of plants could be linked to their 
phylogeny either at the order, family or genus taxonomic rank in all three clusters. The top 
three frequently annotated protein families of shared predicted targets are selected to describe 
the observation. In cluster I, two pairs of plants are shown with similar bioactivity space. The 
first pair, Alpinia officinarum (TCM) and Zingiber officinale (Ayurveda and Malay TM) share 
the same family (Zingiberaceae) and order (Zingiberales). The second pair, Alium sativum 
(Ayurveda and Malay TM) and Aloe vera (Ayurveda and Malay TM) are members of the 
same order, Asparagales. The percentages of identical predicted targets are 67.54% and 
77.53% in both pairs respectively. The compounds of those four plants were predicted to 
modulate targets of all protein families, and the top five frequent target classes are kinase, 
oxireductase, ion channel, GPCR and hydrolase.  
In the Cluster II, three pairs of plants are identified to share similar bioactivity space, 
namely, Spatholobus suberectus (TCM) and Sophora tonkinensis (TCM), and Eclipta 
prostrate (TCM) and Chrysanthemum x morifolium (TCM) are members of the family, 
Fabaceae and Asteraceae, and the order, Fabales and Asterales, respectively. The third pair of 
the plants, Scutellaria barbata (TCM) and Scutellaria baicalensis (TCM), is phylogenetically 
related at the genus level, Scutellaria. The percentages of overlapped bioactivity space for 
each pair of the plants are 73.29%, 72.05% and 70.56% respectively. The family Fabaceae 
and Asteraceae share bioactivity spaces that are frequently annotated to kinase, 
oxidoreductase, ion channel, GPCR and transferase. The pair of genus Scutellaria plants was 
also frequently annotated with the same target classes as previous pairs except the fifth target 
class was hydrolase. 
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In Cluster III, three pairs of plants are phylogenetically related at the family and order 
level. The first pair, Ocimum tenuiflorum (Ayurveda) and Lycopus lucidus (TCM) share the 
same family (Lamiaceae) and order (Lamiales). The top five target classes of the overlapped 
predicted targets between these plants are kinase, hydrolase, oxireductase, nuclear hormone 
receptor (NHR) and GPCR. The final two pairs of plants of this cluster are only 
phylogenetically related at the order level. The first pair, Phyllanthus niruri (Ayurveda and 
Malay TM) and Garcinia atroviridis (Malay TM) are members of the order Malpighiales. The 
second pair, Picrorhiza kurrooa (Ayurveda) and Orthosiphon stamineus (Malay TM) belongs 
to the order, Lamiales. Both plants of the order, Malpighiales and Lamiales were predicted to 
modulate targets that are frequently annotated to oxireductase, kinase, transferase, lyase, and 
hydrolase. The percentages of identical predicted targets are 66.10%, 41.20% and 42.90% for 
the first, second and third pair.  
 Out of eight pairs of plants with similar bioactivity space and phylogenetically 
related, only one pair of plants, Scutellaria barbata (TCM) and Scutellaria baicalensis (TCM) 
is related at genus level. The genus Scutellaria is widely studied for various medicinal 
properties, and phenols and terpenes have been demonstrated with anti-cancer properties 
(244). Five pairs of plants belong to the same source of TM except for Alpinia officinarum 
(TCM) and Zingiber officinale (Ayurveda and Malay TM), Ocimum tenuiflorum (Ayurveda) 
and Lycopus lucidus (TCM) and Picrorhiza kurrooa (Ayurveda) and Orthosiphon stamineus 
(Malay TM). Out of the five pairs of plants, three of them, from Cluster II, belong to TCM, 
which could contribute to the low scaffold diversity of the TCM dataset found in the previous 
section. The annotation of the target classes demonstrates that kinase and oxireductase are the 
two most frequent annotated target classes in all eight pairs of plants. In conclusion, 
generally, TM plants agree with the convergent evolution process, where these plants share 
common MOAs, except in a few cases, where the common MOA can be described from their 
relations in the phylogeny. 
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Figure 3.7: The heatmap compares the bioactivity space of the TM plants based on the 
normalised numbers of compounds modulating the predicted targets. In general, a large 
number of TM plants share similar bioactivity space although they are not phylogenetically 
related. Only eight pairs of plants are shown to be phylogenetically related when compared to 
Figure 3.2. These observations can be described by dividing the heatmap into three clusters, 
Cluster I, II, and III, which for each cluster, at least two pairs of plants (blue box) are 
phylogenetically related and share similar bioactivity space. The evolutionary relationship of 
these plants can either be from the genus, family or order taxonomic rank. 
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3.3.5 Comparison of targets classes of traditional medicines 
In this part of study, the aim was to determine the significant target classes of TMs by 
classifying the predicted targets to their respective target classes. The 1,163 predicted targets 
were annotated to 14 target classes and one type of target class, ‘Other’, of which the target 
class of the remaining targets were not classified. The heatmap in Figure 3.8 compares the 14 
target classes between the TMs. The more saturated colour across the TMs the more 
significant the target class. The number of the target classes in the TMs was normalised due to 
the differences in numbers of the predicted targets per TM. What can be seen from the 
heatmap is that all TMs exhibit kinase as the most significant target class. Kinase, which is 
one of the largest target classes plays many key roles in cellular functions such as signal 
transduction, cell cycle regulation, cell division, and cell differentiation, which genetic 
alterations can often lead to cancer (245). Per target class, the results showed that only three 
target classes, hydrolase, phosphatase and transporter, were more significant in TCM. Four 
target classes were discovered to be more significant in Ayurveda, which are GPCR, ion 
channel, oxireductase, and protease. Six target classes, isomerase, ligase, lipase, lyase, NHR 
and transferase, were identified to be more significant in Malay TM. The observations imply 
that the TMs use could exert diverse MOAs by modulating various target classes, which can 
explain the holistic approach of the TMs. 
In TCM, among the three significant target classes, hydrolase is the most frequently 
annotated. The frequently predicted targets of hydrolase are histone deacetylases (HDACs) 
(246). HDAC is involved in the regulation of gene expression of cell proliferation, cell cycle 
regulation and apoptosis, which mutations of HDAC could lead to cancer (247). It is observed 
that GPCR is the most frequent annotated target class in Ayurveda. The most frequent 
predicted targets of GPCR are serotonin receptors (5-hydroxytryptamine). Serotonin receptor 
is implicated in cancer by acting as a growth factor on several types of tumour (248). In 
relating to Malay TM, transferase is the most frequent annotated target class, which is 
frequently annotated to DNA polymerases. DNA polymerase, an enzyme that synthesises 
DNA, is generally involved in cancer pathogenesis when DNA strand breaks are not 
prohibited for DNA replication as the function of p53 is loss (249). The difference in target 
classes suggests that TMs could exhibit differential MOAs for treating cancers. 
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Figure 3.8: The heat map compares the 14 target classes of the TMs based on the normalised 
numbers of predicted targets. Kinase is observed to be the most significant target class in all 
TMs. Three, four and six target classes are observed to be more significant in TCM, Ayurveda 
and Malay TM. The findings indicate that the TMs could exhibit different MOAs for treating 
cancers. 
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3.4 Conclusion 
TCM, Ayurveda and Malay TM are practiced in different geographical locations but all three 
TMs have been reported for treating cancers. Given the increasing amount of chemical 
information available, this study compared both the chemical and bioactivity space that are 
utilized by such medicines. The phylogenetic tree of 97 TM plants was used to determine 
whether proximity in the tree resembled the similarity of chemical and bioactivity space. It 
was found that in these plants were members of 27 orders, 48 families, and 90 genera 
indicating convergent evolution, where the plants experience similar environmental 
challenges to result similar anti-cancer properties. In the chemical space analysis, seven anti-
cancer drugs, which were derived from plants, were shown to be structurally similar to the 
TM compounds (Tc ≥ 0.3). The scaffold diversity analysis demonstrated that Malay TM is the 
most diverse TM followed by TCM and Ayurveda. The convergent evolution process could 
explain the low diversity of TCM and the high diversity of Malay TM is a common process of 
divergent evolution. In the top ten most frequent scaffolds, benzene, anthraquinone, flavone, 
sterol, pentacyclic tritepene and cyclohexene were the most frequent scaffolds in all TMs. 
Anthraquinone, flavone, sterol and pentacyclic tritepene have been reported for anti-cancer 
activities. There are six different scaffolds that are more frequent in one of the TMs than the 
remaining two TMs, which could be worth exploring for anti-cancer activities due to their 
abundance. The comparison of the bioactivity space showed that only eight pairs of plants 
with similar bioactivity spaces were phylogenetically related at either genus, family or order 
level. The observations indicate that the common MOAs for a large number of TM plants are 
not related to their phylogenies. The annotation of the bioactivity space with target classes 
revealed kinase was the most significant target class in all TMs. Four, three and six targets 
classes were observed to be more significant in TCM, Ayurveda and Malay TM respectively 
suggesting TMs could exhibit differential MOAs. By comparing chemical and bioactivity 
space, these approaches provide a closer understanding of the common and differential MOAs 
of different anti-cancer plants used by TCM, Ayurveda and Malay TM for treating cancers. 
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Chapter 4:  
Evaluating Synergistic Pairwise Combinations of Shexiang Baoxin Pill (SBP) for Coronary 
Heart Disease from Network Topology 
 
 
4.1 Introduction 
The World Health Organization (WHO) has projected that cardiovascular disease (CVD) will 
be the leading cause of death globally by 2030 with 23.6 millions deaths (250). A staggering 
statistic in 2012 already showed that at least 42% of the deaths relating to cardiovascular 
disease were contributed by coronary heart disease (CHD). This is also projected to increase 
(250). CHD is a disease pertaining to the blood vessels supplying the heart muscle, whose 
clinical symptoms include angina, myocardial infarction, sudden death and chronic heart 
failure (251). The pathophysiology of CHD has been generally described as an imbalance of 
supply and demand of oxygen in the heart muscle, which is also known as myocardial 
hypoxia, which eventually leads to a sudden reduction in coronary flow (252). To reduce the 
risk and fatal consequences of CHD, several drugs have been prescribed to patients, such as 
anti-platelet drugs, angiotensin converting enzyme inhibitors, beta-blockers, statins and 
calcium-channel blockers, in addition to a surgery option, coronary angioplasty (253). Despite 
the significant progress that has been observed in the treatment of CHD, there are a subset of 
patients who are not suitable for conventional treatments either due to acquiring complex 
diseases or having side effects to the current drugs (253, 254). Hence, there is an urgent need 
to develop new therapeutic tools to overcome the limitations of current treatments. 
Neovascularization through angiogenesis provides a natural repair mechanism for 
CHD. The mechanism aims to improve blood flow by promoting the formation of new blood 
vessels to resupply blood flow to the hypoxic cardiac tissue (255). In addition to the 
development of therapeutic angiogenesis (255), traditional medicine, such as TCM, also 
offers a natural remedy for treating CHD. Shexiang Baoxin Pill (SBP) is one of the widely 
used TCM formulations for CHD, which has been claimed to promote vasodilation and 
angiogenesis in the heart (82). The therapeutic effects of SBP were recently reported by a 
meta-analysis of 26 studies of 2,634 cases collected between 2010 and 2016, which showed 
SBP improved electrocardiogram rate of patients with fewer side effects than isosorbide 
dinitrate for angina pectoris (256). The therapeutic effects of SBP are derived from seven 
different Chinese materia medica, namely Moschus (musk deer), Panax Ginseng (ginseng 
plant), Calculus Bovis (dried gallstone of cattle), Cortex Cinnamomi (cinnamon twig), Styrax 
(resin of rose maloes), Venenum Bufonis (toad venom) and Borneolum Syntheticum (borneol) 
(257). The determination of the SBP compounds has been reported in a few studies (257-259). 
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The studies have identified at least 17 compounds in the formulation, which are regarded as 
the SBP bioactive compounds. Consequently, the identification of SBP bioactive compounds 
allow mechanistic studies to understand the therapeutic effect of SBP. 
The therapeutic effects have been investigated in a few in vivo studies. Xiang et al. 
reported a comparative serum metabolomics study of experimentally induced myocardial 
infarction (MI) in rats that were treated with SBP, a multicomponent formulation called 
SAHRA and five single agents (260). The study revealed that the SBP-treated group showed 
better therapeutic effects than the remaining two groups by regulating three out of four 
pathological processes that are involved in MI development (260). In a follow-up study, 
experimentally induced MI in rats was treated with seven SBP compounds individually and 
an all in one combination (261). The results showed that the physiological parameters of the 
combination were closer to the control group than the monotherapy (261). The interactions 
between the SBP compounds might contribute to the therapeutic effects (261). Jiang et al., 
demonstrated that borneol, one of the active SBP components, enhanced the plasma 
concentration of four types of ginsenoside after oral administration to male Sprague-Dawley 
rats (262). Given the collection of reports, the studies support the claim of the therapeutic 
effects of SBP, which were achieved by the interactions between the compounds.  
However, the MOAs underlying these therapeutics effects remained unexplained. The 
elucidation process is challenging if the compounds are to be tested using the present 
evaluation paradigm for single chemical compounds (263). For this reason, a combination of 
two compounds was selected to understand the MOAs. The study of compound combination 
has become a more common approach in drug discovery from the understanding of a complex 
disease that involves multiple targets and pathways (264). The effects of compound 
combinations can either be synergistic, additive, antagonistic or none, where synergy is the 
desired effect. A synergistic effect results from two compounds that produce an effect greater 
than the sum of their individual effects. The decision process to determine synergy of a 
combination could be measured using three popular strategies, which are Highest single agent 
(HSA) (265), Loewe additivity (266) and the Bliss independence model (267). The HSA 
defines the expected synergy effect (YHSE) is higher than the maximum effect of individual 
compounds (y1 and y2), YHSE=max (y1, y2). Therefore, synergy is determined if an 
experimental combination shows effect higher than y1 or y2. The Loewe additivity quantifies 
synergy if the Combination Index (CI) < 1. The CI value can be measured from the equation 
below.  
𝐶𝐼 =
𝑎
𝐴
+
𝑏
𝐵
 
Equation (4.1) 
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(a , b) are the doses of compounds 1 and 2 in a combination and (A ,B) are the single doses of 
compounds 1 and 2. The Bliss independence model states that two compounds exert their 
effects independently, which the expected synergy effect (YBLISS) of two compounds (Y1 and 
Y2) can be measured from YBLISS = Y1 + Y2 – Y1Y2. Hence, synergy is determined if an 
experimental combination shows an effect higher than YBLISS. 
Although, the identification of synergistic compound combinations is achievable in 
high-throughput screening, usually only a small number of combinations are identified (264, 
268, 269). Therefore, computational approaches have been preferred to quantify, filter and 
rank compound combinations rapidly for guiding experimental investigations (264, 268, 269). 
One such computational approach is predicting compound combinations based on the PPI 
interaction network (269). For example, Li et al., generated a disease-specific network using 
PPI from HPRD and KEGG (270). Based on the network, an algorithm, Network-target-based 
Identification of Multicomponent Synergy (NIMS) was developed to evaluate synergistic 
combinations calculated from the topological relationships of the combinations of targets on a 
disease-specific network and their phenotypes similarities. The combinations with high 
synergy score were validated experimentally and their MOAs were characterised from the 
constructed network. Synergy evaluation was also investigated using drugs. Huang et al. 
established a systematic tool, DrugComboRanker (271). The tool ranked drug synergy 
combinations measured from the topological properties of a network that was generated using 
genomic profiles (271). The targets of the top-ranked synergy drugs were then mapped onto a 
disease-signalling network that could elucidate the drugs’ MOAs that were supported by the 
literature. Hence, it appears that the topological properties of a PPI network maybe able to 
prioritise synergistic combinations and eventually elucidate the MOAs. 
To address the question of synergistic combinations of SBP compounds, this study 
aimed to identify the synergistic compound combinations of pairwise combinations of 22 SBP 
compounds by calculating the synergy scores from a PPI network. The 20 top-ranked and 
bottom-ranked combinations were validated using Human Umbilical Vascular Endothelial 
Cells (HUVEC). The Bliss synergy scores were measured to determine the robustness of the 
synergy score calculation. In the end, the MOAs of the top-ranked combinations were 
described based on the connections of the predicted targets in the network. Hence, this 
method is able to suggest the MOAs of two SBP compounds to explain the claimed 
synergistic effects.  
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4.2 Materials and methods 
4.2.1 Dataset preparation 
The 22 SBP compounds (Table 4.1) were suggested from an on-going study of SBP by Dr 
Tai-Ping Fan (Department of Pharmacology, University of Cambridge). The structures of the 
compounds were downloaded from PubChem (110). The compounds in SMILES format were 
uploaded to Standardizer (210) to standardise the compounds prior to in silico target 
prediction. Six pre-selected actions were specified in the configuration file; ‘Remove 
Fragment’, ‘Remove Explicit Hydrogens’, ‘Neutralize’, ‘Clean 2D’, ‘Mesomerize’ and 
‘Tautomerize’. The standardised SBP compounds were saved in SMILES format.
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Table 4.1: The structures of 22 SBP compounds, which similar structures are arranged next to each other. PCID stands for PubChem ID. 
Ginsenoside Rb1 
(PCID 9898279) 
 
Ginsenoside Rb2 
(PCID 6917976) 
 
Ginsenoside Rb3 
(PCID 12912363) 
 
Ginsenoside Rc 
(PCID 12855889) 
 
Ginsenoside Rd 
(PCID 11679800) 
 
Ginsenoside Re 
(PCID 441921) 
 
Ginsenoside Rg1 
(PCID 441923) 
 
Ginsenoside Rg3 
(PCID 9918693) 
 
Cholic acid 
(PCID 221493) 
 
Hyodeoxycholic acid 
(PCID 5283820) 
 
Chenodeoxycholic acid 
(PCID 10133) 
 
 
Deoxycholic acid 
(PCID 222528) 
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Bufalin 
(PCID 9547215) 
 
Gamabufotalin 
(PCID 259803) 
 
Cinobufagin 
(PCID 11969542) 
 
 
11-hydroxyprogesterone 
(PCID 92750) 
 
17-hydroxyprogesterone 
(PCID 6238) 
 
Cinnamic acid 
(PCID 444539) 
 
Cinnamaldehyde 
(PCID 637511) 
 
Muscone 
(PCID 10947) 
 
Borneol 
(PCID 6552009) 
 
Benzyl benzoate 
(PCID 2345) 
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4.2.2 Target prediction 
The standardised compounds were run on an in silico target prediction algorithm that was 
modeled using the Random Forest (211). Briefly, the model contained a training set of active 
compounds extracted from ChEMBL v.21.0 (28) and inactive compounds extracted from the 
PubChem Compound and PubChem BioAssay databases (212). In total, the model contained 
5,888,615 ligand-target pairs of actives and inactive associate with 1,651 targets. The active 
training set were active compounds with reported activities (Ki/Kd/IC50/EC50) of lower than 10 
μM with a CONFIDENCE_SCORE of 5 or greater for ‘binding’ or ‘functional’ human 
protein assays (28). The inactive training set were inactive compounds of assays submitted by 
researchers to PubChem Compound and PubChem BioAssay databases (28). The descriptor 
of a molecule was generated based on ECFP_4 circular Morgan-type fingerprints (48) with a 
2,048 bit length, hence stereochemistry of compounds was excluded. The algorithm calculates 
the probability of an orphan compound belonging to a target class by considering both 
chemical features of active and inactive compounds against target classes, giving a more 
holistic perspective of chemical features, which contribute towards or against bioactivity. 
To predict targets of TM compounds, the Random Forest (RF) classifier can be briefly 
described as follows. First, a Scikit-learn (Version 17) RF classifier of 100 trees, with the 
number of features and max depth set to ‘auto’ and the ‘class_weight’ set to ‘balanced’, was 
trained using the binary matrix of the active and inactive compound-target fingerprints on a 
per-target basis (213). Models generate a probability representing the number of trees in the 
forest that predict a target as active, represented as p(activity). Platt scaling (214), a 
calibration method in machine learning, is performed to convert the classification from the 
random forest into the probabilities of the prediction being correct, which is known as True 
Positive Rate (TPR). 
 
4.2.3 The TPR of predicted targets 
The TPR value was selected by assessing the distribution of a fraction of targets predicted for 
each TPR interval of 0.1 between 0 and 1. A curve of the fraction of targets’ predicted TPR 
intervals was evaluated to define a TPR threshold of each SBP compound (Figure 4.1). In 
general, the fraction of targets predicted decreases as the threshold value increases. A 
threshold value of 0.65 was selected for all SBP compounds because at least four targets were 
predicted for ginsenoside compounds. The selected threshold value is a reasonable trade-off 
between false-negative predictions and the number of predicted targets compared to larger 
threshold values. By using the selected TPR threshold, the target prediction algorithm was 
performed, which produced a binary matrix of predicted targets. 
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Figure 4.1: The curves of the fraction of targets predicted decreases when TPR values 
increases. A TPR threshold value of 0.65 was selected in this analysis because at least four 
targets were predicted for ginsenoside compounds. 
 
4.2.4 Generating a representative angiogenesis and CHD network 
To generate the PPI network, angiogenesis and CHD annotated genes were extracted from six 
databases (Table 4.2). By using the keyword “angiogenesis”, the annotated genes were 
extracted from UniProt (272) and Comparative Toxicogenomics Database (CTD) (273). The 
annotated genes from Gene Ontology (GO) were retrieved using an identifier, GO:0001525 
(274). The CHD annotated genes were extracted from UniProt (272) and Target Validation 
Platform (TVP) (215) by using the keyword “coronary heart disease”. In CTD (273), the CHD 
annotated genes were retrieved from six CTD identifiers, D006333 Heart Failure, D001145 
Arrhythmias, Cardiac, D006323 Heart Arrest, D017202 Myocardial Ischemia, D006341 Heart 
Rupture, and D009202 Cardiomyopathies. To prioritise the extracted genes from CTD, the 
top 1,000 angiogenesis annotated genes were selected based on the Inference Score. In 
another approach, the CHD annotated genes from six identifiers were combined and the top 
1,000 CHD annotated genes were selected based on the Inference Score. The CHD annotated 
genes of TVP (215) were filtered based on an Association Score of at least 0.7, which at least 
80% of genes were included. All annotated targets from UniProt (272) and GO (274)were 
kept. For the purpose of this study, all genes were regarded to encode their complementary 
proteins.  
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Table 4.2: The numbers of annotated genes of angiogenesis and CHD, which were extracted 
from six databases and the final numbers of genes to construct the network. 
Angiogenesis Coronary Heart Disease 
Database Number of Genes Database Number of Genes 
Gene Ontology 
(GO:0001525) 
404 Target Validation 
Platform 
727 
Uniprot 494 Uniprot 935 
Comparative 
Toxicogenomics 
Database  
1,000 Comparative 
Toxicogenomics 
Database  
1,000 
Numbers of genes for 
network generation 
407 Numbers of genes for 
network generation 
304 
 
 Initially, two separate networks were generated for angiogenesis and CHD by 
selecting proteins that were consistently found in at least two databases. The PPIs between 
two proteins were retrieved from Reactome (275) before merging them into a new network. 
Singnalink2.0 database (66) was also incorporated to further expand the network. The 
selected layer of Signallink2.0 (66) was Pathway Member composed of 1,086 nodes and 
1,226 edges. Cytoscape v3.3.0 (276) was used in each step of the network generation. In a 
network, the protein is known as a node while the link between two nodes is known as an 
edge. Self-loops and multiple edges between the same pairs of nodes were removed. Only the 
first-degree neighbours of SBP targets were selected for generating the final network.  
 
4.2.5 Network properties analysis 
The properties of the network were assessed based on the topology such as degree 
distribution, average clustering coefficient and average shortest path length. Degree (k) is the 
number of edges a node has. Degree distribution of a network was calculated from the 
frequency (f) of each degree from the total number of nodes (n): 
〈𝑘〉  =  
𝑓𝑘
𝑛
 
(Equation 4.2) 
The degree distribution was analysed based on the annotation of the node attributes in Table 
4.3. The boxplot each node’s attribute was created using boxplot() function of stats package in 
R (114). 
Real biological networks exhibit a scale-free behaviour. To determine this property, the 
average clustering coefficient and average path length of the network were compared to 1,000 
random networks of the same number of nodes and edges and the edges were permutated. The 
random networks were generated by randomising the degree of the original network using 
degree.sequence.game() function of igraph (277) package in R (114), The clustering 
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coefficient is defined as sets of three nodes which are connected to each other. This measure 
provides information on how neighbours are connected in the network, where the value is 
between 0 and 1. The average clustering coefficient <C> of a network can be quantified by: 
〈𝐶〉 =  
1
𝑛
∑ 𝐶𝑖
𝑛
𝑖=1
 
Equation (4.3) 
Here, Ci is the ratio of number of triangles connected to node i to the number of triples (both 
open and closed triangles) centred on node i. The sum of Ci is averaged by the total number of 
nodes (n).  
The average path length is defined as the number of average shortest steps for all possible 
pairs of nodes in the network, in which a shorter average path length is more desirable. The 
average path length <l> of a network can be quantified by: 
〈𝑙〉 =  
1
𝑛(𝑛 − 1)
 ∑ 𝑑(𝑛𝑖, 𝑛𝑗)
𝑖 ≠𝑗
 
Equation (4.4) 
Here, d(ni, nj) is a measure of the shortest distance between node i and node j. The sum of the 
distance for all possible pairs of nodes is averaged by the number of all possible pairs of 
nodes. 
 
4.2.6 Biological process analysis 
The functional pathway enrichment of the SBP predicted targets and all proteins in the 
network was measured by ClueGO (278) by selecting GO Biological Process as the 
background set. The statistical test used for the enrichment was based on a two-sided 
hypergeometric option with a Bonferroni correction, a p-value less than 0.001. A fusion term 
was used with a defined kappa score of 0.65. The level of specificity of GO terms was 
selected between 3 and 13. 
 
4.2.7 Formulating the synergy score of compound combinations 
In total, there were 231 unique pairwise combinations generated from 22 SBP compounds. To 
measure a synergy value of a combination, three elements were integrated. The three elements 
were topological properties, pathway dissimilarity and average node distance. The synergy 
score was calculated by using Equation (4.5). The equation was modified from a previous 
study by Li et al., (270) by adding two new elements, pathway dissimilarity and mean 
distance. The Synergy Score (SS) of compound i and compound j was a product of a 
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Topology Score (TS) and a Pathway Dissimilarity Score (PDS) divided by a Mean Distance 
Score (MDS).  
 
The TS was derived from two topological features and a defined node attribute of the 
predicted targets for compound i and compound j as described below. 
 
𝑇𝑆 (𝑖, 𝑗) =  
1
2
 [
∑ (𝐷𝑒𝑔 × 𝐵𝑒𝑡𝑤 × 𝑊𝐴)−1/3𝑖
𝑛𝑖
+
∑ (𝐷𝑒𝑔 × 𝐵𝑒𝑡𝑤 × 𝑊𝐴)−1/3𝑗
𝑛𝑗
] 
Equation (4.2) 
From the above equation, TS was a harmonic average product of the TS of compound i and 
the TS of compound j. The TS of a compound was defined as a sum of three elements, degree 
(Deg), betweeness (Betw) and weight attribute (WA). The Deg and Betw were calculated 
based on the connections of a node in the network, while the WA was defined as whether a 
node was annotated as an angiogenesis protein, and/or a CHD protein. Both angiogenesis and 
CHD proteins were proteins that were extracted from six databases to construct the network. 
The scheme of the WA was described in Table 4.3. 
 
Table 4.3: The weight attribute of the nodes in the network. 
Node Attribute Weight 
Angiogenesis (An) 2 
Coronary Heart Disease (CHD) 2 
An and CHD 3 
Not An and CHD  1 
 
The sum of product of Betw, Deg and WA was normalised using taking the reciprocal of its 
cube root and the final TS was averaged by the number of predicted SBP targets, n, for that 
compound. 
The second element of the SS score was to calculate the pathway dissimilarity 
between two compounds. The pathways were derived from the gene functional enrichment 
calculation in the network analysis. A matrix of frequency of nodes to a pathway was created. 
Pearson coefficient correlation (PCC) was used to calculate the pathways similarity. The 
calculated value was subtracted by 1 to get the PDS. 
 
𝑃𝐷𝑆 (𝑖, 𝑗) =  1 −  𝑃𝐶𝐶(𝑖, 𝑗) 
Equation (4.3) 
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Prior to calculating the PDS, a heatmap of the bioactivity space similarity of SBP 
compounds was assessed. The frequencies of compounds of per predicted target were 
normalised. The dissimilarity of distances between the normalised frequencies of SBP 
compounds were calculated using ‘Euclidean’ method of the “dist” function. Clustering was 
performed using the Ward method of the “hclust” function, where two SBP compounds were 
merged if the sum of the squared Euclidean distance was minimal. The heatmaps were 
generated using the “heatmap” function. All the aforementioned functions were available in 
the stats package of R (114). 
 
The third element, MDS, was calculated from the sum of the shortest distance between all 
pairwise pairs of targets of compound i and compound j (iCj), which was averaged by the 
number of pairwise targets, niCj.  
 
𝑀𝐷𝑆 (𝑖, 𝑗) =  
∑ 𝑑𝑚𝑖𝑛𝑖𝐶𝑗
𝑛𝑖𝐶𝑗
 
Equation (4.4) 
The three elements were combined into the SS equation as below: 
𝑆𝑆(𝑖, 𝑗) =  
𝑇𝑆 (𝑖, 𝑗)  ×  𝑃𝐷𝑆 (𝑖, 𝑗)
𝑀𝐷𝑆 (𝑖, 𝑗)
 
Equation (4.5) 
 
A Spearman Rank Correlation Coefficient (SRCC) was used to assess the relationship 
between the scores of the three elements and the synergy scores. SRCC was measured using 
the “cor” function of R the stats package (114). 
 
4.2.8 Robustness of Synergy Score evaluation 
To evaluate the robustness of the Equation (4.5), the SS of a combination of the original 
network were compared to SS of a background distribution by computing the SS from 1000 
random graphs of the same number of nodes and edges. The nodes of each compound were 
randomly selected based on the number of targets predicted. The enrichment of a SS from the 
original network was measured based on Estimation Score (ES). 
𝐸𝑆 =  
𝐶
1000
 
Equation (4.8) 
Here, C is defined as where the frequency of SS in the 1000 random graphs is smaller than SS 
in the original network. The absolute frequency obtained is then divided by total number of 
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random graphs giving a value between 0 and 1. A combination is considered enriched when 
ES is ≤ 0.01. 
 
4.2.9 Synergistic evaluation of combinations in HUVEC 
In order to validate the predicted SS, five combinations from the 20 top-ranked and five 
combinations from the bottom ranked were treated in HUVEC. HUVECs were cultured in 
Promocell’s Endothelial Cell Growth Medium 2 containing 2% FBS, human Epidermal 
Growth Factor, human Basic Fibroblast Growth Factor, Insulin-like Growth Factor, human 
Vascular Endothelial Growth Factor 165, Ascorbic Acid and Heparin (EGM-2). The 
HUVECs were incubated at 37°C in humidified air containing 5% carbon dioxide. HUVECs 
were seeded in 96-well plates at a density of 2,500 cells/well in 100μL of EGM-2. 24 hours 
later, the media was aspirated and appropriate compound concentrations diluted in 
Endothelial Cell Basal Medium 2 (EBM-2, Promocell) were added to the relevant wells (total 
volume in each well = 100μL). After 72hr of incubation, 10μL of Cell Counting Kit-8 (CCK-
8, Dijindo) was added to each well. CCK-8 utilises Dojindo’s highly water-soluble 
tetrazolium salt (WST-8). Dehydrogenases within cells reduce WST-8 to produce orange 
formazan. The amount of formazan dye generated is proportional to the number of living 
cells. The plates were incubated for 1-4 hours at 37°C. A MultiSkan Ascent Plate Reader 
measured absorbance at 450nm. The experimental work was performed by Dr Ranjoo Choi.  
 
4.2.10 Bliss independence model measurement 
The combination response (4x4) matrix contained percentages of cell growth and at zero 
concentration, the cell growth was equal to 100%. Each value in the matrix was subtracted 
from 100 to produce percentage cell growth. The combination matrix was plotted as a 
heatmap. A single dose response curve was constructed prior to calculating the Bliss 
independence model. The single dose response curve was fitted using 4-parameter log-logistic 
function (4-PL). The Bliss score of each combination was calculated by averaging (3x3 
matrix) the difference between the actual percentage of cell growth and the expected 
percentage of cell growth. The combination interaction landscape was visualised in a 3D 
contour plot. All the calculations and figures of this section were carried out using the synergy 
finder package (279) in R (114).  
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4.3 Results and Discussions 
4.3.1 Analysis of pathways associated with SBP predicted targets 
Prior to the network construction, the analysis of the SBP predicted targets shows that the 
predicted targets are associated with GO biological processes (BP) that are related to either 
angiogenesis or CHD (Table A.4.1). Such biological processes are mitogen activated protein 
kinase (MAPK)-related pathways (GO:0000187, GO:0032872, GO:0043405), angiogenesis 
(GO:0001525), ERK1 and ERK2 cascade (GO:0070371), T-cell activation (GO:0042110), 
lymphocyte differentiation (GO:0030098), blood vessel morphogenesis (GO:0048514), and 
epidermal growth factor receptor signalling pathway (GO:0030098). Numerous studies have 
demonstrated that angiogenesis and/or CHD affected these biological processes.  
 For example, atherosclerotic process cause thrombosis in arteries that leads to MI in 
CHD (280). The over accumulation of cholesterol on the artery walls induces cholesterol 
crystal formation that can activate an associated inflammasome such as cytokines (280). 
Inflammatory cytokine production is one of the key features in CHD. T cell activation and 
lymphocyte differentiation prevent the accumulation of these pro-inflammatory cytokines, 
hence suppressing the atherosclerotic state (281). The cross talk between inflammation and 
angiogenesis has also been reported, where the infiltration of T cells into autoimmune lesions 
induces pathogenic angiogenesis by secreting VEGF (282). MAPK-related pathways have 
been widely studied for their associations with cardiovascular diseases. Four subfamilies, 
ERK1/2, JNK, p38, and ERK5 of MAPK, have been characterised for their involvements in 
cardiac development, function and diseases (283). One of the subfamilies, ERK1 and ERK2 
cascade, is among the enriched GO BP terms. The up-regulation of ERK 1/2 MAPK 
phosphorylation induces anti-inflammatory cytokine, interlukin-10 (IL-10), to prevent tumour 
necrosis factor-alpha (TNF-alpha) from increasing oxidative stress and apoptosis (284). The 
enrichment of GO terms, angiogenesis (GO:0001525), blood vessel morphogenesis 
(GO:0048514), and epidermal growth factor receptor signalling pathway (GO:0030098) are 
indicative of significant angiogenesis-related proteins being part of the network. Altogether, 
these biological processes indicate that SBP compounds were predicted to modulate targets of 
the pathways that are important in either angiogenesis or CHD. 
 
4.3.2 Evaluating topological properties of the network 
The final representative network of angiogenesis and CHD (Figure 4.2) was composed of 
2,371 nodes and 16,336 edges, of which 396 nodes were angiogenesis and CHD associated 
genes. The 2,371 nodes were annotated to 332 enriched GO biological processes (Table 
A4.2). A total of 259 SBP predicted targets were mapped onto the final network, in addition 
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to 13 targets from the literature that were associated with the MOA of SBP compounds. For 
clarity, the 13 targets (Table A4.3) were also regarded as SBP predicted targets for the rest of 
the analysis.  
 
 
Figure 4.2: The visualisation of the representative network of CHD and angiogenesis, which 
the angiogenesis and CHD annotated nodes (blue and red circle) are mostly aggregated in the 
middle of the network. The observation suggests that these two conditions are in the 
biological context of the network. The SBP targets and their degree (green circle and line) are 
observed to link many of the nodes suggesting the targets could provoke the desired 
therapeutic effects. 
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The topological properties of the network were first evaluated by its degree distribution 
(Figure 4.3) (285). The degree distribution based on the nodes’ attributes shows that the 
median values of two groups, angiogenesis and CHD annotated nodes and angiogenesis, CHD 
and SBP annotated nodes, are higher than the remaining two groups and the median values 
are closer to the upper quartile. The observation indicates that many of the annotated 
angiogenesis/CHD proteins are highly linked nodes suggesting that the two conditions are 
governing the conformation of the network. The highly linked nodes are also known as hub 
proteins. The associations of the top ten hub proteins to either angiogenesis or CHD were 
described in Table 4.4. The results demonstrate that six hub proteins were predicted to be 
modulated by the SBP compounds. Despite the low median value of the SBP predicted 
targets, some of the SBP targets are observed to be distributed outside the upper quartile. The 
observation demonstrates that the SBP compounds were predicted to modulate some of the 
hub proteins, which could be responsible for producing the desirable phenotypes. In addition 
to degree distribution, the properties of the network were analysed by measuring its average 
clustering coefficient, average betweenness and average path length. These properties were 
compared to 1,000 random graphs with the same number of nodes and edges as can be seen in 
Table 4.5. The higher average clustering coefficient and shorter average path length of the 
original network than the random graphs demonstrated that the network is a scale-free 
network.  
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Figure 4.3: The degree distribution of different node attributes in the network. Many of the 
SBP predicted targets and angiogenesis and CHD annotated proteins are highly linked nodes. 
The observation indicates that the two conditions are governing the conformation of the 
network.  
 
 
 
Table 4.5: The comparison of topological properties between a representative network of 
angiogenesis and CHD and 1,000 random graphs.  
Properties Original network 1,000 random networks 
Number of nodes 2,371 2,371 
Number of edges 16,336 16,336 
Average clustering coefficient 0.136 0.00581 ± 0.00029 
Average path length 3.072 3.246 ± 0.00087 
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Table 4.4: The top ten hub proteins in the representative network of angiogenesis and CHD. Six proteins were predicted to be modulated by SBP 
compounds. 
 
Symbol Protein Name Attribute Degree Protein 
Family 
Supporting literature 
CTNNB1 Catenin beta-1 SBP/ 
Angiogenesis 
408 Beta-
catenin 
It was reported that the overexpression of CTNNB1 enhances 
endothelial cells proliferation through cell cycle propagation and 
induces vascular endothelial growth factor (VEGF) in skeletal 
myocytes (286) 
JUN Transcription factor AP-1 SBP/ 
Angiogenesis 
356 Jun The activation of JUN has been showed to mediate VEGF-induced 
endothelial cells proliferation and migration (287). 
RHOA Transforming protein RhoA SBP/ 
Angiogenesis 
299 Rho RHOA has been documented to activate VEGF-induced endothelial 
cells (288). 
MAPK14 Mitogen-activated protein 
kinase 14 
Angiogenesis 290 Kinase MAPK14 is also referred as p38 MAPK, which the inhibition of p38 
MPK has been reported to enhance angiogenesis in VEGF-induced cell 
proliferation (289). 
PIK3CA Phosphatidylinositol 4,5-
bisphosphate 3-kinase catalytic 
subunit alpha isoform 
Angiogenesis 264 Kinase The PIK3CA has been frequently reported in cancer pathogenesis, 
which the mutation of PIK3CA induces angiogenesis and malignant 
cell growth (290). 
RELA Transcription factor p65 SBP/ 
Angiogenesis 
239 Not 
available 
The activation of RELA has been demonstrated to either promote or 
impair angiogenesis through matrix metalloproteinase (291). 
AKT1 RAC-alpha serine/threonine-
protein kinase 
Angiogenesis 221 Kinase AKT1 has been documented to exhibit pro-angiogenic and anti-
angiogenic effects under different conditions (292). 
SHC1 SHC-transforming protein 1 Angiogenesis 214 Not 
available 
It has been reported that the activation of SHC1 induces the 
downstream pathways of epidermal growth factor receptor (EGFR) 
(293). 
EGFR Epidermal growth factor 
receptor 
SBP/CHD 211 Kinase In addition to EGFR’s implication in angiogenesis, the protein has 
been reported to regulate blood pressure by either promoting 
vasodilation or vasoconstriction (294). 
PTK2B Protein-tyrosine kinase 2-beta SBP/ 
Angiogenesis 
208 Kinase The activation of PTK2Bhas been implicated in wound healing by 
stimulating the Src family kinase/EGFR signalling pathway (295). 
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4.3.3 Comparison to previously published network 
A few studies of biological network generation of angiogenesis or CVD have been reported in 
the literature. These studies used different methods in order to generate the biological 
network. In this section, we compare the 2,371 genes of the constructed network to the genes 
of the three angiogenesis networks and one CVD network that were previously published 
(Table 4.5). The comparison discovers that in many cases, the annotated genes that were used 
in the current network were also part of the networks published previously. 
 
Table 4.6: The comparison of overlapped genes of angiogenesis/CHD related networks 
discovered from previous studies. 
Number of 
nodes 
Number of 
edges 
Method Number of 
overlapped genes 
1,233 5,736 
Extracted angiogenesis genes from 
multiple sources; Gene  Ontology, 
SABiosciences, and Gene Cards and used 
GeneHit to expand the  network of 
angiogenesis dynamically (296). 
382 (580 
angiogenesis 
genes) 
362 1,195 
Extracted angiogenesis genes from 
multiple sources to generate an 
angiogenesis network ; 1. Database (Gene 
Ontology, Reactome, Uniprot), 2. 
computational and experimental tools 
(Protein lounge, Ingenuity Pathway, 
Agilent Literature search), 3.commercial 
experimental sets (G-Arrays) (297). 
57 (79 
angiogenesis 
genes) 
unknown 262 
Used ClusteEx method: identifies groups 
of differentially expressed genes and 
connects the genes’ products using shortest 
path in VEGF stimulated human umbilical 
vein endothelial cells (HUVECs) to 
represent inflammation and angiogenesis 
models (298) 
51 (92 
angiogenesis 
genes) 
3,412 13,164 
Used gene co-expression data to extract 
related CVD genes and Gene Ontology to 
develop the interactions between genes 
(299) 
269 (705 CVD 
genes) 
 
 
4.3.4 The modelling of synergy score measurement and the score distribution  
The hypothesis behind the synergy score measurement was to relate the topological 
relations between two sets of predicted targets of a two-compound combination. These 
predicted targets were assumed to be part of different pathways with a small distance between 
them. The TS measurement considered the importance of predicted targets based on their 
connections and attributes in the network. The negative exponential function was utilised to 
normalise the different scales of betweenness, degree and weigh attribute. The sum of the 
products of the three scales was divided by the number of predicted targets due to the high 
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variance from only six to 180 predicted targets. Therefore, TS gave the results that stronger 
desired effects could be achieved from a set of predicted targets with higher connections and 
annotated with high-value attributes.  
The PDS was derived from the analysis of the similarity of predicted SBP targets. 
Many of the SBP compounds were shown to be structurally similar (Table 4.1), for example, 
six types of ginsenoside and four cholic acid derivatives. Based on the “Molecular Similarity 
Principle” (41), these compounds are likely to modulate a similar set of targets. The heatmap 
of Figure 4.4 shows that structurally similar compounds were predicted to modulate similar 
targets, and these compounds are clustered together. Only a few compounds are structurally 
different such as muscone, benzyl benzoate and borneol. The similarity of the predicted 
targets was considered to affect similar pathways; hence compounds with high structure 
similarity would dominate the top ranked combinations. These observations were more likely 
to identify combinations with additive effects than synergistic effects because the compounds 
were expected to modulate the same targets. By considering dissimilar pathways, the synergy 
score calculations accounted for the different targets of two compounds, hence, identifying 
synergistic combinations. These different pathways are still functionally related as only 332 
GO terms (Table A4.3) were enriched from 2,371 genes. 
 
Figure 4.4: The heatmap of predicted target similarities between SBP compounds. Many of 
the SBP compounds are structurally similar such as ginsenoside and cholic acid derivatives. 
These compounds were predicted to modulate similar targets, thus, acting on the same 
pathways. Due to high-predicted targets similarities, the SS measurements considered 
dissimilar pathways annotated to the compounds. 
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 The final element in the SS measurement was the mean distance measured from the 
pairwise distance of all predicted targets of two compounds. A study by Wang et al., indicates 
that combinatorial drugs tend to affect a smaller radius in the gene network in order to 
produce their therapeutic effects (300). In the study, it was found that 62% of the 
combinatorial drugs had a shorter effect radius of 3 and less. Given the result of the previous 
study, the final SS was determined by the mean distance of the predicted targets of both 
compounds. A combination with a smaller mean distance was estimated to show higher 
synergistic effects.  
Spearman Rank Correlation Coefficient (SRCC) was calculated to determine the 
relationships between TS, PDS and MDS and SS, which is visualised in the multi-plots in 
Figure 4.5. Both TS (r = 0.83, p-value < 0.001) and PDS (r = 0.71, p-value < 0.001) show 
strong correlation with that of SS, whereas MDS (r = 0.12, p = 0.072) showed weak 
correlation with that of SS. The results suggest that the weak correlation of MDS with that of 
SS has prioritised combinations with targets that were close to each other (< 2.8). Therefore, 
the evaluation of synergy prioritises combinations that contain targets are close to each other, 
have many high degree nodes and belong to different pathways. 
 
Figure 4.5: The SRCC between TS, PDS and MDS and SS. Both TS and PDS are highly 
correlated with that of SS and MDS is weakly correlated with that of SS. Combinations with 
higher SS are estimated to contain many highly linked predicted targets and both sets of the 
predicted targets are located in smaller radius, which belong to different pathways.  
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4.3.5 Robustness of Synergy Score Evaluation 
It was found that all the combinations were enriched with a p-value of zero. All SS of 231 
combinations measured from the original network were higher than the 1,000 SS of 231 
combinations measured from 1,000 random networks. The boxplot in Figure 4.6 compares 
four types of score distributions, where the scores of the random group are the average scores 
measured from 1,000 random networks. It is observed that all three elements influence the SS. 
The large mean difference of TS between the original and random groups suggesting the 
topological properties, degree, betweenness, and weight attribute, are important factors in 
evaluating synergy of a combination. Combinations with high SS measured from the original 
network are estimated to modulate hub proteins, which in the same combinations in the 
random networks, the edges of these hub proteins were permutated. The PDS distribution of 
the random networks is higher than the original network because the randomised targets of 
each combination are part of different pathways. Similar to the PDS, the MDS distribution of 
the random group is higher than the MDS distribution of the original group but with smaller 
variance. The result implies that a mean distance between set of targets of two compounds is 
an important parameter to emphasise synergistic effects. Hence, the synergy score evaluation 
is robust by emphasising combinations that are modulating high-degree nodes.  
 
Figure 4.6: The boxplot compares four types of score distribution. The lower SS measured 
from 1,000 random networks are observed to be influenced by all three elements. The finding 
indicates that topological properties of predicted targets of a combination are significant 
factors for estimating synergy.  
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4.3.6 Predicted synergy combinations 
231 combinations were arranged in descending order based on the SS (Table A4.4). What can 
be seen throughout in Table A4.4 is that the pairs of compounds of the same or different 
scaffolds are randomly distributed. In most cases, combinations that contain ginsenoside are 
observed in the first half of the rank, while the second half of the rank contains combinations 
of simple structures such as borneol, cinnamic acid and cholic acid derivatives. These small 
molecules were predicted to modulate many targets, however, the targets were found to have 
less impact on the network topology. In many cases, the values of a nodes’ attributes of the 
targets are low, resulting in a small SS of these combinations. Overall, the rank aimed to 
prioritise combinations that were predicted to produce synergistic effects in vitro. 
 
4.3.7 Validation of predicted synergy combinations 
To validate the rank of the combinations, the top and bottom 20 combinations of each 
category were validated using HUVEC cells by quantifying the promotion of cell growth. The 
top 20 combinations were estimated to show higher synergistic effects than the bottom 20 
combinations. At the time of thesis submission, only five combinations from each category 
were validated experimentally and their Bliss scores were calculated (Table 4.7 and Table 
4.8). Three combinations of the 20 top-ranked combinations are combinations of ginsenoside, 
which are ginsenoside Rb3 and ginsenoside Rb2 (SS=9.97E-04), ginsenoside Rg1 and 
ginsenoside Rb2 (SS=8.64E-04) and ginsenoside Rd and ginsenoside Rb2 (SS=8.60E-04). 
The remaining two combinations are ginsenoside Rb3 and cholic acid (SS=1.10E-03) and 
ginsenoside Rb3 and 11-hydroxyprogesterone (SS=9.09 E-04). Three combinations of the 20 
bottom-ranked combinations are combinations of cholic acid derivatives. The combinations 
are cholic acid and chenodeoxycholic acid (SS=4.51E-05), deoxycholic acid and 
chenodeoxycholic acid (SS=3.54E-05) and hyodexycholic acid and chenodeoxycholic acid 
(SS=2.52E-05). One combination contains compounds from Venenum Bufonis (toad venom), 
which is gamabufotalin and bufalin (SS=9.61E-06). One remaining combination is muscone 
and benzyl benzoate (SS=4.00E-04). Overall, Bliss synergy scores of the combinations in the 
top rank are higher than the combinations in the bottom rank except for ginsenoside Rg1 and 
ginsenoside Rb2. The synergistic combinations of dose-response matrices can be found in 
FigureA4.1. The MOAs of the synergistic combinations were proposed in the next section. 
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Table 4.7: The list of top 20 combinations, which are estimated to show synergistic effects. 
Compound i Compound j TDS PDS MDS SS Estimation 
Score 
Bliss 
score 
Ginsenoside Rb3 Cholic acid 6.14E-03 5.10E-01 2.85 1.10E-03 0 6.51 
Ginsenoside Rc Cholic acid 5.51E-03 5.71E-01 2.89 1.09E-03 0 - 
Ginsenoside Re Ginsenoside Rb3 6.79E-03 4.23E-01 2.65 1.09E-03 0 - 
Ginsenoside Rc Ginsenoside Rb3 9.50E-03 3.10E-01 2.82 1.05E-03 0 - 
Ginsenoside Rb3 Ginsenoside Rb1 9.77E-03 3.02E-01 2.95 1.00E-03 0 - 
Ginsenoside Rb3 11-hydroxyprogesterone 5.96E-03 4.83E-01 2.88 1.00E-03 0 - 
Ginsenoside Rb3 Ginsenoside Rb2 6.48E-03 4.05E-01 2.63 9.97E-04 0 13.99 
Ginsenoside Rb1 Ginsenoside Rb3 6.96E-03 4.12E-01 2.94 9.74E-04 0 - 
Ginsenoside Rb1 Cholic acid 5.79E-03 4.77E-01 2.92 9.46E-04 0 - 
Ginsenoside Rb3 Deoxycholic acid 6.03E-03 4.40E-01 2.92 9.09E-04 0 - 
Ginsenoside Rb3 11-hydroxyprogesterone 5.96E-03 5.08E-01 3.33 9.09E-04 0 7.67 
Ginsenoside Rd Ginsenoside Rb3 9.32E-03 2.74E-01 2.86 8.93E-04 0 - 
Ginsenoside Rb3 Gamabufotalin 5.84E-03 4.49E-01 2.94 8.91E-04 0 - 
Ginsenoside Rc 17-hydroxyprogesterone 5.34E-03 4.90E-01 2.96 8.85E-04 0 - 
Ginsenoside Rg1 Ginsenoside Rb2 3.32E-03 7.19E-01 2.76 8.64E-04 0 -10.29 
Ginsenoside Rd Ginsenoside Rb2 5.68E-03 4.10E-01 2.71 8.60E-04 0 -3.71 
Ginsenoside Rb3 Bufalin 5.83E-03 4.23E-01 2.92 8.46E-04 0 - 
Ginsenoside Rg1 Ginsenoside Rc 6.34E-03 3.85E-01 2.91 8.39E-04 0 - 
Ginsenoside Rb3 Cinobufagin 5.93E-03 4.22E-01 2.99 8.38E-04 0 - 
Ginsenoside Rc Chenodeoxycholic acid 5.41E-03 4.52E-01 2.94 8.31E-04 0 - 
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Table 4.8: The list of bottom 20 combinations, which are estimated to show lower synergistic effects. 
Compound i Compound j TDS PDS MDS SS Estimation 
Score 
Bliss 
score 
Gamabufotalin Cinnamic acid 1.25E-03 1.14E-01 3.01 4.73E-05 0 - 
Cinnamaldehyde Bufalin 1.33E-03 1.03E-01 2.97 4.63E-05 0 - 
Deoxycholic acid Cholic acid 2.04E-03 6.16E-02 2.72 4.61E-05 0 - 
Cholic acid Chenodeoxycholic acid 2.04E-03 6.02E-02 2.72 4.51E-05 0 -6.65 
Muscone Cinnamaldehyde 1.40E-03 9.20E-02 2.92 4.40E-05 0 - 
Bufalin Cinnamic acid 1.25E-03 1.02E-01 3.00 4.26E-05 0 - 
Borneol Gamabufotalin 1.54E-03 7.94E-02 2.89 4.22E-05 0 - 
Muscone Benzyl benzoate 1.46E-03 8.32E-02 3.03 4.00E-05 0 -17.12 
Muscone Cinnamic acid 1.31E-03 8.43E-02 2.96 3.74E-05 0 - 
Borneol Bufalin 1.54E-03 6.82E-02 2.88 3.64E-05 0 - 
Deoxycholic acid Chenodeoxycholic acid 1.93E-03 5.11E-02 2.78 3.54E-05 0 -21.71 
17-hydroxyprogesterone 11-hydroxyprogesterone 1.80E-03 5.51E-02 3.19 3.10E-05 0 - 
Hyodeoxycholic acid Chenodeoxycholic acid 1.92E-03 3.73E-02 2.85 2.52E-05 0 -19.83 
Cinnamaldehyde Benzyl benzoate 1.18E-03 6.27E-02 3.13 2.37E-05 0 - 
Borneol Cinnamaldehyde 1.32E-03 4.79E-02 2.97 2.13E-05 0 - 
Benzyl benzoate Cinnamic acid 1.10E-03 6.07E-02 3.17 2.11E-05 0 - 
Borneol Cinnamic acid 1.24E-03 4.87E-02 3.00 2.01E-05 0 - 
Hyodeoxycholic acid Deoxycholic acid 1.92E-03 2.78E-02 2.85 1.87E-05 0 - 
Gamabufotalin Bufalin 1.54E-03 1.79E-02 2.87 9.61E-06 0 -6.57 
Cinnamaldehyde Cinnamic acid 1.04E-03 1.44E-02 3.07 4.87E-06 0 - 
 
 106 
4.3.8 Suggested modes-of-action of synergistic combinations from a target-network 
perspective 
In this section, the MOAs of four synergistic combinations were suggested from the highly 
linked targets of the compounds.  
The first combination that shows the highest SS (SS=1.10E-03) is ginsenoside Rb3 
and cholic acid. Ginsenoside Rb3 was predicted to modulate four targets, in addition to three 
targets (Caspase-3 (CASP3) (301), Caspase-8 (CASP8) (301) and Caspase-9 (CASP9) (301)), 
which were extracted from literature. In total, 201 GO BP were annotated to these seven 
targets. Cholic acid was predicted to modulate 18 targets, which were annotated with 197 GO 
biological processes. The list of predicted targets of all combinations per discussion can be 
found in Table 4.9. The combination did not share any common predicted targets (Figure 
4.7a). However, it was found that both compounds shared 143 common GO BP. Studies have 
been reported on the implications of some of the predicted targets and GO BP in cell 
proliferation. The highest degree node of cholic acid, androgen receptor (AR) (k=206) has 
been reported to modulate androgen-mediated vascular endothelial functions by interacting 
with the VEGF receptor signalling pathway upon androgen treatment (302). AR is also shown 
to recruit Src and activate both the MAPK pathway and the PI3K-Akt cascade leading to cell 
survival and proliferation (MAPK cascade, GO:0000165, p-value=2.4E-165) (303). The next 
highly connected predicted targets of cholic acid were glucocorticoid receptor (NR3C1) 
(k=126) (304), estrogen receptor (ESR1) (k=45) (305), nitric oxide synthase, inducible 
(NOS2) (k=38) and tyrosine-protein phosphatase non-receptor type 1 (PTPN1) (k=26) (306), 
which have been reporter for their activities in vascular angiogenesis. Fibroblast growth factor 
1 (FGF1) (k=41), the highest degree node of ginsenoside Rb3, is involved in tissue repair and 
regeneration, with FGF-induced signalling mainly mediated via the MAPK pathway (307). 
The Bliss score is 6.51. Therefore, the synergy of ginsenoside Rb3 and cholic acid is 
suggested to arise from the modulation of different targets of related pathways. 
Combination of ginsenoside Rb3 and ginsenoside Rb2 shows an SS of 9.97E-04, with 
both compounds predicted to modulate four identical targets (Figure 4.7b). From literature, 
three additional targets were associated to the MOA of ginsenoside Rb3 and four additional 
targets were associated to the MOA of ginsenoside Rb2. 195 GO BP were linked to targets of 
ginsenoside Rb3, while 201 GO BP were associated with ginsenoside Rb2. The combinations 
shared 163 common GO BP. The four additional targets of ginsenoside Rb2 were epidermal 
growth factor receptor (EGFR) (k=211), fibronectin (FN1) (k=143), pro-epidermal growth 
factor (EGF) (k=108) and interstitial collagenase (MMP1) (k=32), which were extracted from 
a study of the wound healing effects of ginsenoside Rb2 (308). CASP3 (k=27), CASP8 (k=17) 
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and CASP9 (k=5) were also extracted from literature. Ginsenoside Rb3 has been shown to 
increase cell viability in ischemic model by significantly attenuated the increase of caspase 
activities in a dose-dependent manner (301). In addition, FGF1 (k=41), one of the predicted 
targets of ginsenoside Rb3, also promotes cell proliferation (307). EGFR, EGF, and FN1 were 
annotated with regulation of angiogenesis (GO:0045765, p-value=5.5E-51), while the caspase 
targets were annotated with positive regulation of cell death (GO:0010942, p-value=1.6E-
103). The inverse actions by two groups of targets might contribute to the large Bliss score of 
13.99, despite the combinations sharing many common GO BPs. Therefore, the combination 
of ginsenoside Rb3 and ginsenoside Rb2 is proposed to exhibit synergy through modulating 
different targets at unrelated pathways. 
 The third combination, ginsenoside Rb3 and 11-hydroxyprogesterone (SS= 9.09E-04) 
shows two sets of different predicted targets (Figure 4.7c). 11-hyrxyprogesterone was 
predicted to modulate 39 targets that were associated with 274 GO BP. 201 GO BP were 
associated with ginsenoside Rb3. The combination shared 185 common GO BP. In addition to 
AR in the list of 39 predicted targets of 11-hydroxyprogesteron and some of the highly linked 
targets such as AR (k=206), retinoic acid receptor RXR-alpha (RXRA) (k=157) (309),  
hypoxia-inducible factor 1-alpha (HIF1A) (k=124) (310), estrogen receptor (ESR1) (k=45) 
(305), nuclear factor erythroid 2-related factor 2 (NFE2L2) (k=20) (311) are implicated in 
cardiac vascular angiogenesis. Similar to the previous discussion, FGF1 of ginsenoside Rb3 is 
implicated in cell proliferation (307) and the inhibition of CASP3, CASP8, and CASP9 has 
been reported to induce angiogenesis (301). FGF1, HIF1A, and NFE2L2 were annotated with 
angiogenesis (GO:0001525, p-value= 2.2E-91) and blood vessel development (GO:0001568, 
p-value= 2E-111). The Bliss score of the combination is 7.67. Thus, the synergy between 
ginsenoside Rb3 and 11-hydroxyprogestrones is believed to be from the modulation of 
different targets of related pathways. 
 The fourth combination from Table 4.7 that shows synergy is between ginsenoside Rd 
and ginsenoside Rb2 (SS=8.60-4) (Figure 4.7d). Ginsenoside Rd was predicted to modulate 
12 targets that were annotated to 288 GO BP, of which 183 GO BP were common for both 
compounds in the combination. The combinations shared two common predicted targets, 
heparanase (HPSE) (k=4) and GBA ((k=1), which might not play significant roles in 
vasculogenesis from the lower k value, but one common highly linked node, FGF1 (k=41). A 
few of the highly linked predicted targets of ginsenoside Rd are associated to vascular 
angiogenesis such as FGF1 (k=41), tyrosine-protein phosphatase non-receptor type 1 
(PTPN1) (k=46) (306), SIRT1 (k=25) (312), apoptosis regulator Bcl-2 (BCL2) (k=22) (313) 
and apoptosis regulator BAX (BAX) (k=19). The association of ginsenoside Rb2’s predicted 
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targets with cell proliferation have been discussed previously. Many of the highly connected 
predicted targets of both were compounds sharing common GO biological processes such as 
angiogenesis (GO:0001525, p-value=2.2E-91), blood vessel morphogenesis (GO:0048514, p-
value=2.6E-100) and cell migration (GO:001647, p-value= 6.7E-133). The Bliss score of the 
combination is -3.71, which is still higher compare to the SS values of combinations in the 
bottom 20. Therefore, the synergy of the combination is suggested from the modulation of 
different targets of related pathways.  
(a) 
 
(b) 
 
 
(c) 
 
(d) 
 
Figure 4.7: The networks of predicted synergistic combinations, which also show synergistic 
effects in vitro. Each network is composed of compounds that are linked to their predicted 
targets. In general, the predicted targets of both compounds (green circle) are observed to be 
linked by at least one target from one of the compounds (such in (a)) or shared predicted 
targets (both (b) and (d)) (red circle).  
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Table 4.9: The list of predicted targets of four combinations with measured Bliss synergy values from the top-ranked group. 
Compound  i Compound j Predicted target i Predicted target j 
Ginsenosise Rb3 Cholic acid Fibroblast growth factor 1 (FGF1) Androgen receptor (AR) 
  
Tyrosine-protein kinase Mer (MERTK)  Glucocorticoid receptor (NR3C1) 
  
Heparanase (HPSE) Estrogen receptor (ESR1) 
  
Glucosylceramidase (GBA) Nitric oxide synthade, inducible (NOS2) 
  
Caspase-3 (CASP3) Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) 
  
Caspase-8 (CASP8) Estrogen receptor beta (ESR2) 
  
Caspase-9 (CASP9)  Ephrin type-A receptor 4 (EPHA4) 
   
Zinc finger protein GLI1 (GLI1) 
   
Mineralocorticoid receptor (NR3C2) 
   
Vitamin D3 receptor (VDR) 
   
Glutamate receptor ionotropic, NMDA 2D (GRIN2D) 
   
Nuclear receptor subfamily 1 group I member 2 (NR1I2) 
   
M-phase inducer phosphatase 1 (CDC25) 
   
Bile acid receptor (NR1H4) 
   
Fatty acid-binding protein, liver (FABP1) 
   
DNA polymerase alpha catalytic subunit (POLA1) 
   
Prostaglandin F2-alpha receptor (PTGFR) 
   
Prostaglandin E2 receptor EP4 subtype (PTGER4) 
      
Prostaglandin E2 receptor EP2 subtype (PTGER2) 
 
Ginsenoside Rb3 Ginsenoside Rb2 Fibroblast growth factor 1 (FGF1) Epidermal growth factor receptor (EGFR) 
  
Tyrosine-protein kinase Mer (MERTK)  Fibronectin (FN1) 
  
Glucosylceramidase (GBA) Pro-epidermal growth factor (EGF) 
  
Caspase-3 (CASP3) Fibroblast growth factor 1 (FGF1 
  
Caspase-8 (CASP8) Interstitial collagenase (MMP1) 
  
Caspase-9 (CASP9) Tyrosine-protein kinase Mer (MERTK) 
   
Heparanase (HPSE) 
   
Glucosylceramidase (GBA) 
 
Ginsenoside Rb3 11-hydroxyprogesterone Fibroblast growth factor 1 (FGF1) Androgen receptor (AR) 
  
Tyrosine-protein kinase Mer (MERTK)  Retinoic acid receptor RXR-alpha (RXRA) 
  
Glucosylceramidase (GBA) Glucocorticoid receptor (NR3C1) 
  
Caspase-3 (CASP3) Hypoxia-inducible factor 1-alpha (HIF1A) 
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Caspase-8 (CASP8) Mitogen-activated protein kinase 3 (MAPK3) 
  
Caspase-9 (CASP9) Nuclear factor NF-kappa-B p105 subunit (NFKB1) 
   
Estrogen receptor (ESR1) 
   
Nuclear factor erythroid 2-related factor 2 (NFE2L2) 
   
Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) 
   
Interleukin-8 (CXCL8) 
   
Estrogen receptor beta (ESR2) 
   
Progesterone receptor (PGR) 
   
Ephrin type-A receptor 4 (EPHA4) 
   
Zinc finger protein GLI1 (GLI1) 
   
Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) 
   
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta (PIP4K2B) 
   
Mineralocorticoid receptor (NR3C2) 
   
Vitamin D3 receptor (VDR) 
   
Nuclear receptor ROR-alpha (RORA) 
   
Nuclear receptor subfamily 0 group B member 1 (NR0B1) 
   
Nuclear receptor subfamily 1 group I member 2 (NR1I2) 
   
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) 
   
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13) 
   
Serine/threonine-protein kinase OSR1 (OXSR1) 
   
Fatty acid-binding protein, liver (FABP1) 
   
Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) 
   
Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) 
   
Nuclear receptor subfamily 1 group I member 3 (NR1I3) 
   
Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) 
   
Calcium/calmodulin-dependent protein kinase kinase 2 
(CAMKK2) 
   
Serine/threonine-protein kinase Nek6 (NEK6) 
   
Gamma-aminobutyric acid receptor subunit theta (GABRQ) 
   
Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) 
   
Death-associated protein kinase 2 (DAPK2) 
   
DNA polymerase alpha catalytic subunit (POLA1) 
   
Acetylcholine receptor subunit beta(CHRNB1) 
   
Corticosteroid 11-beta-dehydrogenase isozyme 1 (HSD11B1) 
   
Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) 
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Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) 
 
Ginsenoside Rd Ginsenoside Rb2 Fibroblast growth factor 1 (FGF1) Epidermal growth factor receptor (EGFR) 
  
Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) Fibronectin (FN1) 
  
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) Pro-epidermal growth factor (EGF) 
  
Apoptosis regulator Bcl-2 (BCL2) Fibroblast growth factor 1 (FGF1) 
  
Apoptosis regulator BAX (BAX) Interstitial collagenase (MMP1) 
  
Voltage-dependent L-type calcium channel subunit alpha-1C 
(CACNA1C) Tyrosine-protein kinase Mer (MERTK) 
  
DNA topoisomerase 2-alpha (TOP2A) Heparanase (HPSE) 
  
Heparanase (HPSE) Glucosylceramidase (GBA) 
  
Nuclear receptor subfamily 1 group I member 2 (NR1I2) 
  
Bile acid receptor (NR1H4) 
 
  
Glucosylceramidase (GBA) 
 
    
Galectin-3 (LGALS3) 
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4.3.9 Discussion on the suggested MOA of synergistic combinations 
 To this end, four combinations with SS values agree with Bliss scores measured from 
the response of cell growths of HUVEC. The synergistic effects of these combinations are 
suggested from the highly connected predicted targets of both compounds. In general, three 
combinations are suggested to exhibit synergistic effects by modulating different targets of 
related pathways and one combination is estimated to exert synergy by modulating different 
targets of unrelated pathways. The proposed types of MOA of compound combinations have 
been reported before; synergistic drug combinations can exert their activities by modulating 
similar/different targets of similar/different pathways (314). For ginsenoside Rb3, the 
synergistic MOA was proposed by modulating FGF1 and inhibiting the activation of 
caspases. Ginsenoside Rb2 was estimated to exhibit synergy from the modulation of growth 
factor related targets such as EGFR and EGF. Both cholic acid and 11-hydroxprogestereone 
were proposed to induce synergy from modulating AR. From the four synergistic 
combinations, the combination that contains either ginsenoside Rb2 and ginsenoside Rb3 was 
discovered to promote cell proliferation when they are combined with each other or 11-
hydorxyprogesterone, cholic acid and ginsenoside Rd. The synergistic effect of ginsenoside 
Rb3 and ginsenoside Rb2 combination seems to be suggested from literature rather than the 
predicted targets but the information from such studies is not always available for other 
components of SBP. For example, many studies have been conducted independently relating 
to ginsenoside Rb1 and ginsenoside Re (315, 316), hence the network-based approach could 
provide an opportunity to identify the synergy between these compounds from a protein-
protein interaction perspective. 
In this study, some of the highly connected predicted targets such as mitogen-activated 
protein kinase 3 (MAPK3) (k=77) and protein kinase C eta type (PRKCH) (k=20) have a 
limited number of studies to link their associations with angiogenesis. In a few cases, low 
connected predicted targets, such as galectin-3 (LGALS3) (k=1) (317) and HPSE (k=4) (318) 
have been implicated in vascular angiogenesis implying the targets might be important 
players in a real biological network but the significance of these predicted targets are not 
captured in the network. The network is only a small representation of a real biological 
network, where a lot of information is not included (319). However, the combinations of the 
bottom rank group, which have lower SS values correspond to the Bliss synergy scores, 
suggest the network is still robust to the set of predicted targets of the compound combination.  
 Despite the proposed MOAs of the combinations from the top-ranked group, one 
combination in the group did not agree with the experimental results. The combination, 
ginsenoside Rb2 and ginsenoside Rg1 with SS value of 8.64E-04 was determined to show no 
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synergy based on Bliss score. The measured Bliss score was -10.29.  From the single dose 
response curve in Appendices (Figure A4.1), ginsenoside Rg1 has already inhibited cell 
growth at a low concentration. The observation disagrees with a study that reports ginsenoside 
Rg1 increases the interactions between glucocorticoid receptor (NR3C1) and FGF1, which 
activate PI3K/Akt/eNOS signalling and eventually enhancing angiogenesis (320). Both of 
these targets are among the highly connected predicted targets of both compounds. However, 
the validation can be further confirmed by repeating the experiment. Therefore, to confirm the 
MOAs of the compounds by modulating the predicted targets, it is necessary to perform 
subsequent experiment such as Western blotting to detect expression of the predicted targets. 
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4.4 Conclusion 
In this work, the evaluation of the synergy of 231 pairs of combinations from 22 SBP were 
measured from a representative network of angiogenesis and CHD. The representative 
network of angiogenesis and CHD was constructed using a knowledge-based approach which 
is demonstrated to be feasible in estimating synergistic SBP compound combinations. In the 
first part of the study, the representative network was built by integrating different data 
sources to identify genes annotated with angiogenesis and CHD. By utilising information of 
PPI extracted from Reactome and Signalink2.0, the network was shown to be a scale free 
network and represented the “desired” biological context where the top ten hub genes were 
related to the biological process of angiogenesis/CHD. In the second part of the study, three 
elements were formulated into an equation to measure synergy of two-compound 
combinations. The three elements were topological properties, pathway dissimilarity and 
mean distance of all the predicted targets of a combination. The integration of the three 
elements are reasonable to measure how the predicted targets are linked to each other in the 
network with their related pathways to produce synergy. The model was robust when 
compared to the background distribution of random networks with permutated edges and 
random targets. In the third part of the study, the results from experimental validation indicate 
four combinations from the 20 top-ranked combinations agree with the SS. These 
combinations are ginsenoside Rb3 and cholic acid, ginsenoside Rb2 and ginsenoside Rb3, 
ginsenoside Rb3 and 11-hydroxyprogesterone and ginsenoside Rb2 and ginsenoside Rd. The 
Bliss scores were higher than the scores of five combinations in the bottom ranks. The MOA 
of the three synergistic combinations were proposed from the modulation of predicted targets 
of related pathways. One synergistic combination showed synergy from modulating the 
different targets of unrelated pathways. Despite one combination in the top-ranked group 
disagreeing with experimental result, the approach of utilising systems biology provides the 
opportunity to identify simplified combinations with a desirable “network” effect. 
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Chapter 5:  
Concluding Remarks 
 
 
This thesis concentrated on understanding the MOA of TM compounds by applying an in 
silico target prediction. A chemogenomic database of ligand-target pairs is developed from 
bioactivity databases that form a training set of the model. The model learns the pattern of 
chemical spaces of the ligands to their protein targets via two machine learning models, Naïve 
Bayes Classifier and Random Forest. To predict a target class of a new compound, the model 
compares the structural similarity of the new compound to those compounds in the model 
based on the “Molecular Similarity Principle”. Hence, the in silico target prediction has the 
ability to correlate the chemical descriptor of TM compounds to their protein targets, which 
the MOA can be rationalise from associating the indications of the TM compounds (plants) to 
their predicted targets.  
In Chapter 2, we showed that the applicability of an in silico target prediction 
improved mechanistic understanding of the relationship between 46 TCM therapeutic action 
classes and subclasses, which are not apparent from the name given to the (sub-)class itself, 
via the dendrogram of 14 clusters. Despite different names are given to the subclasses, the 
frequent enriched predicted targets and annotated pathways are related to immune related 
proteins and digestive system respectively. The findings could be linked to the view of TCM, 
where symptoms are usually regarded as the invasion of pathogenic factors, thus sensitizing 
the immune system to response and the important treatment principle is “the foundation of 
acquired constitution” that includes spleen and stomach. The results from the study can be 
further developed by studying the connections between predicted targets from the significant 
clusters of protein family and pathway motif. This study could help to better understand the 
MOAs of TCM compounds in maintaining a healthy body system by relating the digestive 
system to immune-related targets of the GPCR or protein kinase family. 
In Chapter 3, we explored the similarity and differences of the chemical space and 
bioactivity space of TCM, Ayurveda and Malay TM for treating cancer. The key findings 
indicated that they shared six frequent scaffolds and protein kinase was the most significant 
target class in all three TMs. The small similarity suggested that many of the remaining 
compounds are worth exploring for their anti-cancer activities, as additional nine frequent 
scaffolds are found to abundance in the anti-cancer plants and the compounds were predicted 
to modulate additional 13 targets classes. The comparison of the bioactivity space discovered 
the majority of the plants were not phylogenetically related except for eight pairs of plants. 
The findings of the large compound diversity and high similarity of MOAs could lead to new 
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knowledge of the cancer pathogenesis by identifying which biological pathways these targets 
are annotated with. It is suggested that the chemical and bioactivity space exploration 
strategies could be a stepping-stone to compare more TM datasets of different countries. The 
study could provide an opportunity discover more compound diversity for treating cancer. 
In Chapter 4, we evaluated the synergy of pairwise compound combinations of 22 
SBP compounds by extending the target prediction and pathway annotation to network 
topology in order to understand the MOA of SBP for CHD by promoting angiogenesis. The 
integration of three parameters, topology, pathway dissimilarity and mean distance of the set 
of predicted targets of a compound combination to measure synergy is reasonable to measure 
how the predicted targets are linked to each other in the network with their related pathways 
The findings of four synergistic combinations that agreed with experimental results 
demonstrate that the method can be potentially applied to explore compound combinations of 
other TCM formulations with limited bioactivity data to start with. To confirm the predicted 
targets are responsible for the MOAs of the synergistic combinations, further experimental 
studies such as gene expression analysis and Western blotting are proposed. 
Although the studies have successfully explained the link of predicted targets and 
pathways in suggesting the MOAs of TM compounds, the studies are still limited to targets 
that are only available in the in silico target prediction. For example, the protein kinase family 
is the biggest group of protein family in the model. Thus, extending protein targets of other 
protein families could provide a more comprehensive overview of targets that are implicated 
for the indications of the TM compounds. The available chemical space of the model is 
limited to the version of ChEMBL used when the model was developed. In addition, natural 
compounds only represent approximately 3.85% of the total compounds available. Therefore, 
the limited coverage of chemical space leads to no predicted targets for one of the TCM 
therapeutic action subclasses, “tranquilizing, settling” in Chapter 1. Despite the limitations, 
our in silico target prediction was able to describe a reasonable MOA of the TM compounds, 
hence, the analyses could be beneficial in providing testable hypotheses to guide towards 
finding new molecular entities. 
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Chapter 2: 
Table A2.1: Top three enriched targets across 14 clusters 
Cluster 
TCM Therapeutic Action 
class 
TCM Therapeutic Action subclass Top three enriched targets  
Target function reported 
by literatures 
I Purgative medicinal Offensive purgative 
Protein kinase C beta type immunomodulation 
Protein kinase C delta type immunomodulation 
Sodium/glucose cotransporter 2 glucose homeostasis 
II 
Purgative medicinal Laxative medicinal 
DNA topoisomerase 1 cancer 
Oxysterols receptor LXR-alpha lipid homeostasis 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Hemostatic medicinal Astringent hemostatic 
DNA topoisomerase 1 cancer 
Telomerase reverse transcriptase cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
Liver-pacifying and wind 
extinguishing 
Liver yang calming 
Telomerase reverse transcriptase cancer 
DNA topoisomerase 1 cancer 
Wee1-like protein kinase cancer 
III 
Anti-malarial medicinal Anti-malarial medicinal 
Oxysterols receptor LXR-alpha lipid homeostasis 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Astringent 
Secure essence, reduce urination, and 
check vaginal discharge 
Oxysterols receptor LXR-alpha lipid homeostasis 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Dampness resolving Water draining and anti-icteric 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 2 glucose homeostasis 
Sodium/glucose cotransporter 1 glucose homeostasis 
Tonifying and replenishing Yang tonifying 
Sodium/glucose cotransporter 2 glucose homeostasis 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
Heat clearing medicinal Heat clearing and detoxicating DNA topoisomerase 1 cancer 
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Sodium/glucose cotransporter 2 glucose homeostasis 
Sodium/glucose cotransporter 1 glucose homeostasis 
Tonifying and replenishing Yin tonifying 
Sodium/glucose cotransporter 2 glucose homeostasis 
DNA topoisomerase 1 cancer 
Oxysterols receptor LXR-alpha lipid homeostasis 
Exterior releasing Wind heat dispersing 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 2 glucose homeostasis 
Wind-dampness dispelling Heat clearing 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
Heat clearing medicinal Heat clearing and fire purging 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Oxysterols receptor LXR-alpha lipid homeostasis 
DNA topoisomerase 1 cancer 
Dampness resolving 
Water draining and strangury 
resolving 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Oxysterols receptor LXR-alpha lipid homeostasis 
IV 
Heat clearing medicinal Heat clearing and dampness drying 
Sodium/glucose cotransporter 2 glucose homeostasis 
DNA topoisomerase 1 cancer 
Protein kinase C beta type immunomodulation 
Blood activating and stress 
resolving 
Blood activating trauma curing 
Leukotriene B4 receptor 1 lipid homeostasis 
DNA topoisomerase 1 cancer 
Estrogen receptor cancer 
Liver-pacifying and wind 
extinguishing 
Extinguish wind to resolve 
convulsion 
Oxysterols receptor LXR-alpha lipid homeostasis 
Leukotriene B4 receptor 1 immunomodulation 
Glutamate carboxypeptidase 2 central nervous system 
Blood activating and stress 
resolving 
Blood activating menstruation 
resolving 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Oxysterols receptor LXR-alpha lipid homeostasis 
DNA topoisomerase 1 cancer 
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Cough suppressing and 
panting-calming 
Cough suppressing and panting 
calming 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Leukotriene B4 receptor 1 immunomodulation 
Worm expelling medicinal Worm expelling medicinal 
Leukotriene B4 receptor 1 immunomodulation 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Sodium/glucose cotransporter 2 glucose homeostasis 
V 
Astringent Lung-intestine astringent 
Protein kinase C beta type immunomodulation 
Endothelin B receptor cardio vasodilation 
DNA topoisomerase 1 cancer 
Digestant medicinal Digestant medicinal 
Oxysterols receptor LXR-alpha lipid homeostasis 
Leukotriene B4 receptor 1 immunomodulation 
DNA topoisomerase 1 cancer 
Cough suppressing and 
panting-calming 
Cold phlegm resolving and warming 
DNA topoisomerase 1 cancer 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Telomerase reverse transcriptase cancer 
VI Emetic medicinal 
  Integrin alpha-L immunomodulation 
 
Poly [ADP-ribose] polymerase 1 inflammation 
  Multidrug resistance-associated protein 1 cytotoxicity 
VII 
Heat clearing medicinal Heat clearing and blood cooling 
Protein kinase C beta type immunomodulation 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 2 glucose homeostasis 
Hemostatic medicinal Stasis-resolving hemostatic 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Protein kinase C eta type immunomodulation 
Protein kinase C gamma type immunomodulation 
Tonifying and replenishing Blood tonifying 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Protein kinase C beta type immunomodulation 
Protein kinase C eta type immunomodulation 
VIII Orifice opening Orifice opening 
Steryl-sulfatase immunomodulation 
Testosterone 17-beta-dehydrogenase 3 reproduction system 
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Ileal sodium/bile acid cotransporter bile  
IX 
Purgative medicinal Drastic (purgative) water-expelling 
Protein kinase C beta type immunomodulation 
Protein kinase C delta type immunomodulation 
Protein kinase C eta type immunomodulation 
Dampness resolving 
Water draining and swelling 
dispersing 
Glutamate carboxypeptidase 2 central nervous system 
Protein kinase C beta type immunomodulation 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Wind-dampness dispelling Cold dispersing 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
X 
Wind-dampness dispelling Bone(sinew) strengthening 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
Steryl-sulfatase immunomodulation 
Tonifying and replenishing Qi tonifying 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Sodium/glucose cotransporter 2 glucose homeostasis 
Sodium/glucose cotransporter 1 glucose homeostasis 
Cough suppressing and 
panting-calming 
Clearing and Heat phlegm resolving 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
DNA topoisomerase 1 cancer 
Testosterone 17-beta-dehydrogenase 3 reproductive system 
Tranqulizing Heat nourishing tranquilizing 
Peptidyl-prolyl cis-trans isomerase FKBP1A immunomodulation 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Glutamate carboxypeptidase 2 central nervous system 
XI Astringent Anhidrotic 
Beta-1 adrenergic receptor cardiac contraction 
5-hydroxytryptamine receptor 2A central nervous system 
Glutamate [NMDA] receptor subunit epsilon-2 central nervous system 
XII 
Parasite destroying, dampness 
eliminating and itchiness 
relieving 
  
Dihydrofolate reductase cancer, bacterial infection 
DNA-dependent protein kinase catalytic subunit cancer 
Tumor necrosis factor cancer, bacterial infection 
XII Hemostatic medicinal Meridian warming hemostatic Peptidyl-prolyl cis-trans isomerase FKBP1A immunomodulation 
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Multidrug resistance protein 1 cytotoxicity 
Steryl-sulfatase immunomodulation 
Exterior releasing Wind cold dispersing 
Steryl-sulfatase immunomodulation 
Endothelin B receptor cardio vasodilation 
cAMP-specific 3',5'-cyclic phosphodiesterase 4B immunomodulation 
Interior warming Interior warming 
Protein kinase C delta type immunomodulation 
Multidrug resistance protein 1 cytotoxicity 
Steroid hormone receptor ERR1 relate to estrogen receptor 
XIV 
Heat clearing medicinal Deficiency 
Sodium/glucose cotransporter 2 glucose homeostasis 
DNA topoisomerase 1 cancer 
Sodium/glucose cotransporter 1 glucose homeostasis 
Qi regulating Qi regulating 
DNA topoisomerase 1 cancer 
Glutamate receptor,  ionotropic kainate 1 central nervous system 
Steryl-sulfatase immunomodulation 
Blood activating and stress 
resolving 
Blood activating analgesic 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Tyrosine-protein phosphatase non-receptor type 1 immunomodulation 
Prostaglandin E2 receptor EP2 subtype bone metabolism 
Hemostatic medicinal Blood cooling hemostatic 
Oxysterols receptor LXR-alpha lipid homeostasis 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
Leukotriene B4 receptor 1 lipid homeostasis 
Blood activating and stress 
resolving 
Blood breaking mass eliminating 
Oxysterols receptor LXR-alpha lipid homeostasis 
Leukotriene B4 receptor 1 immunomodulation 
Tyrosine-protein phosphatase non-receptor type 2 immunomodulation 
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Table A2.2: Top three enriched pathways across 14 clusters 
Cluster 
TCM Therapeutic Action 
class 
TCM Therapeutic Action subclass Top three enriched pathways 
Pathway motif according to 
KEGG 
I Purgative medicinal Offensive purgative 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04530  Tight junction Cellular commiunity 
II 
Purgative medicinal Laxative medicinal 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
Hemostatic medicinal Astringent hemostatic 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
Liver-pacifying and wind 
extinguishing 
Liver yang calming 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
III 
Anti-malarial medicinal Anti-malarial medicinal 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
Astringent 
Secure essence, reduce urination, and 
check vaginal discharge 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
Dampness resolving Water draining and anti-icteric 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
Tonifying and replenishing Yang tonifying 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
Heat clearing medicinal Heat clearing and detoxicating 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Tonifying and replenishing Yin tonifying hsa04978  Mineral absorption Digestive system 
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hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Exterior releasing Wind heat dispersing 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Wind-dampness dispelling Heat clearing 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Heat clearing medicinal Heat clearing and fire purging 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Dampness resolving 
Water draining and strangury 
resolving 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
IV 
Heat clearing medicinal Heat clearing and dampness drying 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
Blood activating and stress 
resolving 
Blood activating trauma curing 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
Liver-pacifying and wind 
extinguishing 
Extinguish wind to resolve 
convulsion 
hsa04976  Bile secretion Digestive system 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa04966  Collecting duct acid secretion Excretory system 
Blood activating and stress 
resolving 
Blood activating menstruation 
resolving 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Cough suppressing and 
panting-calming 
Cough suppressing and panting 
calming 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
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hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
Worm expelling medicinal Worm expelling medicinal 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
V 
Astringent Lung-intestine astringent 
hsa04976  Bile secretion Digestive system 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa04530  Tight junction Cellular commiunity 
Digestant medicinal Digestant medicinal 
hsa04976  Bile secretion Digestive system 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
Cough suppressing and 
panting-calming 
Cold phlegm resolving and warming 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa04520  Adherens junction Cellular commiunity 
VI Emetic medicinal 
  hsa03410  Base excision repair Replication and repair 
 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
  hsa04976  Bile secretion Digestive system 
VII 
Heat clearing medicinal Heat clearing and blood cooling 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa02010  ABC transporters Membrane transport 
Hemostatic medicinal Stasis-resolving hemostatic 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Tonifying and replenishing Blood tonifying 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04530  Tight junction Cellular commiunity 
VIII Orifice opening Orifice opening 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
hsa04976  Bile secretion Digestive system 
hsa00900  Terpenoid backbone biosynthesis 
Metabolism of terpenoids and 
polyketides 
IX Purgative medicinal Drastic (purgative) water-expelling hsa04978  Mineral absorption Digestive system 
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hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04530  Tight junction Cellular commiunity 
Dampness resolving 
Water draining and swelling 
dispersing 
hsa00900  Terpenoid backbone biosynthesis 
Metabolism of terpenoids and 
polyketides 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04530  Tight junction Cellular commiunity 
Wind-dampness dispelling Cold dispersing 
hsa04530  Tight junction Cellular commiunity 
hsa05143  African trypanosomiasis Infectious diseases 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
X 
Wind-dampness dispelling Bone(sinew) strengthening 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Tonifying and replenishing Qi tonifying 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Cough suppressing and 
panting-calming 
Clearing and Heat phlegm resolving 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa04976  Bile secretion Digestive system 
Tranqulizing Heat nourishing tranquilizing 
hsa04978  Mineral absorption Digestive system 
hsa04973  Carbohydrate digestion and absorption Digestive system 
hsa00900  Terpenoid backbone biosynthesis 
Metabolism of terpenoids and 
polyketides 
XI Astringent Anhidrotic 
hsa04540  Gap junction Cellular commiunity 
hsa04970  Salivary secretion Digestive system 
hsa04020  Calcium signaling pathway Signal transduction 
XII 
Parasite destroying, dampness 
eliminating and itchiness 
relieving 
  
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa00564  Glycerophospholipid metabolism Lipid metabolism 
hsa04966  Collecting duct acid secretion Excretory system 
XII Hemostatic medicinal Meridian warming hemostatic 
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa05143  African trypanosomiasis Infectious diseases 
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Exterior releasing Wind cold dispersing 
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa00564  Glycerophospholipid metabolism Lipid metabolism 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
Interior warming Interior warming 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa05143  African trypanosomiasis Infectious diseases 
hsa05110  Vibrio cholerae infection Infectious diseases 
XIV 
Heat clearing medicinal Deficiency 
hsa04978  Mineral absorption Digestive system 
hsa00040  Pentose and glucuronate interconversions Carbohydrate metabolism 
hsa00561  Glycerolipid metabolism Lipid metabolism 
Qi regulating Qi regulating 
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
hsa04612  Antigen processing and presentation Immune system 
Blood activating and stress 
resolving 
Blood activating analgesic 
hsa00100  Steroid biosynthesis Lipid metabolism 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
Hemostatic medicinal Blood cooling hemostatic 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
hsa04520  Adherens junction Cellular commiunity 
Blood activating and stress 
resolving 
Blood breaking mass eliminating 
hsa04961  Endocrine and other factor-regulated 
calcium reabsorption 
Excretory system 
hsa00140  Steroid hormone biosynthesis Lipid metabolism 
hsa05143  African trypanosomiasis Infectious diseases 
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Chapter 3: 
 
Table A3.1: The list of 28 anti-cancer compounds that shows to be structurally similar to TM 
compounds. 
 
Anti-cancer 
Drug 
DrugBank 
ID TM Compound Plant Source of TM 
Tc 
value 
1 Abiraterone DB05812 Brassicasterol Houttuynia cordata TCM 0.339 
    
Moringa oleifera Ayurveda, MalayTM 
 
   
Beta-Sitosterol Abrus precatorius Ayurveda, MalayTM 0.331 
    
Alpinia officinarum TCM 
 
    
Angelica sinensis TCM 
 
    
Artemisia argyi TCM 
 
    
Astragalus complanatus TCM 
 
    
Azadirachta indica Ayurveda 
 
    
Brucea javanica TCM 
 
    
Capparis spinosa Ayurveda 
 
    
Carthamus tinctorius TCM 
 
    
Centipeda minima TCM 
 
    
Chrysanthemum indicum TCM 
 
    
Cornus officinalis TCM 
 
    
Cuscuta chinensis TCM 
 
    
Drynaria fortunei TCM 
 
    
Foeniculum vulgare TCM 
 
    
Forsythia suspensa TCM 
 
    
Gynostemma pentaphyllum TCM 
 
    
Imperata cylindrica TCM 
 
    
Inula britannica TCM 
 
    
Isatis tinctoria TCM 
 
    
Lycopus lucidus TCM 
 
    
Ocimum tenuiflorum Ayurveda 
 
    
Oldenlandia diffusa TCM 
 
    
Paeonia suffruticosa TCM 
 
    
Persicaria orientalis TCM 
 
    
Polygonum aviculare TCM 
 
    
Polygonum cuspidatum TCM 
 
    
Portulaca oleracea TCM 
 
    
Prunella vulgaris TCM, MalayTM 
 
    
Pulsatilla chinensis TCM 
 
    
Raphanus sativus Ayurveda 
 
    
Ricinus communis Ayurveda 
 
    
Scutellaria baicalensis TCM 
 
    
Scutellaria barbata TCM 
 
    
Sophora japonica TCM 
 
    
Spatholobus suberectus TCM 
 
    
Terminalia arjuna Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
    
Zanthoxylum nitidum TCM 
 
    
Zingiber officinale 
TCM, Ayurveda 
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24-
Methylcholesta-
5,24-Dien-
3Beta-Ol Withania somnifera Ayurveda 0.331 
   
Cholesterol Allium sativum Ayurveda, MalayTM 0.328 
    
Vitis vinifera Ayurveda 
 
   
Campesterol Abrus precatorius Ayurveda, MalayTM 0.325 
    
Curcuma longa 
TCM, Ayurveda, 
MalayTM 
 
    
Curcuma longa TCM 
 
    
Cuscuta chinensis TCM 
 
    
Senna tora TCM, MalayTM 
 
    
Spatholobus suberectus TCM 
 
    
Vitis vinifera Ayurveda 
 
   
(3S,8S,9S,10R,1
3R,14S,17R)-
17-[(1R,4R)-
1,4-
Dimethylhexyl]-
10,13-Dimethyl-
2,3,4,7,8,9,11,1
2,14,15,16,17-
Dodecahydro-
1H-
Cyclopenta[A]P
henanthren-3-Ol Eclipta prostrata TCM 0.323 
   
Daucosterol Spatholobus suberectus TCM 0.321 
   
Fucosterol Cymbopogon citratus Ayurveda, MalayTM 0.320 
    
Gynostemma pentaphyllum TCM 
 
    
Cuscuta chinensis TCM 
 
    
Withania somnifera Ayurveda 
 
   
(3S,8S,9S,10R,1
3R,14S,17R)-
17-[(E,1R,4R)-
1,4-
Dimethylhex-2-
Enyl]-10,13-
Dimethyl-
2,3,4,7,8,9,11,1
2,14,15,16,17-
Dodecahydro-
1H-
Cyclopenta[A]P
henanthren-3-Ol Eclipta prostrata TCM 0.320 
   
Stigmasterol Abrus precatorius Ayurveda, MalayTM 0.315 
    
Angelica sinensis TCM 
 
    
Artemisia argyi TCM 
 
    
Carthamus tinctorius TCM 
 
    
Centipeda minima TCM 
 
    
Cornus officinalis TCM 
 
    
Curcuma longa 
TCM, Ayurveda, 
MalayTM 
 
    
Drynaria fortunei TCM 
 
    
Eurycoma longifolia MalayTM 
 
    
Foeniculum vulgare TCM 
 
    
Imperata cylindrica TCM 
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Isatis tinctoria TCM 
 
    
Oldenlandia diffusa TCM 
 
    
Prunella vulgaris TCM, MalayTM 
 
    
Pulsatilla chinensis TCM 
 
    
Ricinus communis Ayurveda 
 
    
Scutellaria barbata TCM 
 
    
Senna tora TCM, MalayTM 
 
    
Spatholobus suberectus TCM 
 
    
Vitis vinifera Ayurveda 
 
   
Clerosterol Moringa oleifera Ayurveda, MalayTM 0.313 
2 
Aminolevulinic 
Acid DB00855 Glycine Allium sativum Ayurveda, MalayTM 0.450 
    
Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
   
Succinic Acid Allium sativum Ayurveda, MalayTM 0.450 
    
Angelica sinensis TCM 
 
    
Carthamus tinctorius TCM 
 
    
Forsythia suspensa TCM 
 
    
Isatis tinctoria TCM 
 
    
Oldenlandia diffusa TCM 
 
    
Portulaca oleracea TCM 
 
    
Ricinus communis Ayurveda 
 
    
Spatholobus suberectus TCM 
 
    
Vitis vinifera Ayurveda 
 
   
Gamma-
Aminobutyric 
Acid Annona squamosa Ayurveda 0.400 
    
Isatis tinctoria TCM 
 
    
Vitis vinifera Ayurveda 
 
3 Azacitidine DB00928 Guanosine Allium sativum Ayurveda, MalayTM 0.407 
    
Carthamus tinctorius TCM 
 
   
Adenosine Allium sativum Ayurveda, MalayTM 0.385 
   
Uridine Isatis tinctoria TCM 0.361 
4 Choline C 11 DB09277 Choline Allium sativum Ayurveda, MalayTM 1.000 
    
Capparis spinosa Ayurveda 
 
5 Clofarabine DB00631 Adenosine Allium sativum Ayurveda, MalayTM 0.367 
   
Guanosine Allium sativum Ayurveda, MalayTM 0.344 
    
Carthamus tinctorius TCM 0.344 
6 Cytarabine DB00987 Uridine Isatis tinctoria TCM 0.420 
   
Guanosine Allium sativum Ayurveda, MalayTM 0.357 
    
Carthamus tinctorius TCM 
 
   
Adenosine Allium sativum Ayurveda, MalayTM 0.333 
7 Decitabine DB01262 Thymidine Eurycoma longifolia MalayTM 0.368 
8 Epirubicin DB00445 Glutathione Allium sativum Ayurveda, MalayTM 0.545 
9 Floxuridine DB00322 Thymidine Eurycoma longifolia MalayTM 0.591 
10 Fludarabine DB01073 Adenosine Allium sativum Ayurveda, MalayTM 0.324 
   
Guanosine Allium sativum Ayurveda, MalayTM 0.318 
    
Carthamus tinctorius TCM 
 
11 Hydroxyurea DB01005 Urea Aloe vera Ayurveda, MalayTM 0.455 
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12 Idarubicin DB01177 Glutathione Allium sativum Ayurveda, MalayTM 0.411 
13 
Ingenol 
Mebutate DB05013 
Ingenol-
Triacetate Euphorbia hirta Ayurveda 0.456 
14 Melphalan DB01042 Tyrosine Abrus precatorius Ayurveda, MalayTM 0.436 
    
Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
   
Phenylalanine Albizia lebbeck Ayurveda 0.389 
    
Carthamus tinctorius TCM 
 
    
Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
   
Levodopa Spatholobus suberectus TCM 0.317 
    
Portulaca oleracea 
  
15 Mesna DB09110 Taurine Allium sativum Ayurveda, MalayTM 0.474 
16 Methotrexate DB00563 Folacin Aloe vera Ayurveda, MalayTM 0.388 
    
Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
17 
Methyltestoster
one DB06710 
4-Campesten-3-
One Melia azedarach Ayurveda 0.367 
   
Stigmast-4-En-
3-One Melia azedarach Ayurveda 0.360 
    
Scutellaria barbata TCM 
 
    
Isatis tinctoria TCM 
 
18 Nelarabine DB01280 Guanosine Allium sativum Ayurveda, MalayTM 0.456 
    
Carthamus tinctorius TCM 
 
   
Adenosine Allium sativum Ayurveda, MalayTM 0.420 
19 Pemetrexed DB00642 Folacin Aloe vera Ayurveda, MalayTM 0.379 
    
Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
20 Pralatrexate DB06813 Folacin Aloe vera Ayurveda, MalayTM 0.367 
    
Raphanus sativus Ayurveda 0.367 
    
Vitis vinifera Ayurveda 0.367 
21 
Sodium 
phenylbutyrate DB06819 
Hydrocinnamic 
acid Aloe vera Ayurveda, MalayTM 0.541 
    
Vitis vinifera Ayurveda 
 
   
Benzyl-acetone Aloe vera Ayurveda, MalayTM 0.439 
    
Alpinia officinarum TCM 
 
   
Phenylethanol Lawsonia inermis MalayTM 0.405 
    
Vitis vinifera Ayurveda 
 
   
2-phenylethyl-
amine Vitis vinifera Ayurveda 0.368 
   
Benzyl alcohol Albizia lebbeck Ayurveda 0.333 
    
Lawsonia inermis MalayTM 
 
    
Vitis vinifera Ayurveda 
 
   
Tetra-
decylbenzene Aloe vera Ayurveda, MalayTM 0.327 
   
Tridecylbenzene Aloe vera Ayurveda, MalayTM 0.327 
   
Phenethyl 
isobutyrate Alpinia officinarum TCM 0.327 
   
Isoamylbenzene Angelica sinensis TCM 0.326 
   
Phenylalanine Albizia lebbeck Ayurveda 0.304 
    
Carthamus tinctorius TCM 
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Raphanus sativus Ayurveda 
 
    
Vitis vinifera Ayurveda 
 
   
Benzyl-acetate Melia azedarach Ayurveda 0.304 
   
Hyacinthin Artemisia argyi TCM 0.300 
    
Carthamus tinctorius TCM 
 
    
Cinnamomum aromaticum TCM 
 
    
Gynostemma pentaphyllum TCM 
 
    
Magnolia officinalis TCM 
 
    
Scutellaria barbata TCM 
 
22 
Uridine 
Triacetate DB09144 Uridine Isatis tinctoria TCM 0.361 
23 Valrubicin DB00385 Glutathione Allium sativum Ayurveda, MalayTM 0.446 
24 Vinblastine DB00570 
Leurosidine 
(Vinrosidine) Catharanthus roseus MalayTM 1.000 
   
Vincaleukoblast
ine 
 
MalayTM 0.883 
   
Leurocristine 
 
MalayTM 0.758 
   
Vinblastine 
(Vincaleucoblas
tine) 
 
MalayTM 0.702 
   
3’,4’-
Anhydrovinblas
tine 
 
MalayTM 0.682 
   
N-
Deformylvincris
tine 
 
MalayTM 0.634 
   
Catharine 
 
MalayTM 0.623 
   
Leurosinone 
 
MalayTM 0.579 
   
Pleurosine 
 
MalayTM 0.500 
   
Vincathicine 
 
MalayTM 0.469 
   
Vindolicine 
 
MalayTM 0.454 
   
Vindoline 
 
MalayTM 0.409 
   
Deacetylvindoli
ne 
 
MalayTM 0.300 
25 Vincristine DB00541 Leurocristine Catharanthus roseus MalayTM 1.000 
   
Leurosidine 
(Vinrosidine) 
 
MalayTM 0.758 
   
Vincaleukoblast
ine 
 
MalayTM 0.687 
   
N-
Deformylvincris
tine 
 
MalayTM 0.652 
   
Vinblastine 
(Vincaleucoblas
tine) 
 
MalayTM 0.525 
   
3’,4’-
Anhydrovinblas
tine 
 
MalayTM 0.507 
   
Catharine 
 
MalayTM 0.491 
   
Leurosinone 
 
MalayTM 0.438 
   
Pleurosine 
 
MalayTM 0.384 
   
Vindoline 
 
MalayTM 0.342 
   
Vindolicine 
 
MalayTM 0.342 
   
Vincathicine 
 
MalayTM 0.342 
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26 Vincristine DB00541 Leurocristine Catharanthus roseus MalayTM 1.000 
   
Leurosidine 
(Vinrosidine) 
 
MalayTM 0.758 
   
Vincaleukoblast
ine 
 
MalayTM 0.687 
   
N-
Deformylvincris
tine 
 
MalayTM 0.652 
   
Vinblastine 
(Vincaleucoblas
tine) 
 
MalayTM 0.525 
   
3’,4’-
Anhydrovinblas
tine 
 
MalayTM 0.507 
   
Catharine 
 
MalayTM 0.491 
   
Leurosinone 
 
MalayTM 0.438 
   
Pleurosine 
 
MalayTM 0.384 
   
Vindoline 
 
MalayTM 0.342 
   
Vindolicine 
 
MalayTM 0.342 
   
Vincathicine 
 
MalayTM 0.342 
27 Vindesine DB00309 
Leurosidine 
(Vinrosidine) Catharanthus roseus MalayTM 0.773 
   
Vincaleukoblast
ine 
 
MalayTM 0.754 
   
Leurocristine 
 
MalayTM 0.641 
   
N-
Deformylvincris
tine 
 
MalayTM 0.562 
   
Vinblastine 
(Vincaleucoblas
tine) 
 
MalayTM 0.537 
   
Leurosine 
 
MalayTM 0.537 
   
3’,4’-
Anhydrovinblas
tine 
 
MalayTM 0.518 
   
Catharine 
 
MalayTM 0.475 
   
Leurosinone 
 
MalayTM 0.436 
   
Pleurosine 
 
MalayTM 0.377 
   
Vincathicine 
 
MalayTM 0.351 
   
Deacetylvindoli
ne 
 
MalayTM 0.351 
   
Catharosine 
 
MalayTM 0.349 
   
Vindolicine 
 
MalayTM 0.307 
28 Vinorelbine DB00361 
3’,4’-
Anhydrovinblas
tine Catharanthus roseus MalayTM 0.765 
   
Leurosidine 
(Vinrosidine) 
 
MalayTM 0.603 
   
Vinblastine 
(Vincaleucoblas
tine) 
 
MalayTM 0.583 
   
Catharine 
 
MalayTM 0.577 
   
Leurosinone 
 
MalayTM 0.572 
   
Vincaleukoblast
ine 
 
MalayTM 0.532 
   
Pleurosine 
 
MalayTM 0.474 
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Vincathicine 
 
MalayTM 0.462 
   
Vindolicine 
 
MalayTM 0.461 
   
Leurocristine 
 
MalayTM 0.440 
   
Vindoline 
 
MalayTM 0.400 
   
N-
Deformylvincris
tine 
 
MalayTM 0.363 
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Chapter 4:  
Table A4.1: The list of enriched GO biological processes based on SBP predicted targets. 
GOID GO Term 
Term  
p-value 
GO Levels 
% 
Associated 
Genes 
GO:0000187 activation of MAPK activity 65.0E-15 [7, 8, 9, 10, 11, 12, 13] 13.55 
GO:0032872 regulation of stress-activated MAPK cascade 270.0E-18 [5, 6, 7, 8, 9, 10, 11] 12.75 
GO:0051403 stress-activated MAPK cascade 28.0E-21 [5, 6, 7, 9, 10] 12.10 
GO:0002224 toll-like receptor signaling pathway 2.4E-12 [6, 8, 9, 10, 11] 12.05 
GO:0043406 positive regulation of MAP kinase activity 7.1E-15 [6, 7, 8, 9, 10, 11, 12] 11.16 
GO:0051091 
positive regulation of sequence-specific DNA 
binding transcription factor activity 130.0E-15 [4, 6, 7, 8, 9, 10, 11, 12] 10.37 
GO:0018108 peptidyl-tyrosine phosphorylation 9.4E-18 [7, 8, 9] 9.72 
GO:0043405 regulation of MAP kinase activity 6.0E-24 [6, 7, 8, 9, 10, 11] 9.62 
GO:0006367 
transcription initiation from RNA polymerase II 
promoter 36.0E-15 [7, 8, 9, 10, 11] 9.52 
GO:0006352 DNA-templated transcription, initiation 4.3E-15 [6, 7, 8, 9, 10] 9.14 
GO:0002758 
innate immune response-activating signal 
transduction 320.0E-15 [4, 6, 7, 8, 9] 9.09 
GO:0051090 
regulation of sequence-specific DNA binding 
transcription factor activity 99.0E-18 [3, 6, 7, 8, 9, 10, 11] 9.02 
GO:0032147 activation of protein kinase activity 10.0E-21 [7, 8, 9, 10, 11] 8.94 
GO:0071902 
positive regulation of protein serine/threonine 
kinase activity 270.0E-15 [7, 8, 9, 10, 11] 8.78 
GO:0018105 peptidyl-serine phosphorylation 47.0E-12 [7, 8, 9] 8.71 
GO:0070371 ERK1 and ERK2 cascade 60.0E-12 [5, 6, 7, 9, 10] 8.61 
GO:0071900 
regulation of protein serine/threonine kinase 
activity 1.0E-24 [7, 8, 9, 10] 8.46 
GO:0070372 regulation of ERK1 and ERK2 cascade 620.0E-12 [6, 7, 8, 9, 10, 11] 8.43 
GO:0000186 activation of MAPKK activity 2.6E-9 [6, 7, 8, 9, 10, 11, 12] 8.20 
GO:0033674 positive regulation of kinase activity 10.0E-24 [5, 6, 7, 8, 9] 8.08 
GO:0045860 positive regulation of protein kinase activity 370.0E-24 [6, 7, 8, 9, 10] 7.98 
GO:0045859 regulation of protein kinase activity 240.0E-33 [6, 7, 8, 9] 7.95 
GO:0043408 regulation of MAPK cascade 120.0E-30 [5, 6, 7, 8, 9, 10] 7.95 
GO:0043410 positive regulation of MAPK cascade 9.7E-21 [5, 6, 7, 8, 9, 10, 11] 7.74 
GO:0000165 MAPK cascade 14.0E-30 [4, 5, 6, 8, 9] 7.70 
GO:0007173 epidermal growth factor receptor signaling pathway 18.0E-12 [8, 9] 7.39 
GO:0008286 insulin receptor signaling pathway 390.0E-12 [7, 8, 9] 7.20 
GO:0006606 protein import into nucleus 12.0E-9 [4, 5, 6, 7, 8, 9] 7.14 
GO:0001525 angiogenesis 15.0E-12 [3, 4, 5, 7, 8, 9, 10] 6.74 
GO:0001934 positive regulation of protein phosphorylation 640.0E-27 [6, 7, 8, 9] 6.56 
GO:0030098 lymphocyte differentiation 65.0E-9 [4, 6, 7, 8, 9] 6.48 
GO:0006816 calcium ion transport 5.6E-9 [8, 9] 6.33 
GO:0048514 blood vessel morphogenesis 13.0E-12 [3, 4, 6, 7, 8, 9] 6.22 
GO:0045944 
positive regulation of transcription from RNA 
polymerase II promoter 2.5E-21 [6, 7, 8, 9, 10, 11, 12] 6.00 
GO:0007411 axon guidance 1.1E-9 [5, 6, 7, 8, 9, 10, 11, 12, 13] 5.37 
GO:0006874 cellular calcium ion homeostasis 1.5E-6 [8, 9] 5.34 
GO:0045893 positive regulation of transcription, DNA-templated 63.0E-24 [5, 6, 7, 8, 9, 10, 11] 5.30 
GO:0048666 neuron development 260.0E-15 [4, 5, 6, 8, 9] 4.44 
GO:0031175 neuron projection development 10.0E-12 [4, 5, 6, 7, 9, 10] 4.43 
GO:0042110 T cell activation 37.0E-6 [4, 6, 8, 9] 4.34 
GO:0048667 
cell morphogenesis involved in neuron 
differentiation 51.0E-9 [5, 6, 7, 8, 9, 10] 4.20 
 
GO Levels = Level of term specificity  
% Associated Genes = Percentage of the genes from the SBP predicted targets that were associated 
with the term, com-pared with all the genes associated with the term.   
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Table A4.2: The list of 332 GO term that were used in calculating Pathway Distance 
Similarity (PDS) 
GOID GO Term Term p-value 
Term p-value 
Corrected 
with 
Bonferroni 
step down 
GO Levels 
% 
Associated 
Genes 
GO:0006468 protein phosphorylation 430.0E-264 140.0E-261 [6, 7] 43.38 
GO:0071310 
cellular response to organic 
substance 180.0E-261 59.0E-258 (321) 40.12 
GO:0044093 
positive regulation of molecular 
function 450.0E-237 140.0E-234 [3] 41.74 
GO:1902531 
regulation of intracellular signal 
transduction 51.0E-216 16.0E-213 [4, 5, 6] 41.55 
GO:0043085 
positive regulation of catalytic 
activity 620.0E-210 200.0E-207 (321) 42.97 
GO:0009967 
positive regulation of signal 
transduction 12.0E-198 4.1E-195 [3, 4, 5, 6] 43.60 
GO:0031399 
regulation of protein modification 
process 6.6E-195 2.1E-192 [5, 6, 7] 40.74 
GO:0023056 positive regulation of signaling 600.0E-192 190.0E-189 [2, 3, 4] 41.37 
GO:0010647 
positive regulation of cell 
communication 700.0E-192 220.0E-189 [3, 4, 5] 41.45 
GO:0019220 
regulation of phosphate metabolic 
process 380.0E-186 120.0E-183 [5, 6] 40.31 
GO:0042325 regulation of phosphorylation 39.0E-183 12.0E-180 [6, 7] 42.95 
GO:0051247 
positive regulation of protein 
metabolic process 15.0E-180 4.8E-177 [4, 5, 6] 41.25 
GO:0010941 regulation of cell death 1.1E-177 350.0E-177 [3, 4] 40.84 
GO:0001932 
regulation of protein 
phosphorylation 4.9E-174 1.5E-171 [6, 7, 8] 43.45 
GO:0043067 
regulation of programmed cell 
death 39.0E-174 12.0E-171 [4, 5] 41.61 
GO:0023014 
signal transduction by protein 
phosphorylation 17.0E-171 5.4E-168 [3, 4, 5, 7, 8] 50.05 
GO:0032270 
positive regulation of cellular 
protein metabolic process 33.0E-171 10.0E-168 [4, 5, 6, 7] 41.55 
GO:0042981 regulation of apoptotic process 430.0E-171 130.0E-168 [5, 6] 41.42 
GO:0000165 MAPK cascade 2.4E-165 750.0E-165 [4, 5, 6, 8, 9] 50.27 
GO:0031401 
positive regulation of protein 
modification process 480.0E-165 140.0E-162 [5, 6, 7, 8] 44.61 
GO:0045937 
positive regulation of phosphate 
metabolic process 41.0E-156 12.0E-153 [5, 6, 7] 45.22 
GO:0007167 
enzyme linked receptor protein 
signaling pathway 3.1E-153 960.0E-153 [5, 6] 46.58 
GO:0071495 
cellular response to endogenous 
stimulus 390.0E-150 120.0E-147 [3] 42.35 
GO:0042327 
positive regulation of 
phosphorylation 5.9E-147 1.8E-144 [6, 7, 8] 46.72 
GO:0001934 
positive regulation of protein 
phosphorylation 1.7E-141 530.0E-141 [6, 7, 8, 9] 46.90 
GO:0051338 regulation of transferase activity 26.0E-141 7.9E-138 (321) 45.56 
GO:0072359 circulatory system development 28.0E-138 8.4E-135 [4, 5] 45.05 
GO:0014070 
response to organic cyclic 
compound 60.0E-135 18.0E-132 (321) 45.41 
GO:0016477 cell migration 670.0E-135 200.0E-132 [3, 4, 5] 40.09 
GO:0022603 
regulation of anatomical structure 
morphogenesis 20.0E-132 6.1E-129 [3, 4] 44.18 
GO:0048646 
anatomical structure formation 
involved in morphogenesis 7.7E-129 2.3E-126 [2, 3, 4] 43.47 
GO:0098609 cell-cell adhesion 17.0E-129 5.2E-126 [3] 40.66 
GO:0051094 
positive regulation of 
developmental process 68.0E-129 20.0E-126 [2, 3, 4] 40.33 
GO:0007169 
transmembrane receptor protein 
tyrosine kinase signaling pathway 53.0E-126 15.0E-123 [6, 7] 50.28 
GO:1902533 
positive regulation of intracellular 
signal transduction 650.0E-126 190.0E-123 [4, 5, 6, 7] 44.13 
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GO:0043549 regulation of kinase activity 10.0E-123 3.0E-120 [5, 7, 8] 46.83 
GO:1901701 
cellular response to oxygen-
containing compound 45.0E-123 13.0E-120 (321) 43.41 
GO:0051347 
positive regulation of transferase 
activity 6.8E-120 2.0E-117 [5] 50.52 
GO:0033993 response to lipid 22.0E-120 6.6E-117 (321) 44.10 
GO:0060548 negative regulation of cell death 430.0E-117 120.0E-114 [3, 4, 5] 42.84 
GO:0051345 
positive regulation of hydrolase 
activity 640.0E-117 180.0E-114 [5] 42.87 
GO:0009887 animal organ morphogenesis 66.0E-114 19.0E-111 [3, 4, 5, 6] 41.30 
GO:0045859 
regulation of protein kinase 
activity 590.0E-114 170.0E-111 [6, 7, 8, 9] 46.64 
GO:0001568 blood vessel development 2.0E-111 570.0E-111 [3, 5, 6, 7, 8] 50.64 
GO:0009725 response to hormone 4.2E-111 1.2E-108 [3, 4] 43.50 
GO:0048729 tissue morphogenesis 45.0E-111 12.0E-108 [3, 4] 49.17 
GO:0072358 
cardiovascular system 
development 940.0E-111 260.0E-108 [4, 5, 6] 49.08 
GO:0043069 
negative regulation of 
programmed cell death 12.0E-108 3.5E-105 [4, 5, 6] 43.15 
GO:1901698 response to nitrogen compound 90.0E-108 25.0E-105 [3] 42.11 
GO:0098602 single organism cell adhesion 160.0E-108 45.0E-105 [2, 3] 44.23 
GO:0043066 
negative regulation of apoptotic 
process 1.8E-105 500.0E-105 [5, 6, 7] 43.05 
GO:0043068 
positive regulation of 
programmed cell death 12.0E-105 3.3E-102 [4, 5, 6] 49.84 
GO:0009611 response to wounding 21.0E-105 5.9E-102 [3] 47.70 
GO:0010942 positive regulation of cell death 160.0E-105 45.0E-102 [3, 4, 5] 48.52 
GO:0043065 
positive regulation of apoptotic 
process 250.0E-105 69.0E-102 [5, 6, 7] 49.75 
GO:0033674 
positive regulation of kinase 
activity 2.5E-102 700.0E-102 [6, 7, 8, 9] 52.15 
GO:0043408 regulation of MAPK cascade 74.0E-102 20.0E-99 [5, 6, 7, 8, 9, 10] 45.87 
GO:0016337 
single organismal cell-cell 
adhesion 120.0E-102 34.0E-99 [3, 4] 44.58 
GO:0048514 blood vessel morphogenesis 260.0E-102 70.0E-99 [3, 4, 6, 7, 8, 9] 51.68 
GO:0034097 response to cytokine 820.0E-102 220.0E-99 (321) 43.05 
GO:0001775 cell activation 3.1E-99 830.0E-99 [3] 40.50 
GO:0051270 
regulation of cellular component 
movement 4.7E-99 1.2E-96 [3, 4] 42.75 
GO:0045597 
positive regulation of cell 
differentiation 530.0E-99 140.0E-96 [3, 4, 5, 6] 41.50 
GO:0008284 
positive regulation of cell 
proliferation 790.0E-99 210.0E-96 [3, 4, 5] 41.38 
GO:0010243 
response to organonitrogen 
compound 2.2E-96 580.0E-96 [3, 4] 42.58 
GO:0018108 peptidyl-tyrosine phosphorylation 3.3E-96 880.0E-96 [7, 8, 9] 58.35 
GO:0071407 
cellular response to organic cyclic 
compound 7.8E-96 2.0E-93 [5] 50.27 
GO:0045860 
positive regulation of protein 
kinase activity 800.0E-96 210.0E-93 [7, 8, 9, 10] 51.91 
GO:2000145 regulation of cell motility 2.4E-93 630.0E-93 [3, 4, 5] 43.13 
GO:0030334 regulation of cell migration 8.6E-93 2.2E-90 [4, 5, 6] 44.24 
GO:0002009 morphogenesis of an epithelium 90.0E-93 23.0E-90 [4, 5] 49.01 
GO:0040012 regulation of locomotion 210.0E-93 56.0E-90 [2, 3] 41.41 
GO:0001525 angiogenesis 220.0E-93 58.0E-90 [3, 4, 5, 7, 8, 9, 10] 53.42 
GO:0071396 cellular response to lipid 4.1E-90 1.0E-87 [5] 49.17 
GO:0042060 wound healing 73.0E-90 18.0E-87 (321) 48.30 
GO:0032870 
cellular response to hormone 
stimulus 240.0E-90 62.0E-87 [4, 5] 45.30 
GO:0030155 regulation of cell adhesion 280.0E-90 71.0E-87 [2, 3] 44.25 
GO:0070848 response to growth factor 300.0E-90 76.0E-87 (321) 44.64 
GO:0071363 
cellular response to growth factor 
stimulus 4.5E-87 1.1E-84 [5] 45.19 
GO:1905114 
cell surface receptor signaling 
pathway involved in cell-cell 
signaling 130.0E-87 32.0E-84 [4, 5, 6] 47.19 
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GO:0071900 
regulation of protein 
serine/threonine kinase activity 200.0E-87 50.0E-84 [7, 8, 9, 10] 50.10 
GO:0031347 regulation of defense response 310.0E-87 76.0E-84 [4, 5] 43.35 
GO:0043410 
positive regulation of MAPK 
cascade 1.8E-84 460.0E-84 [5, 6, 7, 8, 9, 10, 11] 49.12 
GO:0071345 
cellular response to cytokine 
stimulus 3.5E-84 850.0E-84 [5] 42.45 
GO:0016055 Wnt signaling pathway 700.0E-84 170.0E-81 [5, 6, 7] 48.62 
GO:0019221 
cytokine-mediated signaling 
pathway 22.0E-81 5.5E-78 [5, 6] 46.05 
GO:1901699 
cellular response to nitrogen 
compound 510.0E-78 120.0E-75 (321) 44.60 
GO:2000027 
regulation of organ 
morphogenesis 280.0E-75 68.0E-72 [4, 5, 6, 7] 60.36 
GO:0043087 regulation of GTPase activity 28.0E-72 6.7E-69 [5] 40.14 
GO:0043405 regulation of MAP kinase activity 140.0E-72 33.0E-69 [6, 7, 8, 9, 10, 11] 53.76 
GO:0032147 
activation of protein kinase 
activity 130.0E-72 33.0E-69 [8, 9, 10, 11] 56.05 
GO:0071417 
cellular response to 
organonitrogen compound 660.0E-72 150.0E-69 [4, 5] 45.98 
GO:0043547 
positive regulation of GTPase 
activity 23.0E-69 5.4E-66 (322) 40.76 
GO:0070482 response to oxygen levels 25.0E-69 5.8E-66 [3] 54.46 
GO:0046649 lymphocyte activation 100.0E-69 24.0E-66 [3, 5] 40.24 
GO:0060070 canonical Wnt signaling pathway 200.0E-69 46.0E-66 [6, 7, 8] 55.34 
GO:0007159 leukocyte cell-cell adhesion 320.0E-69 75.0E-66 [4, 5] 44.66 
GO:0002764 
immune response-regulating 
signaling pathway 530.0E-69 120.0E-66 [4, 5] 42.51 
GO:0051272 
positive regulation of cellular 
component movement 1.0E-66 230.0E-66 [3, 4, 5] 47.30 
GO:0045088 
regulation of innate immune 
response 7.2E-66 1.6E-63 [4, 5, 6] 51.10 
GO:0051056 
regulation of small GTPase 
mediated signal transduction 14.0E-66 3.2E-63 [5, 6, 7] 53.73 
GO:0050878 regulation of body fluid levels 14.0E-66 3.2E-63 [3] 43.69 
GO:0031400 
negative regulation of protein 
modification process 20.0E-66 4.7E-63 [5, 6, 7, 8] 41.98 
GO:0040017 positive regulation of locomotion 130.0E-66 31.0E-63 [2, 3, 4] 45.81 
GO:0097190 apoptotic signaling pathway 170.0E-66 38.0E-63 [4, 5, 6] 40.57 
GO:0006935 chemotaxis 340.0E-66 76.0E-63 [3, 4] 41.60 
GO:0061061 muscle structure development 370.0E-66 82.0E-63 [3] 41.05 
GO:0036293 
response to decreased oxygen 
levels 500.0E-66 110.0E-63 (321) 54.43 
GO:0007507 heart development 1.0E-63 240.0E-63 [3, 4, 5, 6] 42.75 
GO:0050852 T cell receptor signaling pathway 8.5E-63 1.8E-60 [6, 8, 9, 10] 66.84 
GO:0001666 response to hypoxia 11.0E-63 2.5E-60 [3, 5] 54.55 
GO:0048545 response to steroid hormone 45.0E-63 9.7E-60 [4, 5] 47.55 
GO:0070486 leukocyte aggregation 750.0E-63 160.0E-60 [5, 6] 44.17 
GO:0018105 peptidyl-serine phosphorylation 1.2E-60 250.0E-60 [7, 8, 9] 56.39 
GO:0048732 gland development 1.8E-60 390.0E-60 [3, 4, 5, 6] 44.54 
GO:0002521 leukocyte differentiation 2.0E-60 420.0E-60 [5, 6, 7, 8] 43.83 
GO:0042110 T cell activation 3.2E-60 690.0E-60 [4, 6, 8, 9] 44.28 
GO:0002768 
immune response-regulating cell 
surface receptor signaling 
pathway 11.0E-60 2.5E-57 [5, 6] 45.17 
GO:0051090 
regulation of sequence-specific 
DNA binding transcription factor 
activity 45.0E-60 9.4E-57 [3, 6, 7, 8, 9, 10, 11] 47.67 
GO:0046777 protein autophosphorylation 68.0E-60 14.0E-57 [7, 8] 57.49 
GO:0002757 
immune response-activating 
signal transduction 78.0E-60 16.0E-57 [3, 5, 6, 7] 41.35 
GO:0018209 peptidyl-serine modification 100.0E-60 21.0E-57 [7, 8] 54.48 
GO:0070997 neuron death 150.0E-60 30.0E-57 (321) 52.10 
GO:1901652 response to peptide 390.0E-60 81.0E-57 [4, 5] 43.97 
GO:0045785 
positive regulation of cell 
adhesion 1.0E-57 200.0E-57 [2, 3, 4] 45.89 
 153 
GO:0050851 
antigen receptor-mediated 
signaling pathway 1.1E-57 220.0E-57 [5, 7, 8, 9] 56.57 
GO:0031349 
positive regulation of defense 
response 1.3E-57 280.0E-57 [3, 4, 5, 6] 45.99 
GO:1901342 
regulation of vasculature 
development 7.9E-57 1.6E-54 [4, 5, 6, 7, 8] 55.64 
GO:0030111 
regulation of Wnt signaling 
pathway 8.6E-57 1.7E-54 [4, 5, 6, 7, 8] 49.85 
GO:0060537 muscle tissue development 12.0E-57 2.5E-54 (321) 47.00 
GO:0030198 extracellular matrix organization 20.0E-57 4.1E-54 (321) 48.99 
GO:0007599 hemostasis 33.0E-57 6.5E-54 (321) 47.68 
GO:0035239 tube morphogenesis 41.0E-57 8.1E-54 [3, 4, 5] 47.44 
GO:0043434 response to peptide hormone 100.0E-57 20.0E-54 [4, 5, 6] 44.81 
GO:0050817 coagulation 190.0E-57 38.0E-54 [3] 47.41 
GO:1901214 regulation of neuron death 260.0E-57 51.0E-54 [4, 5] 53.68 
GO:0050900 leukocyte migration 740.0E-57 140.0E-54 [2, 4, 5, 6] 45.82 
GO:0022407 regulation of cell-cell adhesion 840.0E-57 160.0E-54 [3, 4, 5] 45.12 
GO:0050673 epithelial cell proliferation 2.5E-54 480.0E-54 [3] 46.21 
GO:0071902 
positive regulation of protein 
serine/threonine kinase activity 2.7E-54 510.0E-54 [8, 9, 10, 11] 50.00 
GO:1905330 
regulation of morphogenesis of 
an epithelium 42.0E-54 8.0E-51 [4, 5, 6] 61.58 
GO:0014706 
striated muscle tissue 
development 66.0E-54 12.0E-51 [5] 46.47 
GO:2001233 
regulation of apoptotic signaling 
pathway 68.0E-54 12.0E-51 [4, 5, 6, 7] 44.23 
GO:0007156 
homophilic cell adhesion via 
plasma membrane adhesion 
molecules 89.0E-54 16.0E-51 [5] 66.25 
GO:0060562 epithelial tube morphogenesis 150.0E-54 28.0E-51 [4, 5, 6] 48.20 
GO:0001667 ameboidal-type cell migration 170.0E-54 32.0E-51 [4, 5, 6] 47.16 
GO:0045862 positive regulation of proteolysis 380.0E-54 69.0E-51 [5, 6, 7, 8] 46.20 
GO:0007265 Ras protein signal transduction 630.0E-54 110.0E-51 [6, 7] 47.01 
GO:0045765 regulation of angiogenesis 5.5E-51 1.0E-48 
[4, 5, 6, 7, 8, 9, 10, 
11] 55.36 
GO:0034330 cell junction organization 6.9E-51 1.2E-48 [3] 52.04 
GO:0048017 inositol lipid-mediated signaling 17.0E-51 3.0E-48 [5, 6] 56.62 
GO:0002429 
immune response-activating cell 
surface receptor signaling 
pathway 21.0E-51 3.7E-48 [4, 6, 7, 8] 43.48 
GO:0031589 cell-substrate adhesion 45.0E-51 8.0E-48 [3] 47.43 
GO:0048015 
phosphatidylinositol-mediated 
signaling 78.0E-51 13.0E-48 [6, 7] 56.74 
GO:0001763 
morphogenesis of a branching 
structure 87.0E-51 15.0E-48 [3, 4] 57.42 
GO:0043406 
positive regulation of MAP 
kinase activity 350.0E-51 61.0E-48 
[6, 7, 8, 9, 10, 11, 
12] 54.51 
GO:0050730 
regulation of peptidyl-tyrosine 
phosphorylation 350.0E-51 61.0E-48 [7, 8, 9, 10] 54.51 
GO:0098742 
cell-cell adhesion via plasma-
membrane adhesion molecules 350.0E-51 61.0E-48 (321) 54.51 
GO:0061138 
morphogenesis of a branching 
epithelium 430.0E-51 74.0E-48 [4, 5, 6] 58.67 
GO:0014065 
phosphatidylinositol 3-kinase 
signaling 1.3E-48 230.0E-48 [7, 8] 61.99 
GO:0002223 
stimulatory C-type lectin receptor 
signaling pathway 1.7E-48 290.0E-48 [6, 8, 9, 10, 11] 75.93 
GO:0051348 
negative regulation of transferase 
activity 1.7E-48 290.0E-48 [5] 45.05 
GO:0014066 
regulation of phosphatidylinositol 
3-kinase signaling 4.9E-48 830.0E-48 [5, 6, 7, 8, 9] 65.33 
GO:0003012 muscle system process 5.0E-48 840.0E-48 [3] 43.07 
GO:0002218 
activation of innate immune 
response 5.3E-48 880.0E-48 [3, 5, 6, 7, 8] 51.75 
GO:0060828 
regulation of canonical Wnt 
signaling pathway 14.0E-48 2.3E-45 [5, 6, 7, 8, 9] 51.98 
GO:0051402 neuron apoptotic process 14.0E-48 2.4E-45 [5, 6] 54.42 
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GO:0097191 
extrinsic apoptotic signaling 
pathway 66.0E-48 10.0E-45 [5, 6, 7] 52.02 
GO:0071383 
cellular response to steroid 
hormone stimulus 80.0E-48 13.0E-45 [5, 6] 51.37 
GO:1903037 
regulation of leukocyte cell-cell 
adhesion 100.0E-48 16.0E-45 [4, 5, 6] 45.83 
GO:0001933 
negative regulation of protein 
phosphorylation 160.0E-48 26.0E-45 [6, 7, 8, 9] 42.82 
GO:0038093 Fc receptor signaling pathway 250.0E-48 40.0E-45 [6, 7] 49.64 
GO:0050678 
regulation of epithelial cell 
proliferation 280.0E-48 44.0E-45 [4, 5] 46.56 
GO:0002237 
response to molecule of bacterial 
origin 300.0E-48 47.0E-45 [4, 6] 45.32 
GO:0045089 
positive regulation of innate 
immune response 340.0E-48 53.0E-45 [4, 5, 6, 7] 47.83 
GO:0042326 
negative regulation of 
phosphorylation 560.0E-48 87.0E-45 [6, 7, 8] 41.15 
GO:1901653 cellular response to peptide 1.6E-45 250.0E-45 [5, 6] 45.62 
GO:0032496 response to lipopolysaccharide 2.2E-45 340.0E-45 [4, 5, 7] 45.73 
GO:0035567 
non-canonical Wnt signaling 
pathway 2.4E-45 370.0E-45 [6, 7, 8] 61.88 
GO:0048738 
cardiac muscle tissue 
development 2.6E-45 400.0E-45 [4, 5, 6, 7] 56.63 
GO:0043401 
steroid hormone mediated 
signaling pathway 2.8E-45 420.0E-45 [5, 6, 7] 56.99 
GO:0030098 lymphocyte differentiation 3.4E-45 510.0E-45 [4, 6, 7, 8, 9] 46.23 
GO:0090130 tissue migration 14.0E-45 2.1E-42 [3] 50.39 
GO:0070371 ERK1 and ERK2 cascade 22.0E-45 3.3E-42 [5, 6, 7, 9, 10] 48.39 
GO:0009755 
hormone-mediated signaling 
pathway 22.0E-45 3.3E-42 [4, 5, 6] 51.68 
GO:0007517 muscle organ development 75.0E-45 10.0E-42 [4, 5, 6] 42.52 
GO:0031098 
stress-activated protein kinase 
signaling cascade 80.0E-45 11.0E-42 [4, 5, 6] 49.24 
GO:0050863 regulation of T cell activation 79.0E-45 11.0E-42 [5, 6, 7, 9, 10] 45.48 
GO:0030178 
negative regulation of Wnt 
signaling pathway 100.0E-45 14.0E-42 [4, 5, 6, 7, 8, 9] 54.03 
GO:0071375 
cellular response to peptide 
hormone stimulus 120.0E-45 17.0E-42 [5, 6, 7] 45.98 
GO:0001503 ossification 170.0E-45 23.0E-42 [3] 42.30 
GO:0051403 stress-activated MAPK cascade 220.0E-45 30.0E-42 [5, 6, 7, 9, 10] 49.42 
GO:0060326 cell chemotaxis 390.0E-45 54.0E-42 [4, 5, 6] 48.18 
GO:0048754 
branching morphogenesis of an 
epithelial tube 560.0E-45 77.0E-42 [4, 5, 6, 7] 60.25 
GO:0030177 
positive regulation of Wnt 
signaling pathway 560.0E-45 77.0E-42 [4, 5, 6, 7, 8, 9] 60.25 
GO:0030168 platelet activation 590.0E-45 80.0E-42 [4, 5, 6] 58.38 
GO:0043523 
regulation of neuron apoptotic 
process 610.0E-45 83.0E-42 [5, 6, 7] 54.73 
GO:0090132 epithelium migration 970.0E-45 130.0E-42 (321) 50.00 
GO:0050867 
positive regulation of cell 
activation 3.0E-42 400.0E-42 [3, 4, 5] 43.60 
GO:0050731 
positive regulation of peptidyl-
tyrosine phosphorylation 4.8E-42 640.0E-42 [7, 8, 9, 10, 11] 56.98 
GO:0090090 
negative regulation of canonical 
Wnt signaling pathway 10.0E-42 1.4E-39 [5, 6, 7, 8, 9, 10] 57.47 
GO:0042176 
regulation of protein catabolic 
process 12.0E-42 1.6E-39 [4, 5, 6] 41.62 
GO:0022409 
positive regulation of cell-cell 
adhesion 19.0E-42 2.4E-39 [3, 4, 5, 6] 48.11 
GO:0038095 
Fc-epsilon receptor signaling 
pathway 27.0E-42 3.4E-39 [7, 8] 53.14 
GO:0002696 
positive regulation of leukocyte 
activation 27.0E-42 3.4E-39 [3, 4, 5, 6] 43.71 
GO:0045216 cell-cell junction organization 47.0E-42 6.0E-39 (321) 50.00 
GO:0042692 muscle cell differentiation 81.0E-42 10.0E-39 [4, 5] 41.60 
GO:0051091 
positive regulation of sequence-
specific DNA binding 
transcription factor activity 88.0E-42 10.0E-39 
[2, 3, 4, 7, 8, 9, 10, 
11, 12] 49.19 
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GO:0070372 
regulation of ERK1 and ERK2 
cascade 90.0E-42 11.0E-39 [6, 7, 8, 9, 10, 11] 48.08 
GO:0060759 
regulation of response to cytokine 
stimulus 100.0E-42 12.0E-39 [3, 4, 5] 60.13 
GO:0031329 
regulation of cellular catabolic 
process 280.0E-42 34.0E-39 [4, 5] 40.77 
GO:0001655 urogenital system development 370.0E-42 45.0E-39 [4, 5] 42.73 
GO:0071453 cellular response to oxygen levels 470.0E-42 56.0E-39 (321) 58.86 
GO:0007160 cell-matrix adhesion 1.1E-39 130.0E-39 (321) 51.90 
GO:0034612 response to tumor necrosis factor 1.1E-39 130.0E-39 [5] 45.94 
GO:1903039 
positive regulation of leukocyte 
cell-cell adhesion 1.4E-39 160.0E-39 [4, 5, 6, 7] 49.57 
GO:1904018 
positive regulation of vasculature 
development 2.0E-39 230.0E-39 [3, 4, 5, 6, 7, 8, 9] 59.60 
GO:0051251 
positive regulation of lymphocyte 
activation 4.1E-39 470.0E-39 [4, 5, 6, 7] 44.16 
GO:0003007 heart morphogenesis 5.6E-39 640.0E-39 [4, 5, 6, 7] 48.75 
GO:0034329 cell junction assembly 6.7E-39 750.0E-39 (321) 51.17 
GO:1901215 
negative regulation of neuron 
death 7.9E-39 880.0E-39 [4, 5, 6] 54.01 
GO:0001959 
regulation of cytokine-mediated 
signaling pathway 8.9E-39 980.0E-39 [4, 5, 6, 7] 59.86 
GO:0060071 
Wnt signaling pathway, planar 
cell polarity pathway 10.0E-39 1.1E-36 [6, 7, 8, 9] 66.38 
GO:0071356 
cellular response to tumor 
necrosis factor 14.0E-39 1.5E-36 (322) 46.77 
GO:0043542 endothelial cell migration 58.0E-39 6.2E-36 [6, 7, 8] 55.56 
GO:0007178 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 120.0E-39 12.0E-36 [6, 7] 42.09 
GO:0043281 
regulation of cysteine-type 
endopeptidase activity involved 
in apoptotic process 130.0E-39 14.0E-36 [6, 7, 8, 9, 10] 50.23 
GO:0050870 
positive regulation of T cell 
activation 200.0E-39 21.0E-36 [5, 6, 7, 8, 9, 10, 11] 49.12 
GO:0045766 
positive regulation of 
angiogenesis 320.0E-39 32.0E-36 
[4, 5, 6, 7, 8, 9, 10, 
11, 12] 61.19 
GO:2001236 
regulation of extrinsic apoptotic 
signaling pathway 320.0E-39 32.0E-36 [5, 6, 7, 8] 53.89 
GO:0001738 
morphogenesis of a polarized 
epithelium 360.0E-39 37.0E-36 [5, 6] 59.44 
GO:0009896 
positive regulation of catabolic 
process 420.0E-39 42.0E-36 [3, 4, 5] 41.52 
GO:0036294 
cellular response to decreased 
oxygen levels 780.0E-39 77.0E-36 [5] 58.50 
GO:0051098 regulation of binding 840.0E-39 82.0E-36 [3] 43.04 
GO:0001736 establishment of planar polarity 1.3E-36 130.0E-36 [4, 5, 6, 7] 61.54 
GO:0032943 mononuclear cell proliferation 1.8E-36 170.0E-36 (321) 44.77 
GO:0070661 leukocyte proliferation 2.9E-36 270.0E-36 [3] 43.69 
GO:0034332 adherens junction organization 5.6E-36 520.0E-36 [5] 61.90 
GO:0071456 cellular response to hypoxia 7.2E-36 670.0E-36 [4, 6] 58.87 
GO:0030099 myeloid cell differentiation 9.1E-36 840.0E-36 [5, 6, 7, 8] 40.75 
GO:0071559 
response to transforming growth 
factor beta 13.0E-36 1.1E-33 [3, 5] 48.02 
GO:2001234 
negative regulation of apoptotic 
signaling pathway 15.0E-36 1.4E-33 [4, 5, 6, 7, 8] 47.06 
GO:0090263 
positive regulation of canonical 
Wnt signaling pathway 25.0E-36 2.3E-33 [5, 6, 7, 8, 9, 10] 61.60 
GO:0031331 
positive regulation of cellular 
catabolic process 31.0E-36 2.8E-33 [4, 5, 6] 44.20 
GO:2000116 
regulation of cysteine-type 
endopeptidase activity 42.0E-36 3.6E-33 [7, 8, 9] 46.67 
GO:0070302 
regulation of stress-activated 
protein kinase signaling cascade 59.0E-36 5.0E-33 [4, 5, 6, 7] 49.28 
GO:0007259 JAK-STAT cascade 87.0E-36 7.4E-33 [6, 7] 51.61 
GO:0010565 
regulation of cellular ketone 
metabolic process 110.0E-36 9.4E-33 [4, 5] 53.53 
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GO:0006936 muscle contraction 250.0E-36 21.0E-33 (321) 40.79 
GO:0000187 activation of MAPK activity 390.0E-36 32.0E-33 
[7, 8, 9, 10, 11, 12, 
13] 55.13 
GO:0097193 
intrinsic apoptotic signaling 
pathway 570.0E-36 46.0E-33 [5, 6, 7] 42.28 
GO:1900180 
regulation of protein localization 
to nucleus 910.0E-36 73.0E-33 [5, 6, 7] 46.55 
GO:0090257 
regulation of muscle system 
process 950.0E-36 75.0E-33 [4, 5] 49.75 
GO:1903050 
regulation of proteolysis involved 
in cellular protein catabolic 
process 1.4E-33 110.0E-33 [6, 7, 8] 46.35 
GO:0090287 
regulation of cellular response to 
growth factor stimulus 2.8E-33 220.0E-33 [3, 4, 6] 44.98 
GO:1903706 regulation of hemopoiesis 7.1E-33 540.0E-33 [3, 4, 5, 6, 7, 8] 40.43 
GO:0050679 
positive regulation of epithelial 
cell proliferation 8.9E-33 660.0E-33 [4, 5, 6] 51.72 
GO:0030278 regulation of ossification 9.6E-33 710.0E-33 [3, 4] 49.74 
GO:0007266 Rho protein signal transduction 13.0E-33 950.0E-33 [7, 8] 51.12 
GO:0046822 
regulation of nucleocytoplasmic 
transport 38.0E-33 2.7E-30 [5, 6, 7] 45.85 
GO:1903362 
regulation of cellular protein 
catabolic process 64.0E-33 4.5E-30 [5, 6, 7] 43.75 
GO:0045732 
positive regulation of protein 
catabolic process 77.0E-33 5.4E-30 [4, 5, 6, 7] 43.18 
GO:1903320 
regulation of protein modification 
by small protein conjugation or 
removal 160.0E-33 11.0E-30 [6, 7, 8] 41.75 
GO:0006367 
transcription initiation from RNA 
polymerase II promoter 210.0E-33 14.0E-30 [7, 8, 9, 10, 11] 49.73 
GO:0001649 osteoblast differentiation 260.0E-33 17.0E-30 [4, 5] 46.51 
GO:1904589 regulation of protein import 280.0E-33 18.0E-30 [5, 6, 7] 49.20 
GO:0001101 response to acid chemical 1.1E-30 75.0E-30 [3] 41.03 
GO:0061448 connective tissue development 1.3E-30 84.0E-30 (321) 43.55 
GO:0010632 
regulation of epithelial cell 
migration 1.6E-30 100.0E-30 [3, 4, 5, 6, 7, 8] 49.44 
GO:0042306 
regulation of protein import into 
nucleus 2.2E-30 140.0E-30 [6, 7, 8, 9, 10] 48.91 
GO:0030217 T cell differentiation 2.3E-30 140.0E-30 [5, 7, 8, 9, 10] 45.83 
GO:0033209 
tumor necrosis factor-mediated 
signaling pathway 3.4E-30 200.0E-30 [6, 7] 51.55 
GO:1903052 
positive regulation of proteolysis 
involved in cellular protein 
catabolic process 4.5E-30 270.0E-30 [6, 7, 8, 9] 49.71 
GO:1903364 
positive regulation of cellular 
protein catabolic process 4.9E-30 280.0E-30 [5, 6, 7, 8] 48.15 
GO:0051146 striated muscle cell differentiation 5.4E-30 300.0E-30 [5, 6] 42.47 
GO:0033673 
negative regulation of kinase 
activity 11.0E-30 620.0E-30 [6, 7, 8, 9] 42.41 
GO:0072001 renal system development 11.0E-30 620.0E-30 [4, 5, 6] 40.00 
GO:0006352 
DNA-templated transcription, 
initiation 14.0E-30 750.0E-30 [6, 7, 8, 9, 10] 44.16 
GO:0042063 gliogenesis 15.0E-30 780.0E-30 [6, 7] 42.80 
GO:0007179 
transforming growth factor beta 
receptor signaling pathway 17.0E-30 910.0E-30 [5, 7, 8] 48.62 
GO:0006606 protein import into nucleus 23.0E-30 1.1E-27 [5, 6, 7, 8, 9] 40.14 
GO:0001822 kidney development 32.0E-30 1.6E-27 [3, 4, 5, 6, 7] 40.64 
GO:0046578 
regulation of Ras protein signal 
transduction 36.0E-30 1.7E-27 [6, 7, 8] 44.59 
GO:0031396 
regulation of protein 
ubiquitination 39.0E-30 1.8E-27 [7, 8, 9, 10] 41.92 
GO:0006469 
negative regulation of protein 
kinase activity 57.0E-30 2.6E-27 [7, 8, 9, 10] 43.28 
GO:0060485 mesenchyme development 78.0E-30 3.5E-27 [4, 5, 6] 42.13 
GO:1903322 
positive regulation of protein 
modification by small protein 
conjugation or removal 140.0E-30 6.3E-27 [6, 7, 8, 9] 45.81 
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GO:0050920 regulation of chemotaxis 190.0E-30 8.3E-27 [3, 4, 5] 46.00 
GO:0032944 
regulation of mononuclear cell 
proliferation 190.0E-30 8.3E-27 [5, 6] 45.02 
GO:2000377 
regulation of reactive oxygen 
species metabolic process 360.0E-30 15.0E-27 [4, 5] 49.40 
GO:0070663 
regulation of leukocyte 
proliferation 400.0E-30 16.0E-27 [4, 5] 44.09 
GO:0043524 
negative regulation of neuron 
apoptotic process 410.0E-30 16.0E-27 [5, 6, 7, 8] 52.05 
GO:0072073 kidney epithelium development 1.5E-27 59.0E-27 [4, 5, 6, 7, 8] 50.32 
GO:0010810 
regulation of cell-substrate 
adhesion 2.2E-27 83.0E-27 [3, 4] 45.45 
GO:0042113 B cell activation 3.5E-27 120.0E-27 [4, 6] 41.27 
GO:0071216 
cellular response to biotic 
stimulus 4.0E-27 140.0E-27 [3] 45.83 
GO:0002263 
cell activation involved in 
immune response 5.6E-27 190.0E-27 [3, 4] 42.61 
GO:0002573 myeloid leukocyte differentiation 8.8E-27 290.0E-27 [6, 7, 8, 9] 44.78 
GO:0007254 JNK cascade 8.8E-27 290.0E-27 [6, 7, 8, 10, 11] 44.78 
GO:0070374 
positive regulation of ERK1 and 
ERK2 cascade 9.7E-27 310.0E-27 
[6, 7, 8, 9, 10, 11, 
12] 46.45 
GO:0010952 
positive regulation of peptidase 
activity 10.0E-27 330.0E-27 [6, 7, 8, 9] 48.77 
GO:2001235 
positive regulation of apoptotic 
signaling pathway 11.0E-27 350.0E-27 [4, 5, 6, 7, 8] 45.99 
GO:0072593 
reactive oxygen species metabolic 
process 23.0E-27 690.0E-27 [3] 40.47 
GO:0046425 regulation of JAK-STAT cascade 29.0E-27 810.0E-27 [6, 7, 8] 49.04 
GO:1903034 
regulation of response to 
wounding 38.0E-27 1.0E-24 [4, 5] 48.45 
GO:0031398 
positive regulation of protein 
ubiquitination 40.0E-27 1.0E-24 [7, 8, 9, 10, 11] 45.70 
GO:1902105 
regulation of leukocyte 
differentiation 47.0E-27 1.1E-24 [4, 5, 6, 7, 8, 9] 40.89 
GO:0043393 regulation of protein binding 53.0E-27 1.2E-24 (321) 45.90 
GO:0006140 
regulation of nucleotide 
metabolic process 56.0E-27 1.3E-24 [5, 6, 7, 8] 42.11 
GO:0030595 leukocyte chemotaxis 180.0E-27 4.1E-24 [3, 5, 6, 7] 43.27 
GO:0051216 cartilage development 240.0E-27 5.2E-24 [4, 5, 6] 44.74 
GO:0042180 cellular ketone metabolic process 430.0E-27 8.2E-24 [3, 4] 40.66 
GO:0043122 
regulation of I-kappaB 
kinase/NF-kappaB signaling 430.0E-27 8.2E-24 [5, 6, 7] 40.66 
GO:2000146 
negative regulation of cell 
motility 420.0E-27 8.4E-24 [3, 4, 5, 6] 40.93 
GO:0048762 mesenchymal cell differentiation 1.0E-24 16.0E-24 [5, 6, 7] 43.65 
GO:0071219 
cellular response to molecule of 
bacterial origin 940.0E-27 16.0E-24 [4, 5, 7] 46.20 
GO:0071229 cellular response to acid chemical 1.2E-24 16.0E-24 (321) 46.43 
GO:0030336 
negative regulation of cell 
migration 1.1E-24 16.0E-24 [4, 5, 6, 7] 41.52 
GO:0003205 cardiac chamber development 1.3E-24 16.0E-24 [3, 4, 5, 6, 7] 47.20 
GO:0042098 T cell proliferation 1.1E-24 17.0E-24 [5, 6, 7, 9, 10] 44.62 
GO:0071222 
cellular response to 
lipopolysaccharide 1.0E-24 17.0E-24 [5, 6, 8] 46.95 
GO:0046328 regulation of JNK cascade 2.0E-24 22.0E-24 
[6, 7, 8, 9, 10, 11, 
12] 46.15 
GO:0097529 myeloid leukocyte migration 2.8E-24 28.0E-24 [3, 5, 6, 7] 45.20 
GO:0002685 regulation of leukocyte migration 5.7E-24 51.0E-24 [3, 4, 5, 6, 7] 46.34 
GO:0060541 respiratory system development 6.9E-24 55.0E-24 [4, 5] 41.78 
GO:0051147 
regulation of muscle cell 
differentiation 8.1E-24 57.0E-24 [4, 5, 6] 45.35 
GO:1900542 
regulation of purine nucleotide 
metabolic process 10.0E-24 64.0E-24 [6, 7, 8, 9] 41.28 
GO:0045637 
regulation of myeloid cell 
differentiation 62.0E-24 310.0E-24 [4, 5, 6, 7, 8, 9] 43.48 
GO:0031960 response to corticosteroid 340.0E-24 1.0E-21 [5, 6] 43.93 
GO:0030323 respiratory tube development 330.0E-24 1.3E-21 [3, 4, 5, 6] 42.55 
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GO:0010001 glial cell differentiation 1.5E-21 3.1E-21 [5, 7, 8] 42.02 
GO:0032869 
cellular response to insulin 
stimulus 5.4E-21 5.4E-21 [6, 7, 8] 40.70 
 
Table A4.3: The list of additional thirteen targets from literature, which ginsenoside 
compounds are found to be implicated in the modulation of the targets. 
 
Gene ID Protein name SBP compound Ref. 
BAX Apoptosis regulator BAX ginsenoside Rd (323) 
BCL2 Apoptosis regulator Bcl-2 ginsenoside Rd (323) 
CASP3 Caspase-3 ginsenoside Rb3 (301) 
CASP8 Caspase-8 ginsenoside Rb3 (301) 
CASP9 Caspase-9 ginsenoside Rb3 (301) 
EGF Pro-epidermal growth factor ginsenoside Rb2 (308) 
EGFR Epidermal growth factor receptor ginsenoside Rb2 (308) 
ESR2 Estrogen beta receptor ginsenoside Rb1 (324) 
FN1 Fibronectin ginsenoside Rb2 (308) 
FOS Proto-oncogene c-Fos ginsenoside Rc (325) 
FOS Proto-oncogene c-Fos ginsenoside Re (325) 
MMP1 Interstitial collagenase ginsenoside Rb2 (308) 
NOS3 Nitric oxide synthase ginsenoside Re (326) 
NOS3 Nitric oxide synthase ginsenoside Rg3 (327) 
NR3C1 Glucocorticoid receptor ginsenoside Re (328) 
NR3C1 Glucocorticoid receptor ginsenoside Rg1 (329) 
 
 
Table A4.4: The values of SS, TS, PDS and MDS of 231 combinations of SBP. 
ID compound i compound j TS PDS MDS SS 
108 Ginsenoside Rb3 Cholic acid 0.0061373 0.5104493 2.849 0.00109953 
119 Ginsenoside Rc Cholic acid 0.0055149 0.5713448 2.889 0.00109070 
153 Ginsenoside Re Ginsenoside Rb3 0.0067909 0.4234194 2.646 0.00108676 
128 Ginsenoside Rc Ginsenoside Rb3 0.0095032 0.3102916 2.821 0.00104547 
115 Ginsenoside Rb3 Ginsenoside Rb1 0.0097747 0.3023365 2.949 0.00100222 
117 Ginsenoside Rb3 17-hydroxyprogestrone 0.0059602 0.4826925 2.876 0.00100025 
116 Ginsenoside Rb3 Ginsenoside Rb2 0.0064827 0.4052489 2.635 0.00099714 
170 Ginsenoside Rg1 Ginsenoside Rb3 0.0069584 0.4119944 2.944 0.00097363 
89 Ginsenoside Rb1 Cholic acid 0.0057864 0.4769261 2.916 0.00094643 
112 Ginsenoside Rb3 Deoxycholic acid 0.0060271 0.4404201 2.920 0.00090906 
113 Ginsenoside Rb3 11-hydroyprogesterone 0.0059610 0.5081140 3.333 0.00090866 
140 Ginsenosde Rd Ginsenoside Rb3 0.0093223 0.2742955 2.864 0.00089277 
114 Ginsenoside Rb3 Gamabufotalin 0.0058351 0.4490800 2.940 0.00089116 
129 Ginsenoside Rc 17-hydroxyprogestrone 0.0053377 0.4900444 2.956 0.00088502 
169 Ginsenoside Rg1 Ginsenoside Rb2 0.0033154 0.7187246 2.758 0.00086397 
139 Ginsenosde Rd Ginsenoside Rb2 0.0056794 0.4104020 2.710 0.00086019 
107 Ginsenoside Rb3 Bufalin 0.0058343 0.4229923 2.916 0.00084633 
171 Ginsenoside Rg1 Ginsenoside Rc 0.0063359 0.3852619 2.911 0.00083851 
111 Ginsenoside Rb3 Cinobufagin 0.0059342 0.4222491 2.990 0.00083809 
120 Ginsenoside Rc Chenodeoxycholic acid 0.0054058 0.4518561 2.940 0.00083083 
123 Ginsenoside Rc Deoxycholic acid 0.0054047 0.4511290 2.953 0.00082557 
124 Ginsenoside Rc 11-hydroyprogesterone 0.0053386 0.5110724 3.423 0.00079706 
208 Hyodeoxycholic acid Ginsenoside Rb3 0.0060221 0.3907532 2.972 0.00079171 
 159 
109 Ginsenoside Rb3 Chenodeoxycholic acid 0.0060282 0.3770864 2.886 0.00078773 
209 Hyodeoxycholic acid Ginsenoside Rc 0.0053997 0.4339484 3.032 0.00077271 
127 Ginsenoside Rc Ginsenoside Rb2 0.0058602 0.3387305 2.578 0.00077006 
190 Ginsenodie Rg3 Ginsenoside Rb3 0.0077555 0.2819174 2.851 0.00076696 
168 Ginsenoside Rg1 Ginsenoside Rb1 0.0066075 0.3369864 2.956 0.00075337 
96 Ginsenoside Rb1 17-hydroxyprogestrone 0.0056093 0.4004635 2.994 0.00075017 
131 Ginsenosde Rd Cholic acid 0.0053340 0.3926011 2.798 0.00074841 
29 Borneol Ginsenoside Rb3 0.0058267 0.3746318 2.940 0.00074237 
152 Ginsenoside Re Ginsenoside Rb2 0.0031479 0.5823789 2.491 0.00073599 
155 Ginsenoside Re Ginsenosde Rd 0.0059876 0.3211465 2.675 0.00071884 
90 Ginsenoside Rb1 Chenodeoxycholic acid 0.0056773 0.3744867 2.973 0.00071505 
225 Muscone Ginsenoside Rb3 0.0058999 0.3404798 2.836 0.00070839 
93 Ginsenoside Rb1 Deoxycholic acid 0.0056762 0.3695216 2.967 0.00070701 
94 Ginsenoside Rb1 11-hydroyprogesterone 0.0056101 0.4240120 3.433 0.00069281 
105 Ginsenoside Rb2 Ginsenoside Rb1 0.0061318 0.2894868 2.667 0.00066565 
206 Hyodeoxycholic acid Ginsenoside Rb1 0.0056712 0.3600544 3.069 0.00066525 
122 Ginsenoside Rc Cinobufagin 0.0053118 0.3862229 3.089 0.00066408 
142 Ginsenosde Rd 17-hydroxyprogestrone 0.0051569 0.3698512 2.877 0.00066284 
61 Cinnamaldehyde Ginsenoside Rb3 0.0056234 0.3413805 2.959 0.00064868 
118 Ginsenoside Rc Bufalin 0.0052119 0.3730060 3.056 0.00063624 
125 Ginsenoside Rc Gamabufotalin 0.0052127 0.3735706 3.065 0.00063537 
11 Benzyl benzoate Ginsenoside Rb3 0.0056860 0.3370369 3.026 0.00063323 
136 Ginsenosde Rd 11-hydroyprogesterone 0.0051577 0.4028853 3.310 0.00062769 
98 Ginsenoside Rb2 Cholic acid 0.0024944 0.6611088 2.639 0.00062490 
189 Ginsenodie Rg3 Ginsenoside Rb2 0.0041126 0.4024809 2.649 0.00062477 
135 Ginsenosde Rd Deoxycholic acid 0.0052238 0.3369640 2.855 0.00061650 
110 Ginsenoside Rb3 Cinnamic acid 0.0055391 0.3304779 2.996 0.00061099 
172 Ginsenoside Rg1 Ginsenosde Rd 0.0061551 0.2827583 2.879 0.00060449 
141 Ginsenosde Rd Ginsenoside Rc 0.0086999 0.1922611 2.896 0.00057767 
30 Borneol Ginsenoside Rc 0.0052042 0.3397520 3.086 0.00057302 
95 Ginsenoside Rb1 Gamabufotalin 0.0054842 0.3215150 3.116 0.00056592 
210 Hyodeoxycholic acid Ginsenosde Rd 0.0052188 0.3172761 2.932 0.00056466 
223 Muscone Ginsenoside Rb1 0.0055490 0.3035850 3.013 0.00055920 
88 Ginsenoside Rb1 Bufalin 0.0054834 0.3104770 3.102 0.00054890 
226 Muscone Ginsenoside Rc 0.0052775 0.3032066 2.942 0.00054397 
27 Borneol Ginsenoside Rb1 0.0054758 0.3055238 3.120 0.00053629 
132 Ginsenosde Rd Chenodeoxycholic acid 0.0052249 0.2926457 2.852 0.00053616 
92 Ginsenoside Rb1 Cinobufagin 0.0055833 0.2983934 3.131 0.00053211 
62 Cinnamaldehyde Ginsenoside Rc 0.0050010 0.3224239 3.050 0.00052873 
59 Cinnamaldehyde Ginsenoside Rb1 0.0052725 0.3083327 3.115 0.00052195 
151 Ginsenoside Re Ginsenoside Rb1 0.0064400 0.2047906 2.667 0.00049457 
138 Ginsenosde Rd Ginsenoside Rb1 0.0089714 0.1550928 2.910 0.00047807 
9 Benzyl benzoate Ginsenoside Rb1 0.0053351 0.2793350 3.131 0.00047601 
12 Benzyl benzoate Ginsenoside Rc 0.0050636 0.2850652 3.077 0.00046912 
102 Ginsenoside Rb2 Deoxycholic acid 0.0023841 0.5240455 2.710 0.00046103 
121 Ginsenoside Rc Cinnamic acid 0.0049167 0.2897426 3.094 0.00046049 
106 Ginsenoside Rb2 17-hydroxyprogestrone 0.0023172 0.5427370 2.738 0.00045941 
180 Ginsenodie Rg3 Cholic acid 0.0037672 0.3401296 2.791 0.00045910 
 160 
99 Ginsenoside Rb2 Chenodeoxycholic acid 0.0023853 0.5176688 2.700 0.00045732 
91 Ginsenoside Rb1 Cinnamic acid 0.0051882 0.2761886 3.158 0.00045381 
137 Ginsenosde Rd Gamabufotalin 0.0050318 0.2695963 3.000 0.00045219 
103 Ginsenoside Rb2 11-hydroyprogesterone 0.0023181 0.6164160 3.160 0.00045214 
134 Ginsenosde Rd Cinobufagin 0.0051310 0.2669244 3.039 0.00045068 
173 Ginsenoside Rg1 Ginsenoside Re 0.0036236 0.3389415 2.731 0.00044976 
167 Ginsenoside Rg1 Gamabufotalin 0.0026679 0.4949464 2.955 0.00044692 
154 Ginsenoside Re Ginsenoside Rc 0.0061685 0.1912693 2.658 0.00044390 
197 Ginsenodie Rg3 17-hydroxyprogestrone 0.0035900 0.3469515 2.839 0.00043866 
130 Ginsenosde Rd Bufalin 0.0050311 0.2596079 2.982 0.00043800 
207 Hyodeoxycholic acid Ginsenoside Rb2 0.0023791 0.5085757 2.799 0.00043235 
191 Ginsenodie Rg3 Ginsenoside Rc 0.0071331 0.1689280 2.836 0.00042483 
144 Ginsenoside Re Cholic acid 0.0028026 0.3885680 2.605 0.00041806 
150 Ginsenoside Re Gamabufotalin 0.0025004 0.4493520 2.757 0.00040753 
159 Ginsenoside Rg1 Bufalin 0.0026671 0.4468832 2.946 0.00040462 
186 Ginsenodie Rg3 11-hydroyprogesterone 0.0035909 0.3639052 3.288 0.00039744 
143 Ginsenoside Re Bufalin 0.0024996 0.4315939 2.746 0.00039280 
175 Ginsenoside Rg1 Muscone 0.0027327 0.4093855 2.909 0.00038456 
31 Borneol Ginsenosde Rd 0.0050234 0.2286708 2.992 0.00038392 
145 Ginsenoside Re Chenodeoxycholic acid 0.0026935 0.3722801 2.647 0.00037876 
228 Muscone Ginsenoside Re 0.0025652 0.3803266 2.692 0.00036245 
32 Borneol Ginsenoside Re 0.0024919 0.4029976 2.781 0.00036113 
194 Ginsenodie Rg3 Ginsenoside Rg1 0.0045883 0.2263224 2.880 0.00036056 
158 Ginsenoside Rg1 Borneol 0.0026594 0.4035820 2.978 0.00036047 
227 Muscone Ginsenosde Rd 0.0050967 0.2056309 2.912 0.00035986 
195 Ginsenodie Rg3 Hyodeoxycholic acid 0.0036520 0.2861029 2.922 0.00035763 
148 Ginsenoside Re Deoxycholic acid 0.0026924 0.3535186 2.676 0.00035564 
161 Ginsenoside Rg1 Chenodeoxycholic acid 0.0028610 0.3504024 2.832 0.00035393 
185 Ginsenodie Rg3 Deoxycholic acid 0.0036570 0.2722805 2.850 0.00034935 
160 Ginsenoside Rg1 Cholic acid 0.0029701 0.3236896 2.766 0.00034758 
165 Ginsenoside Rg1 Deoxycholic acid 0.0028598 0.3433353 2.827 0.00034727 
187 Ginsenodie Rg3 Gamabufotalin 0.0034650 0.2985135 2.983 0.00034671 
176 Ginsenoside Rg1 17-hydroxyprogestrone 0.0027929 0.3509641 2.828 0.00034664 
147 Ginsenoside Re Cinobufagin 0.0025995 0.3731483 2.799 0.00034655 
174 Ginsenoside Rg1 Hyodeoxycholic acid 0.0028549 0.3525642 2.916 0.00034520 
211 Hyodeoxycholic acid Ginsenoside Re 0.0026874 0.3518738 2.744 0.00034461 
101 Ginsenoside Rb2 Cinobufagin 0.0022913 0.4275393 2.879 0.00034021 
193 Ginsenodie Rg3 Ginsenoside Re 0.0044208 0.2069379 2.692 0.00033979 
181 Ginsenodie Rg3 Chenodeoxycholic acid 0.0036581 0.2612411 2.842 0.00033624 
224 Muscone Ginsenoside Rb2 0.0022570 0.4059781 2.734 0.00033510 
156 Ginsenoside Re 17-hydroxyprogestrone 0.0026254 0.3388738 2.659 0.00033464 
188 Ginsenodie Rg3 Ginsenoside Rb1 0.0074046 0.1253121 2.836 0.00032714 
64 Cinnamaldehyde Ginsenoside Re 0.0022887 0.3990170 2.796 0.00032660 
179 Ginsenodie Rg3 Bufalin 0.0034642 0.2787548 2.966 0.00032553 
63 Cinnamaldehyde Ginsenosde Rd 0.0048201 0.2032004 3.015 0.00032488 
162 Ginsenoside Rg1 Cinnamic acid 0.0023719 0.4170929 3.051 0.00032421 
164 Ginsenoside Rg1 Cinobufagin 0.0027670 0.3495501 2.986 0.00032386 
184 Ginsenodie Rg3 Cinobufagin 0.0035641 0.2727763 3.011 0.00032291 
 161 
146 Ginsenoside Re Cinnamic acid 0.0022044 0.4110862 2.831 0.00032012 
163 Ginsenoside Rg1 Cinnamaldehyde 0.0024562 0.3813532 3.018 0.00031039 
157 Ginsenoside Rg1 Benzyl benzoate 0.0025188 0.3799268 3.115 0.00030717 
14 Benzyl benzoate Ginsenoside Re 0.0023513 0.3734563 2.881 0.00030475 
192 Ginsenodie Rg3 Ginsenosde Rd 0.0069522 0.1231611 2.874 0.00029794 
10 Benzyl benzoate Ginsenoside Rb2 0.0020430 0.4130322 2.850 0.00029609 
166 Ginsenoside Rg1 11-hydroyprogesterone 0.0027938 0.3452908 3.261 0.00029579 
133 Ginsenosde Rd Cinnamic acid 0.0047358 0.1872005 3.050 0.00029071 
28 Borneol Ginsenoside Rb2 0.0021837 0.3700235 2.805 0.00028809 
149 Ginsenoside Re 11-hydroyprogesterone 0.0026263 0.3263788 3.107 0.00027588 
196 Ginsenodie Rg3 Muscone 0.0035298 0.2237633 2.902 0.00027215 
13 Benzyl benzoate Ginsenosde Rd 0.0048827 0.1716580 3.094 0.00027092 
215 Muscone Cholic acid 0.0019116 0.3942771 2.801 0.00026913 
60 Cinnamaldehyde Ginsenoside Rb2 0.0019805 0.3815768 2.831 0.00026697 
97 Ginsenoside Rb2 Bufalin 0.0021914 0.3402093 2.819 0.00026450 
104 Ginsenoside Rb2 Gamabufotalin 0.0021921 0.3271152 2.840 0.00025247 
183 Ginsenodie Rg3 Cinnamaldehyde 0.0032533 0.2287672 2.994 0.00024855 
178 Ginsenodie Rg3 Borneol 0.0034566 0.2123170 2.975 0.00024670 
182 Ginsenodie Rg3 Cinnamic acid 0.0031690 0.2091304 3.034 0.00021844 
2 Benzyl benzoate Cholic acid 0.0016977 0.3797622 2.997 0.00021515 
100 Ginsenoside Rb2 Cinnamic acid 0.0018962 0.3240599 2.860 0.00021482 
177 Ginsenodie Rg3 Benzyl benzoate 0.0033159 0.1969754 3.069 0.00021280 
81 Gamabufotalin Cholic acid 0.0018468 0.3129027 2.828 0.00020431 
41 Cholic acid Cinnamic acid 0.0015508 0.3732538 2.933 0.00019734 
220 Muscone Deoxycholic acid 0.0018014 0.3025681 2.834 0.00019232 
230 Muscone 17-hydroxyprogestrone 0.0017345 0.2999613 2.835 0.00018350 
52 Cinnamaldehyde Cholic acid 0.0016351 0.3230877 2.898 0.00018226 
126 Ginsenoside Rc Ginsenoside Rb1 0.0091523 0.0538366 2.710 0.00018184 
39 Cholic acid Bufalin 0.0018460 0.2688748 2.811 0.00017654 
221 Muscone 11-hydroyprogesterone 0.0017353 0.3254281 3.213 0.00017578 
16 Benzyl benzoate 17-hydroxyprogestrone 0.0015205 0.3453838 3.036 0.00017301 
216 Muscone Chenodeoxycholic acid 0.0018025 0.2634202 2.810 0.00016898 
229 Muscone Hyodeoxycholic acid 0.0017964 0.2696328 2.874 0.00016856 
19 Borneol Cholic acid 0.0018384 0.2555726 2.834 0.00016579 
7 Benzyl benzoate 11-hydroyprogesterone 0.0015214 0.3449843 3.424 0.00015330 
86 Gamabufotalin 11-hydroyprogesterone 0.0016705 0.2856633 3.240 0.00014726 
6 Benzyl benzoate Deoxycholic acid 0.0015875 0.2811236 3.045 0.00014658 
25 Borneol 11-hydroyprogesterone 0.0016621 0.2826002 3.230 0.00014542 
48 Cinnamic acid 11-hydroyprogesterone 0.0013745 0.3524914 3.350 0.00014462 
49 Cinnamic acid 17-hydroxyprogestrone 0.0013737 0.3122880 2.969 0.00014448 
3 Benzyl benzoate Chenodeoxycholic acid 0.0015886 0.2662406 3.023 0.00013989 
68 Cinobufagin Cholic acid 0.0019459 0.2060480 2.867 0.00013984 
37 Bufalin 11-hydroyprogesterone 0.0016697 0.2652003 3.230 0.00013710 
85 Gamabufotalin Deoxycholic acid 0.0017366 0.2227425 2.876 0.00013448 
66 Cinnamaldehyde 17-hydroxyprogestrone 0.0014580 0.2701721 2.938 0.00013409 
57 Cinnamaldehyde 11-hydroyprogesterone 0.0014588 0.3016150 3.324 0.00013238 
205 Hyodeoxycholic acid Gamabufotalin 0.0017316 0.2155613 2.910 0.00012828 
35 Borneol 17-hydroxyprogestrone 0.0016612 0.2209447 2.865 0.00012811 
 162 
76 Deoxycholic acid Cinnamic acid 0.0014406 0.2603647 2.974 0.00012613 
82 Gamabufotalin Chenodeoxycholic acid 0.0017377 0.2048424 2.856 0.00012462 
15 Benzyl benzoate Hyodeoxycholic acid 0.0015825 0.2425826 3.086 0.00012438 
87 Gamabufotalin 17-hydroxyprogestrone 0.0016696 0.2087172 2.850 0.00012226 
56 Cinnamaldehyde Deoxycholic acid 0.0015249 0.2314236 2.940 0.00012001 
38 Bufalin 17-hydroxyprogestrone 0.0016689 0.1953745 2.846 0.00011458 
45 Chenodeoxycholic acid Cinnamic acid 0.0014417 0.2343363 2.952 0.00011443 
214 Muscone Bufalin 0.0016086 0.1982825 2.845 0.00011212 
73 Deoxycholic acid Bufalin 0.0017358 0.1824320 2.864 0.00011058 
222 Muscone Gamabufotalin 0.0016094 0.1949796 2.851 0.00011008 
201 Hyodeoxycholic acid Cinnamic acid 0.0014356 0.2294984 3.015 0.00010927 
53 Cinnamaldehyde Chenodeoxycholic acid 0.0015260 0.2082235 2.917 0.00010894 
219 Muscone Cinobufagin 0.0017085 0.1852218 2.917 0.00010848 
198 Hyodeoxycholic acid Bufalin 0.0017308 0.1763738 2.901 0.00010524 
24 Borneol Deoxycholic acid 0.0017281 0.1737789 2.866 0.00010479 
44 Chenodeoxycholic acid Bufalin 0.0017369 0.1706277 2.835 0.00010453 
65 Cinnamaldehyde Hyodeoxycholic acid 0.0015199 0.1970686 2.982 0.00010043 
8 Benzyl benzoate Gamabufotalin 0.0013955 0.2207313 3.080 0.00010002 
5 Benzyl benzoate Cinobufagin 0.0014946 0.2093215 3.139 0.00009968 
69 Cinobufagin Chenodeoxycholic acid 0.0018368 0.1535312 2.902 0.00009719 
46 Chenodeoxycholic acid 11-hydroyprogesterone 0.0018636 0.1605815 3.162 0.00009464 
33 Borneol Hyodeoxycholic acid 0.0017231 0.1587758 2.911 0.00009400 
1 Benzyl benzoate Bufalin 0.0013947 0.2052891 3.075 0.00009311 
77 Deoxycholic acid Cinobufagin 0.0018357 0.1411650 2.919 0.00008878 
71 Cinobufagin 11-hydroyprogesterone 0.0017696 0.1627538 3.282 0.00008776 
20 Borneol Chenodeoxycholic acid 0.0017293 0.1432727 2.850 0.00008694 
23 Borneol Cinobufagin 0.0016353 0.1572838 2.960 0.00008690 
202 Hyodeoxycholic acid Cinobufagin 0.0018307 0.1390198 2.958 0.00008604 
55 Cinnamaldehyde Cinobufagin 0.0014320 0.1816085 3.035 0.00008569 
72 Cinobufagin 17-hydroxyprogestrone 0.0017688 0.1364611 2.883 0.00008371 
70 Cinobufagin Cinnamic acid 0.0013477 0.1875296 3.070 0.00008233 
47 Chenodeoxycholic acid 17-hydroxyprogestrone 0.0018628 0.1163772 2.764 0.00007842 
212 Hyodeoxycholic acid 17-hydroxyprogestrone 0.0018566 0.1182700 2.830 0.00007760 
34 Borneol Muscone 0.0016010 0.1341892 2.856 0.00007522 
204 Hyodeoxycholic acid 11-hydroyprogesterone 0.0018575 0.1251134 3.229 0.00007197 
43 Cholic acid 17-hydroxyprogestrone 0.0019719 0.0968127 2.709 0.00007047 
42 Cholic acid 11-hydroyprogesterone 0.0019727 0.1109740 3.117 0.00007023 
79 Deoxycholic acid 17-hydroxyprogestrone 0.0018616 0.1010832 2.768 0.00006798 
84 Gamabufotalin Cinobufagin 0.0016437 0.1142128 2.939 0.00006387 
199 Hyodeoxycholic acid Cholic acid 0.0020338 0.0869326 2.796 0.00006324 
78 Deoxycholic acid 11-hydroyprogesterone 0.0018625 0.1039276 3.182 0.00006082 
17 Borneol Benzyl benzoate 0.0013870 0.1329471 3.087 0.00005974 
58 Cinnamaldehyde Gamabufotalin 0.0013329 0.1227309 2.978 0.00005492 
67 Cinobufagin Bufalin 0.0016429 0.0914737 2.930 0.00005129 
83 Gamabufotalin Cinnamic acid 0.0012486 0.1140554 3.010 0.00004731 
51 Cinnamaldehyde Bufalin 0.0013321 0.1032419 2.968 0.00004633 
74 Deoxycholic acid Cholic acid 0.0020388 0.0615986 2.724 0.00004611 
40 Cholic acid Chenodeoxycholic acid 0.0020399 0.0601707 2.721 0.00004511 
 163 
218 Muscone Cinnamaldehyde 0.0013977 0.0919643 2.918 0.00004405 
36 Bufalin Cinnamic acid 0.0012478 0.1024529 3.001 0.00004260 
26 Borneol Gamabufotalin 0.0015361 0.0794001 2.889 0.00004221 
213 Muscone Benzyl benzoate 0.0014603 0.0832178 3.034 0.00004005 
217 Muscone Cinnamic acid 0.0013134 0.0842688 2.956 0.00003744 
18 Borneol Bufalin 0.0015354 0.0682438 2.879 0.00003639 
75 Deoxycholic acid Chenodeoxycholic acid 0.0019297 0.0510757 2.783 0.00003541 
231 17-hydroxyprogestrone 11-hydroyprogesterone 0.0017956 0.0550709 3.191 0.00003099 
200 Hyodeoxycholic acid Chenodeoxycholic acid 0.0019247 0.0372885 2.849 0.00002519 
50 Cinnamaldehyde Benzyl benzoate 0.0011838 0.0627316 3.132 0.00002371 
22 Borneol Cinnamaldehyde 0.0013245 0.0479287 2.974 0.00002135 
4 Benzyl benzoate Cinnamic acid 0.0010995 0.0606778 3.167 0.00002107 
21 Borneol Cinnamic acid 0.0012402 0.0487210 3.004 0.00002011 
203 Hyodeoxycholic acid Deoxycholic acid 0.0019236 0.0277914 2.853 0.00001874 
80 Gamabufotalin Bufalin 0.0015438 0.0178793 2.873 0.00000961 
54 Cinnamaldehyde Cinnamic acid 0.0010369 0.0143999 3.065 0.00000487 
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Figure A4.1: The dose response matrices of five combinations from the 20 top-ranked combinations. 
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